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 I. Introduction 
 
I/1. Nicotinic Acetylcholine Receptors (nAChRs) 
I/1.1. Historical perspective of the receptor 
Almost 100 years ago, John Langley of Cambridge University developed the idea of 
the "receptive substance" or "receptor" by using nicotine as an experimental tool 1. He 
suggested “pharmacological substances could possess the structure necessary for the 
combination with appropriate molecules on cells” 2. Between 1905 and 1907, Langley 
carried out a series of experiments on the somatic neuromuscular junction and 
postulated the existence of transmitter receptors 3. Later, Dale and his colleagues 
identified acetylcholine (ACh) 1 as the transmitter that acts on the receptors 
discovered by Langley (neuromuscular junction) as well as on receptors in the heart. 
In 1914, Dale distinguished the action of muscarine 2 and (S)(-)-nicotine 3 that 
historically resulted in the recognition of two pharmacologically distinct families of 
receptors for ACh 1 4. 
I/1.2. The endogenous neurotransmitter acetylcholine 
Acetylcholine (ACh) 1 (Fig. I/1.1) is an endogenous neurotransmitter synthesized at 
the axon terminal from choline 4 and acetyl-CoA by action of the synthesizing 
enzyme, choline acetyl transferase (Fig. I/1.1) and is stored in vesicles in the 
presynaptic neuron. Depolarisation of the nerve terminal and the influx of calcium 
ion produce the release of ACh 1 from storage vesicles in the synaptic cleft. The 
neurotransmitter combines with receptors present on the postsynaptic neuron 
causing conformational change that allows the passage of cations. Afterwards, ACh 1 
is broken down by hydrolysis into acetate and choline 4 in the reaction catalysed by 
the metabolising enzyme acetylcholinesterase 5.  
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Figure I/1.1: On the left: structure of acetylcholine (ACh) 1. On the right: acetylcholine release and re-
uptake in synaptic junction. ACh 1 is stored in vesicles in the presynaptic neuron until released. The 
enzyme acetylcholine esterase inactivates acetylcholine after combining with its receptor 5. 
 
Acetylcholine 1 exerts its effect both in the central and peripheral nervous systems 
through two distinct classes of cholinergic receptors: the muscarinic and nicotinic 
acetylcholine receptors (mAChRs and nAChRs), respectively named on the basis of 
their natural agonists, the plant alkaloids muscarine 2 and (-)-nicotine 3 6. 
I/1.2.1. Muscarinic receptors 
The muscarinic receptors are members of the membrane bound G-protein coupled 
receptor family (GPCRs), which mediate their responses by activating a cascade of 
intracellular pathways. Muscarinic receptors are characterized by a single 
polypeptide chain of 400-500 residues, likely to correspond to transmembrane α-
helices (7-transmembrane (7-TM) spanning receptors) (Fig. I/1.2). Acetylcholine 1 
binds a site surrounded by the transmembrane regions of the receptor protein 7. The 
carboxy-terminal is on the intracellular side of the membrane and is involved in 
coupling to G-proteins. G-proteins are compounds of three subunits of different size, 
weight and function (α, β and γ) 7. The α subunit activates the appropriate second 
messenger system (e.g. activation of phospholipase C (inositol phosphate pathway), 
producing the mobilization of intracellular Ca2+, for M1 or M3 and M5 receptors; 
inhibition of adenylyl cyclase for M2 or M4, reducing the cytoplasmatic concentration 
of cAMP) 8. The β and γ subunit can exert independent actions 8. 
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Figure I/1.2: There are five subtypes of muscarinic acetylcholine receptors that mediate the effects of 
acetylcholine. M1, M3 and M5 receptors have a stimulatory function. They promote the release of the 
intracellular Ca2+. M2 and M4 receptors have an inhibitory function and negatively modulate adenylyl 
cyclase (AC). This process reduces the cytoplasmatic concentrations of cAMP 9. 
 
Muscarine 2 4-Hydroxy-5-methyl-tetrahydro-furan-2-ylmethyl-)trimethyl-ammonium is 
the prototypical muscarinic agonist and derives from the poisonous fly agaric 
mushroom Amanita muscaria (Fig. I/1.3) 7. Similar to acetylcholine 1, muscarine 2 
contains a quaternary nitrogen that is important for action at the anionic site of the 
receptor (an aspartate residue in transmembrane domain III) 8 (Fig. I/1.3).  
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Figure I/1.3: Structure of muscarine 2, the alkaloids from the poisonous mushroom amanita muscaria 10. 
 
Muscarine simulates the interaction of ACh 1 with the acetylcholine receptors, thus 
mediating (interaction with G protein) its metabotropic effect. Several subtypes of 
muscarinic receptors have been identified: the M1 subtype has been found in various 
secretory glands and within the CNS (cortex and hippocampus). The M2 receptors 
predominate in the heart, particularly in the myocardium and can also be found in 
I. Introduction  4  nAChRs 
smooth muscle. The M3 and M4 subtypes are located in smooth muscle and secretory 
glands. The last subtype known so far is the M5 subtype whose mRNA is found in 
the substantia nigra 8. The activation of muscarinic receptors produces 
parasympathetic responses, including increased sweating, secretion of glands in the 
digestive system, decreased heart rate, constricted pupils, and contraction of the 
smooth muscle of the respiratory, digestive and urinary systems 9. 
I/1.2.2. Nicotinic acetylcholine receptors (nAChRs) 
The nAChRs are members of the ligand-gated ion channels (LGIC) family 11(Fig. 
I/1.4). The LGIC family includes different subfamilies that can be classified into three 
different groups. The “cis loop” receptor family includes the nAChR, the γ-
aminobutyric acid receptor (GABAA, GABAC), glycine receptor (glyR) and serotonine 
(5-hydroxytryptamine, 5-HT3) receptor 11-14. They are characterized by a pentameric 
structure and by the presence of a disulfide bridge between two cysteine residues in 
the extracellular domain of each subunit 15. The second group comprises the 
ionotropic glutamate receptors that have a tetrameric structure and mediate 
excitatory response 16. The last group is the ATP-gated purinoreceptor family (PX2R) 
that seems to be constituted by three homomeric subunits and contains only two 
transmembrane domains in each subunit 17. All nAChR known so far are selective 
with regard to cations whereas other members of the LGIC family are anionic-
permeable channels (e.g. chloride permeable glutamate receptors (GluRCl), glyR, 
etc.) 11. NAChRs are responsible for mediating cholinergic neurotransmission at the 
neuromuscular junction of striated muscles, in the autonomous peripheral ganglia 
and at several sites in the central nervous system 6,15. The receptor of this family 
controls the fast synaptic events in the nervous system by increasing transient 
permeability to particular ions 12. In nAChRs, binding of two ACh molecules causes a 
rapid (ms) opening of the sodium channel. The opening of the channel results in a 
flux of ions that diffuse in the direction of their gradient (Na+ in and K+ out-currents) 
thereby causing depolarisation and an excitatory postsynaptic potential (EPSP) 18,19 
(Fig. I/1.4).  
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Figure I/1.4: The nicotinic acetylcholine receptor is composed of five subunits that are arranged to 
form a pore. The α subunit carries the binding site for ACh. The binding of two ACh molecules causes 
a rapid (ms) opening of the sodium channel. Na+ flows down its concentration gradient into the cell 
causing depolarisation and an excitatory postsynaptic potential (EPSP) 15. 
(S)(-)-Nicotine 3 (-)-1-methyl-2-(3-pyridyl)-pyrrolidine is the prototypical agonist of the 
nicotinic acetylcholine receptors 20. The structure of (S)(-)-nicotine 3 consists of a 
pyridine and a pyrrolidine ring (Fig. I/1.5).  
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Figure I/1.5: Nicotinana tabacum, the tobacco plant. The structure of (S)(-)-nicotine 3 the most known 
alkaloid present in the tobacco leaves 21. 
(S)(-)-Nicotine 3 acts on the neuromuscular junction, in the autonomic peripheral 
ganglia, in adrenal medullar cells and at several sites in the central nervous system 
(CNS) (see chapter I/2 for pharmacological actions of nicotine). (S)(-)-Nicotine 3 is an 
alkaloid that is found in the leaves of Nicotiana tabacum (Fig. I/1.5), the tobacco plant. 
Christopher Columbus, who brought it back from the Bahamas in 1492, introduced it 
to Europe. He wrote in his log that he had "met men and women who carried fire in 
their hands, and who smoked to keep off the tiredness". In 1828, Posselt and 
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Reimann at the University of Heidelberg were the first to extract nicotine from 
tobacco 22. The name “nicotine” originates from Jean Nicot, a French ambassador to 
Portugal who introduced the Queen Consort and Regent of France, Catherine de 
Medici, to tobacco. 
I/1.3. The architecture of the nAChR 
The ACh receptor–channel complex has a molecular weight of approximately. 300 
kDa. The channel is approximately 12 nm long in total and protrudes from the 
external surface of the membrane by about 6.5 nm and reaches 2 nm into the 
cytoplasm 23,24 (Fig. I/1.6). NAChRs are composed of five membrane spanning 
subunits forming a barrel-like structure around the central ion channel (Fig. I/ 1.6b) 
25. This pore has a diameter of ~ 25 Å at the synaptic entrance and becomes narrower 
at the transmembrane level 26(Fig. I/1.6c). Each subunit consists of a number of 
distinct functional domains 26:  
1) The long N-terminal extracellular domain (constinsting of about 210 amino 
acids) that carries the ACh binding sites and a conserved disulphide bridge 
between two cysteine residues separated by 15 amino acids 26-28. 
2) Four highly hydrophobic segments named M1, M2, M3 and M4 29 form the 
transmembrane domains 30. The second membrane spanning segment, M2, 
shapes the lumen of the pore in the ion channel and determines ion´s 
conductance and selectivity 11, 23, 28, 31, 32.  
3) A short extracellular C-terminal domain 11, 23, 28, 31, 32.  
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Figure I/1.6: Structure of the nicotinic acetylcholine receptor (nAChR). a: The functional domain of the 
receptor through the membrane: the amino terminal hydrophilic portion, the transmembrane domain 
and the small hydrophilic C-terminal domain. b: Schematic representation of the subunits in the 
muscle-type receptor, the location of the two acetylcholine (ACh) binding sites (between an α and γ-
subunit, and an α and δ-subunit), and the central ion conducting channel. c: A cross-section through 
the 4.6-Å structure of the receptor determined by electron microscopy of tubular crystals of Torpedo 
californica membrane embedded in ice 15. 
 
NAChRs are commonly divided into three subfamilies 20, 33:  
• Heteromeric muscle type receptors that are selectively labelled and blocked by 
the antagonist α-bungarotoxin (α-Bgt) 5 as present in snake venom of Bungarus 
multicinctus 34. 
• Heteromeric neuronal nicotinic receptors composed of a combination of α and β 
subunits that are α-bungarotoxin-insensitive or resistant 20, 33. 
• Homomeric neuronal nAChRs composed of an association of α7, α8 or α9-
subunits which binds α-bungarotoxin (α-Bgt) 5 20. 
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I/1.3.1. Composition of nAChRs in the neuromuscular junction (NMJ) 
The major structural information of LGIC has been obtained from studies conducted 
on the muscle-type AChRs 35. In the 1970s, the large amount of nAChRs protein 
available in the electric organs of Torpedo californica (Eel, Electrophorus) and the high 
degree of homology with the embryonic vertebrate muscle type receptor allowed the 
elucidation of the structure and function of nAChRs 30, 36. Muscle nAChRs are located 
on the postsynaptic membrane of the neuromuscular endplate 37 and are built up of 
α1, β1, γ and δ subunits in the fixed stoichiometry 2:1:1:1. (Fig. I/1.6b) 20, 38. The order 
of assembly of the subunits that form the pentameric muscle receptor is highly 
constrained in a clockwise sequence of α1γα1β1δ (Fig. I/1.6b). In adult muscle the γ 
subunit is replaced by an ε to give α1εα1β1δ 39. 
I/1.3.2. Composition of nAChRs in the brain 
Neuronal nAChR are pentameric receptors that differ from the muscle type as they 
have no δ, ε, or γ subunits. So far, 12 neuronal nAChRs subunits have been identified, 
of these nine are α (α2 to α10) and three β (β2 to β4) 40,41. Neuronal nAChRs will have 
distinct pharmacological and physiological properties resulting from the 
combination of different subunits 42 43. Heteromeric nAChRs are composed of α and β 
subunits that combine an αxβy stoichiometry to form functional channels. The α2, α3, 
α4, α5 and α6 subunits can assemble with β2, β3 or β4 20, 38, 42 with the exception of α5 
and β3 which do not form functional receptors when expressed alone or with a single 
β subunit 40, 44, 45. The α10 subunit is only incorporated into a functional nAChR when 
co-expressed with α9 41. Homomeric receptors are formed by α7, α8 and α9 subunits. 
These receptors share many different physiological features. Each of them is able to 
form functional homomers, bind α-bungarotoxin (α-Bgt) 5, and exhibit high calcium 
permeability and fast desensitisation 46, 47, 48. 
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I/1.4. Ligand binding sites 
I/1.4.1. ACh binding sites 
The structure of the ACh binding sites has been investigated by a number of different 
methods, including photoaffinity labelling and site-directed mutagenesis 32. It was 
found that a specific agonist-binding site is located on both α subunits 52 in a pocket 
approximately 30-35 Å above the membrane surface 32. Studies of the muscle-type 
receptor suggest that the receptor contains two different ligand-binding sites with 
different affinities for ACh. One binding site is located at the interface of the α and 
the δ subunit and a second binding site is at the interface of the α and the γ subunit 
(analogous to α/β subunit interface in neuronal nAChRs) (Fig. I/1.7a) 24, 26. Six loops of 
amino acids, termed A-F, have been identified to participate in the formation of the 
ACh binding site. The principal component of the binding site comprises three loops A-
B-C, located on the α-subunit. They are involved in the binding of ACh 53. The 
complementary component of the binding pocket, made up of loops D-E-F, is located on 
the neighbouring subunit residues (α in homomeric, β in heteromeric) (Fig. I/1.7b) 26. 
The α subunit is defined by the presence of a cysteine pair (e.g. α1 Cys192-Cys193 in 
loop C) 24, 32. The loop B contains aromatic side chains (amino acid Trp 143, 
homologues to Trp 149 in torpedo), which are presumed to exert cation-π interaction 
with the quaternary ammonium group of ACh 54. At least two binding sites have to 
be occupied for a maximal activation of nAChR. The disulphide bridge between 
Cys192-Cys193 in loop C is essential for the stability of the open channel 
conformation 32.  
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Figure I/1.7: a: The subunit composition of the muscle type nicotinic acetylcholine receptors (α1, β1, γ 
and δ subunits in the fixed stoichiometry 2:1:1:1.). b: The principal component for the binding site, 
located on an α-subunit and formed by the three loops A-B-C. The complementary component of the 
binding pocket made up of loops D-E-F and located on a neighbouring subunit 55. 
 
Our understanding of the ligand binding sites has been greatly improved by the 
discovery of a soluble protein in a snail (Lymnaea stagnalis) from European fresh 
waters that binds nicotinic ligands and α-bungarotoxin (α-Bgt) 5 56. This 
acetylcholine-binding protein (AChBP) is produced and stored in glial cells and 
released into cholinergic synaptic clefts where it modulates synaptic transmission 56. 
Recently, Brejc reported the crystal structure of acetylcholine-binding protein 
(AChBP) at 2.7 Å resolutions 57. The X-ray crystallographic analysis of AChBP reveals 
an oligomer of five identical subunits (composed of 210 amino acid chains), arranged 
in an anticlockwise manner along an axis (Fig. I/1.8). AChBP amino acids domain 
resemble for ~ 24% the extracellular parts of the α subunit (α7). However, unlike 
nAChR, AChBP lacks the transmembranic and intracellular domains 56, 57. 
I. Introduction  11  nAChRs 
 
Figure I/1.8: The acetylcholine-binding protein (AChBP) viewed down the fivefold axis. Different 
colours are used to indicate the five subunits, and they are categorized as A, B, C, D or E. 
 
I/1.4.1. Allosteric binding sites 
The function of neuronal nAChRs is subject to modulation by a variety of 
compounds that interact at other receptors or other sites of the receptor protein. They 
belong to different classes of drugs, have different structures and can have activatory 
or inhibitory effects (Tab. I/1.1).  
Table I/1.1: Allosteric activators and allosteric inhibitors of AChRs 
Allosteric activators Allosteric inhibitors 
Physostigmine, Galantamine, Tacrine  
Ivermectine 
Benzoquinonium 
Codeine 
5-HT 
Ethanol a 
Phencyclidine, Chlorpromazine a 
Progesterone, Corticosterone, Dexamethasone b 
Nimodipine, Nifedipine c 
 a: binds to the negative allosteric site 
b: binds to the steroid site 
c: binds to the dihydropyridine site 
 
Non-competitive allosteric activator site: The allosteric activator combines with a 
site located on the α subunit of the receptor protein which is distinct from the 
classical binding site for ACh 1 58, 59. The acetylcholinesterase inhibitors, including 
galantamine 6, tacrine 7 and physostigmine 8 have been shown to act as allosterically 
potentiating ligands (APLs) (Fig. I/1.9). They increase the probability and the 
frequency of channel opening and thus potentiate the channel activity of nicotinic 
receptors in response to ACh 1 60-62.  
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Figure I/1.9: Structure of galantamine 6, tacrine 7 and physostigmine 8 
Other allosteric potentiators are for example the opiate codeine, the anthelminthic 
drug ivermectin 9 and the neurotransmitter serotonin (5-HT, µM range). Ivermectine 
9 potentiates ACh evoked currents at chick and human α7* nAChRs in Xenopous 
oocytes 63 (Fig. I/1.10).  
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Figure I/1.10: Structure of ivermectine 9 
Non-competitive negative allosteric site ligands: Negative allosteric ligands include 
ethanol, phencyclidine, chlorpromazine, local anaesthetics and barbiturates for 
instance (Tab. I/1.1). They inhibit ion channel function without interacting with the 
ACh binding site by acting on two distinct sites. The first site binds ligands in the 
nanomolar range (high affinity site). It is thought to be located within the ion channel 
and produces rapid reversible channel blockade by steric hindrance 25, 64. The second 
site binds ligands with low affinity (µM range) and is probably located at the 
interface between the lipid membrane and the receptor protein. 
Dihydropyridine site: Some Ca2+ channel antagonists such as nifedipine and 
nimodipine have been found able to block agonist induced activation of nicotinic 
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receptors. The mechanism of action is unknown, but it is assumed that they bind to a 
site that exists within the ion channel 65. 
Steroid binding site: The binding site for steroids is located in the extracellular 
hydrophilic domain that is distinct from the ACh 1 binding site. Progesterone, 
corticosterone and dexamethasone have been classified as negative allosteric 
effectors due to their ability to desensitise nAChRs 25, 66 (Tab. I/1.1). 
I/1.5. Transition and functional states of the nAChR 
The nAChR is a prototype of allosteric membrane protein 11. The term allosteric, from 
the Greek meaning “other site”, refers to the characteristic to possess multiple ligand 
binding sites. It also refers to other properties associated with classical allosteric 
proteins, such as multiple possible conformations and stabilization of specific protein 
conformation by ligands 19,67. The binding of a ligand to a specific allosteric site leads 
to a reversible alteration of the protein conformation that modifies the properties of 
the biologically active site. In 1965, Monod et al. proposed the first allosteric enzyme 
models 68. They hypothesized that 1) regulatory proteins are oligomers 2) the 
allosteric oligomers can spontaneously exist in a minimum of two freely 
interconvertible states (open↔closed) and 3) ligand binding stabilizes the state for 
which it has a higher affinity. Further investigation led to the hypothesis that the 
nAChR pass through a cycle involving three types of functional states: an active state 
(A), a desensitised state (D) and a resting state (R) 11,19 (Fig. I/1.11). The active state 
(A), when the channel is open (on a microsecond to millisecond scale), allows the 
passage of monovalent and divalent cations in favour of the electrochemical 
gradient. This state has a low affinity for ACh (1-10 µM) 12. The continued presence of 
any agonists leads to receptor desensitisation (D) and ion channel closure (R). In the 
desensitised condition, the receptor is refractory to activation (on a millisecond-
minute timescale) although it displays a higher affinity for agonist binding (ACh 10 
nM-1µM) 12, After a prolonged exposition to an agonist, the receptor in the 
desensitised channel state (D) (closed) may change to an inactivated state (I), from 
which the rate of recovery is very slow (Fig. I/1.11) 12. 
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Figure I/1.11: Transition and functional states of nicotinic receptors 
I/1.5.1. Up-regulation 
It is known that continued exposure to agonists causes receptor down-regulation, 
while over-exposure to antagonists induces receptor up-regulation 25. However, 
nicotinic receptors go against this convention: a prolonged exposure to an agonist 
produces an up-regulation, with an increase in the density of nicotine binding sites in 
the brain tissue 25,69. Two models have been proposed to explain the mechanism of 
functional up-regulation of α4β2* receptors (Fig. I/1.12) 70.  
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Figure I/1.12: Possible mechanisms for the functional up-regulation of α4ß2-subtype nicotinic 
acetylcholine receptors (nAChRs). a: The conformational equilibrium hypothesis. b: The ligand-locked 
receptor hypothesis70 . 
In the first model (Fig. I/1.12a), the conformational equilibrium hypothesis 
proposes that α4β2 receptors exist in two interconvertible states, one with high 
affinity for nicotine and the other with low affinity for nicotine, and that chronic 
exposure to nicotine (or an another nAChR ligand) stabilizes a larger fraction of 
receptors in the high affinity, large conductance state. In the second model (Fig. 
I/1.12b), the ligand-locked receptor hypothesis presumes that α4β2 receptors may 
be rapidly recycled on the cell membrane. Chronic exposure to nicotine slows down 
receptor endocytosis and increases the membrane density by inserting additional, 
pre-synthesized receptors (high affinity receptor) from a sub-membranous pool. 
NAChRs subtypes have different levels of sensitivity to up-regulation by nicotine 
exposure. For instance, α4β2 and α7 nAChRs are more sensitive to up-regulation 
than other subtypes 25. The α4β2 are readily up-regulated following chronic exposure 
to nicotine and return slowly to control levels 71,72. Instead, α3-containing nAChRs are 
usually less readily up-regulated, but appear to recover more rapidly from whatever 
up-regulation does occur 73. 
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I/1.6. NAChRs in the central nervous system 
I/1.6.1. Distribution of nAChRs in the brain 
The topographical distribution of nAChRs in the brain has been studied through 
various methods: immunohistological and immunoprecipitation experiments, 
radioligand binding and autoradiographic techniques. The subunit composition of 
functional receptors in different brain areas is an ongoing question. Zoli and others 
mapped the distribution of    (-)-[3H]ACh, (-)-[3H]nicotine, (-)-[3H]cytisine, (±)-
[3H]epibatidine and [125I]α-Bgt binding site in β2 knock-out (KO) mice and wild mice 
74. Through autoradiographic and patch clamp studies they identified four types of 
nAChRs (Table I/1.2) 74. 
Table I/1.2: Classification of nAChRs in the mouse brain 74. 
Receptor 
type 
Subunit 
composition 
Predominant localization in CNS Pharmacology 
I α7 
cortex, limbic area, hippocampal 
formation, hypothalamus and other 
telencephalic areas 
α-Bgt and MLA sensitive 
very fast desensitising 
α4β2 (α5?) CNS 
(α2?)β2 interpeduncular nucleus 
(α3?)β2 hippocampus 
II 
(α6β3?)β2 catecholaminergic nuclei 
nicotine > cytisine 
III α3β4 (α5?) 
medial habenula, interpeduncular 
nucleus, dorsal medulla 
MLA-insensitive 
(concentration 
dependent) 
nicotine = cytisine 
(α4β4?) lateral habenula 
IV 
(α2β4?) dorsal interpeduncular nucleus 
MLA insensitive 
nicotine = cytisine 
 
Type I - receptors: they are α-Bgt and MLA sensitive. Their distribution does not 
change in β2 -/- KO mice, whereas they disappear in α7* mutant mice. The α7* 
nAChRs are present in high density in the hippocampal formation, hypothalamus 
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and other telencephalic areas 75,76. This subunit distribution correlates well with the 
high level of [125I]α-Bgt binding in these regions (KD = 1 nM for [125I]α-Bgt) 75. 
Type II- receptors: They contain the β2 subunit and represent the vast majority of 
nAChRs in the mouse brain. (-)-[3H]nicotine-binding sites disappear in β2 -/- KO 
mice. The composition of the major expressed subunits is α4β2*nAChRs which are all 
localized ubiquitously in the CNS. They are present in high density in the cerebral 
cortex (layers III and IV), thalamus, ventral tegmental area (VTA), the media 
habenula and substantia nigra. 77 (Tab. I/1.2). Other subunits, namely α2, α3 and α5, 
are likely to co-assemble with β2 78 and β4 79. The α3β2* nAChR is reported to be 
expressed mostly in the CNS, in the habenula system and in dopaminergic regions 80. 
In situ hybridisation studies of the α6 mRNA in the adult rat central nervous system 
show that the distribution is especially high in several catecholaminergic nuclei, the 
locus coeruleus, the ventral tegmental area and the substantia nigra 81,82. The β3 
subunit is predominantly present in the midbrain 79,83. It has to be co-expressed with 
other subunits, such as α3, α4, α6 or β2/β4 to form functional receptors.  
Type III- receptors: They do not contain the β2 subunit; but they bind (±)-epibatidine 
13 with high affinity in equilibrium binding experiments. The type III corresponds to 
the distribution of α3β4* nAChRs. This subtype is predominant in ganglions, in 
MHb, in the habenulo-peduncular system, in the locus coeruleus, area postrema, 
cerebellum and the pineal gland 79, 80, 83. The α5 subunit can participate in α3β4* 
receptors with αxαyβ combinations 44, 84. 
Type IV-receptors: These receptors do not contain β2 subunit. They bind (±)-
[3H]epibatidine and (-)-[3H]cytisine with high affinity, but the binding of other 
nicotinic agonists is limited or absent. They display a faster desensitisation rate 
suggesting a composition of α2 and α4 with β4 46, 74. 
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I/1.6.2. Distribution and function of nAChRs in the autonomous nervous system 
(ANS) 
The CNS integrates the sensory inputs and sends neuronal commands back to the 
organ through the ANS. Autonomic ganglia are the peripheral sites for the control of 
organs and tissues by the nervous system. Nicotinic acetylcholine receptors are 
involved in the neuronal information process because they are mediators of fast 
synaptic transmission in ganglia 85. Ganglionic nAChRs possess different functional 
and pharmacological characteristics due to the expression of various nAChRs 
subunits. Despite their various functions, they share some common features, 
including relatively slow gating, moderate Ca2+ permeability and significant 
rectification of the postsynaptic responses 86. Autonomic ganglia present high levels 
of mRNA coding for α3 and β4 nAChRs subunits, but they also contain transcripts 
for α4, α5, α7 and β2 nAChRs subunits 87-89. In vivo and in vitro studies indicate that 
the principal receptors involved in neurotransmission in the intracardiac ganglia 
contain at least two different subtypes on nAChRs: one consist of α3β4 subunits and 
one of α7 subunits 89,90. For instance, it was found that α3 subunits in the rat are 
mostly combined with β4 and it seems that this subunit combination contributes to 
the positive chronotropic effects of nicotine, resulting in an increase in the heart rate 
91. The α7 subunit is expressed in both para- and sympathetic neurons innervating 
the heart, whereby they contribute to the negative chronotropic effects, resulting in 
decrease in the heart rate 91. It has been suggested that α7 in the rat intrinsic cardiac 
neurons interact with other nAChRs subunit to form heteromeric nAChRs 91. 
NAChRs in ANS are also involved in the control of other organ systems, such as the 
gut and bladder systems 92. Very little information is available about the subunit 
composition of nAChRs in these organs. The presence of β2 and β4 subunits was 
revealed from the disruption of gut mobility in mutant mice lacking these two 
subunit nAChRs 89. Recent studies also reported the presence of α3 in the human gut 
93. Furthermore, nAChR containing the α3β4 subtype are able to mediate ganglionic 
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transmission in the bladder 92. In fact, nicotine failed to induce the contraction of the 
bladder smooth muscle in α3, β2 and β4 null-mutant mice 93. 
I/1.7. Distribution and function of nAChRs in non-neuronal cells 
There is growing evidence that activation of nAChRs via acetylcholine 1 can 
modulate some cellular functions outside the synaptic transmission in the central and 
peripheral nervous system. This is supported by the fact that non-neuronal cells, 
such as skin keratinocytes 94, bronchial epithelial 95, aortic endothelial cells and 
immune tissue, express functional nAChRs of various subtypes (Tab. I/1.3) 96, 97. Skok 
et al. identified α4 and α7-containing nAChRs in B-lymphocyte cell lines by using a 
various α-subunit specific antibody 97. The localization of nAChRs in lymphocytes is 
of special interest because it would demonstrate the participation of α7* nAChRs in 
the promotion of tumor cell proliferation as well as in antibody production 97. In situ 
hybridisation studies revealed that the α9 and α10 subunits are distributed in the 
lymphoid system (tonsil, thymus and spleen) 41,98. The α9 subunit is expressed in 
sensory organs and in particular in outer hair cells where it modulates the encoding 
of auditory stimuli 49 (Table I/1.3).  
Table I/1.3: Distribution of nAChRs in non-neuronal cells 
Cell type Subunit Reference 
Lymphocytes α7, α4, α9 and α10 97 
Vascular endothelial cells (human) α3, α5, α7, β4, β2 99 
Bronchial epithelium (human, rat) α3, α5, α7, β4, β 95 
Keratocytes α5, α3, 94 
 
I/1.8. Knock-out (KO) mice  
The creation of knock-out mice, missing one or more genes for the nAChRs subunits, 
or mice which express mutant genes 100 paves the way for the investigation of the 
relationship between subunit diversity and in vivo receptor function in the brain and 
in the autonomous nervous system (ANS) 101-104. KO mice have been created lacking 
the α3 88, α4 102,103 α5 85, α6 104, α7* 105, α9 106, β2 74, 89 or β4 89 subunit. The antinociceptive 
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effects of nicotine are reduced in both α4 and β2 null mutant mice 102. Mice lacking 
the β2 have a superficial normal phenotype, but show abnormal passive avoidance 
and increased neurodegeneration 101, 107, 108. The lack of the nAChR β4 subunit alters 
the behavioural responses to certain anxiety-provoking experimental paradigms 109. 
Mice lacking β2 and β4 have some autonomic nervous system defects, such as 
enlarged bladder and dilated ocular pupils 89. The deletion of β3 subunit increases 
locomotors activity, a behaviour that is related to alterations in nicotine-induced 
dopamine release in the striatum 110. Mice lacking the α6 subunit did not display any 
obvious neuro-anatomical or behavioural abnormalities 104. Neither the α5 nor α4 
subunits are obligatory for normal development and survival 85. The α5 null mice 
grow to adulthood with no visible phenotypic abnormalities and show normal 
behaviour in basic conditions 85. The function of the α3 subunit, which is expressed 
ubiquitously in autonomic ganglia and in some parts of the brain, is poorly 
understood in the living system. KO mice lacking the α3 subunit usually die in the 
first week after birth due to multiorgan autonomic dysfunction 88. The phenotype in 
α3 (-/-) mice may be similar to the rare human genetic disorder of megacystis-
microcolon-intestinal-hypo-peristalsis syndrome 111. Moreover, the α3-KO-mice 
exhibit extreme bladder enlargement, dribbling urination, bladder infection, urinary 
stones, and widely dilated ocular pupils that do not contract in response to light. 
These conditions can be attributed to a failure of α3 in the autonomic ganglia 88. KO 
mice lacking the α9 subunit showed abnormal development of synaptic connections 
in the cochlear outer hair cells 106. 
 
 
 
 
 
 
 
I. Introduction  21  nAChRs 
I/1.9. Pathophysiology 
Interest in the field of neuronal nicotinic receptors has recently been stimulated by 
the discovery of the association between the decrease of nicotinic receptors in 
binding sites or mutation and between human neurobiological and psychiatric 
conditions, such as attention-deficit disorders, Parkinson’s disease, Alzheimer’s 
disease, schizophrenia, Tourette’s syndrome, epilepsy, anxiety, depression, tobacco 
dependence or analgesia 112, 113 (Tab. I/1.4).  
Table I/1.4: Classification and brain location of subunits linked to pathological conditions 
Subunit involved Brain location 
Physiological functions and 
Pathological links 
α4, α5, α7, α3, α4, β2 Temporal and frontal cortex 
Hippocampus 
Possible role in AD 114, 115 
α4 mutation (replacing a serine 
at position 247 of the M2 channel 
with a phenylalanine)  
All layers of the frontal cortex Human autosomal dominant 
nocturnal frontal lobe 
epilepsy 116 
α7 (dinucleotide polymorphism 
at chromosome 15, which is the 
locus for the α7 nAChR) 
CA 3 regions of hippocampus 
Auditory cortex  
Visual cortex 
Schizophrenia 117 
α4 Nucleus raphé magnus Pain 118 
β2 Mesolymbic regions  Nicotine addiction108 
 
NAChRs, which were expressed in non-neuronal cells, have been found to be 
responsible for the development of other illnesses, such as cell lung carcinoma, 
respiratory disease, asthma, chronic bronchitis, tumours, skin aging, arteriosclerosis, 
megacystis-microcolon-intestinal hypoperistalsis syndrome and Chron’s disease. 
Advances in the understanding of the structure, function and the distribution of 
nAChRs in the CNS and non-neuronal cells are required to understand the role that 
these receptors may play in the human physiology 119. 
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I/1.9.1. Tobacco Dependence 
Tobacco dependence is the most common substance abuse disorder and preventable 
cause of death in the United States 120. Over three million smoking related deaths are 
reported annually worldwide 120. Smoking contributes to coronary heart disease, 
stroke, vascular disease, chronic lung disease and lung cancer. Although the dangers 
of smoking are well known, people continue to smoke and tobacco use is increasing 
in many developing countries 121. Even though tobacco smoke contains more than 
4,000 chemical compounds, the alkaloid nicotine is recognized as the primary 
psychoactive ingredient in tobacco. It is considered to be responsible for the 
withdrawal syndrome, tolerance and dependence effects of smoking in both animals 
and humans 122, 123. Nicotine 3 and other addictive drugs, such as cocaine, heroin and 
marijuana generate feelings of pleasure in combination with an increased level of the 
neurotransmitter dopamine in the nucleus accumbens (nACC) and ventral tegmental 
area (VTA) in the mesolymbic region which control the mesolymbic reward-
pathways in humans and other species 124, 125. A particular subunit, the β2, has been 
pinpointed as a critical component in nicotine addiction. Mice that lack this subunit 
fail to self-administer nicotine, implying that without the β2 subunit mice do not 
experience the positive reinforcing properties of nicotine 108. 
I/1.9.2. Alzheimer’s Disease (AD) 
AD is a progressive neurodegenerative disorder affecting almost one in 10 
individuals over the age of 65. It is correlated to deterioration of higher cognitive 
function and memory related dysfunctions. Clinical manifestation of AD is first 
observed as short-term memory, progressing to language problems, social 
withdrawal, and deterioration of executive function 119. The histological hallmark of 
AD is the deposition of β-amyloid plaques in the limbic, cerebral cortices (mainly 
extra-cellular deposit) 126, 127 and the formation of neurofibrillary tangles in neurons 
(intra-cellularly) 128. The major constituents of the amyloid plaques are β-amyloid 
peptides, derived from the proteolytic cleavage of the amyloid precursor protein 
(APP) that is present in almost all tissues and whose physiological functions are still 
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unknown 126, 127. The most consistent and severe neurochemical abnormality 
associated with AD is the loss of cholinergic innervations of the cerebral cortex and 
hippocampus 115 ("cholinergic hypothesis”) 129. Loss of high affinity binding sites, 
measured in post-mortem tissue, is a consistent marker of AD 130. Evidence indicates 
that α4β2 nAChRs constitute the major subtype of nAChRs lost in AD, associated 
with a dramatic reduction in the cortex of α4 (but not α3 or α7) nAChRs subunits 
80,114,130. These data are also supported by the observation that α4 and β2 subunit 
mRNA levels decrease in the frontal cortex of human brain with age 62. Many 
therapeutic agents for AD are under development. The design of clinical trials has 
been hampered by the difficulty of identifying patients at an early stage of the 
disease. Even today, the only FDA approved drugs for symptomatic treatment of AD 
are inhibitors of acetylcholinesterase (e.g. tacrine 7 (Cognex), donepezil (Aricept), 
rivastigmine (Exelon) and galantamine 6 (Reminyl)) 131. These agents do not stop 
the progression of the disease but rather prevent the breakdown of ACh that is 
released from cholinergic neurons and thereby increase the concentration of the 
transmitter that is able to interact with the receptors. Other strategies have been 
investigated to enhance the cholinergic function, such as the use of precursors, e.g. 
choline 4, as well as the use of other nicotinic and muscarinic agonists. However, up 
to now, none of these strategies have been proven to be effective, due to poor 
bioavailability, limited efficacy and various side effects. In 1999, Potter et al. 
examined the effects of the novel selective cholinergic channel activator (ChCA) 
ABT-418 10 on cognitive functioning in Alzheimer's disease 132. Improvements were 
seen in non-verbal learning tasks such as spatial learning, memory and repeated 
acquisition 133. These findings suggest that selective ChCAs have a potential as 
therapeutic agents in neurodegenerative disorders. Nevertheless, further study into 
AD and/or Parkinson's disease is warranted. 
I/1.9.3. Parkinson's disease 
Parkinson’s disease is a progressive neurodegenerative disease, involving the 
dopaminergic neurons of the substantia nigra. 114. It is characterized by motor 
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dysfunction resulting in muscular rigidity, tremor and difficulty in initiating and 
sustaining movement. In addition to the movement disorder, PD patients often show 
cognitive impairment or dementia due to the loss of cholinergic transmission 134. 
Receptor binding studies with (-)-[3H]nicotine demonstrated a decrease of up to 50% 
ligand binding site in the frontal and temporal cortex and hippocampus. These 
regions are associated with memory and teaching 80. Nicotine administration may be 
neuroprotective in animal models of nigrostriatal degeneration. In fact, smokers were 
observed to have a lower incidence of PD than the rest of the population, with half 
the risk of developing PD 135. Prolonged nicotine administration prevents neuronal 
dopaminergic degeneration and increases synaptic dopamine levels in the substantia 
nigra and striatum 133. These positive effects are probably due to an inhibition of 
dopamine breakdown by MAO-B 136. With regard to the nAChRs subtype involved, 
recent evidence suggests the participation of the synaptic α4-containing receptors 137. 
In fact, the nicotine analogue, SIB-1508Y 11, selective for the α4β2 nAChRs 
demonstrated to be active in experimental models of PD 138. The neuroprotective 
effects of nicotine also involve the activation of α7 receptors 134, 139. Stimulation of this 
nAChRs subtype determines a Ca2+ influx that triggers a wide range of processes, 
including an increase of neurotrophic factors in the brain 139. 
I/1.9.4. Dementia with Lewy Bodies 
Dementia with Lewy Bodies is reported (after Alzheimer’s) to be the second most 
common degenerative disease associated with ageing 140. It is characterized by a loss 
of nicotinic receptors from dopaminergic neurons, and a higher reduction of nicotine 
binding in the parietal cortex and in the reticular nucleus 140. 
I/1.9.5. Tourette's syndrome 
Gilles de la Tourette’s syndrome (TS) is a neuropsychiatry disorder of unknown 
aetiology and is probably transmitted in an autosomal dominant manner. It is 
generally diagnosed before the age of 18 and involves severe learning difficulties, 
persistent motor and verbal tics; as well as anxieties, phobias or obsessive-
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compulsive disorders 25,39,141. The pathogenesis is not yet known. The disease is 
believed to be associated with abnormal dopamine-transmission in the basal ganglia 
via a receptor hypersensibilitation. A number of studies support the thesis that oral 
or transdermal administration of nicotine may enhance cognition, thus ameliorating 
the symptoms of TS in therapy with neuroleptics such as haloperidol 142-144. The 
underlying mechanistic principle for using nicotine with beneficial effects in TS is 
still unclear. It may possibly involve modulation of dopamine release or is related to 
a desensitization and eventually permanent inactivation of nAChRs (in particular 
α4β2 and α7 nAChRs) 25, 145. Studies with antagonists such as mecamylamine 12 or 
agonists with desensiting properties are therefore of great interest 143. 
I/1.9.6. Schizophrenia 
Schizophrenia is a common and complex disorder with diverse symptoms including 
auditory hallucinations, delusion and flat affect 146. Neuronal nicotinic receptors have 
been implicated in the occurrence of schizophrenia on the basis of several reasons. 
The first is due to the high incidence of tobacco smoking in patients effected by this 
disease, which was 90% compared to 30% of the control group 147, 148. Secondly, [125I]-
α-Bgt binding sites in the hippocampus have been reduced in post-mortem tissue 117, 
149. Finally, the linkage between auditory P50 deficits and the region of chromosome 
15 coding the α7 nAChR subunit has to be taken into account 146. In fact, P50 auditory 
evoked potential gating deficit is a neuronal defect, considered to be characteristic of 
schizophrenia. The inheritance has been linked to a dinucleotide polymorphism at 
chromosome 15 q13-14 that is also the locus for the α7 subunit gene 149. 
I/1.9.7. Epilepsy 
Epilepsy affects around 1% of the general population 39. Autosomal dominant 
nocturnal frontal lobe epilepsy (ADNFLE) is the human idiopathic epilepsy that was 
first linked to specific gene defects. It has been associated with mutations in the gene 
coding for either the α4 or β2 subunit of the nAChRs 150. The gene coding for the α4 
subunit is located on chromosome 20(20q.13.33) and the gene coding for β2 subunit is 
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on chromosome 1q.23.1. To date, five different mutations that lead to ADNFLE have 
been identified in different families 116, 151, 152. It is genetically transmitted in an 
autosomal dominant mode 153; this indicates that sufferers are heterozygous for this 
locus and carry one normal and one mutated allele. ADNFLE is characterized by a 
seizure that originates from the frontal lobe during sleep. In more than half of the 
patients, the seizures start in the first or second decade of the expected lifetime 151, 154. 
One minor locus has been identified for this disorder, but additional loci are still to 
be discovered 152. 
I/1.9.8. Depression 
A considerable body of evidence shows a positive correlation between nicotine 
dependence and major depression 132, 155. Bupropion, originally marketed as an 
atypical antidepressant, was the first non-nicotine drug that demonstrates efficacy in 
the treatment of tobacco dependence (Wellbutrin®; GlaxoSmithKline) 156. Individuals 
with major depression may use nicotine 3 as a form of self-medication, since nAChR 
activation enhances the release of some neurotransmitters (norepinephrine (NE), 
dopamine (DA), serotonine (5-HT) that are reduced in depression 119. Various 
antidepressants act through modulation of the biogenic amine neurotransmitter 
pathway, e.g. MAO-inhibitor drugs. MAO A and B are enzymes with different 
substrate and inhibitor specifities, responsible for breaking down the biogenic amine 
neurotransmitters norepinephrine, serotonine, and dopamine. Recently, it has been 
shown that smokers have reduced levels of MAO, both in peripheral organs as well 
as in the brain 136. 
I/1.9.9. Pain 
In the U.S.A., more than 100 million people will suffer from moderate to severe pain 
within any year 118. There are several therapeutic approaches towards pain relief, and 
the most powerful agents so far are those that bind to opioid receptors and inhibitors 
of cyclooxygenase (NSAIDs). Both general classes of agents have undesirable side 
effects. This has prompted a search for mechanistically different analgesic agents. 
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Activation of the cholinergic pathway through smoking and nicotine has been shown 
to reduce pain in humans. The analgesic effect of nicotine 3 was first reported in the 
early 1930s. However, interest in nAChRs agonists as potential analgesics emerged 
after the discovery of the frog alkaloid, (±)-epibatidine 13 by Daly et al. The 
antinociceptive effect of (±)-epibatidine 13 is 200 times stronger than morphine by 
acting on nAChRs rather than on opioid receptors 157. Although analgesic properties 
of (±)-epibatidine 13 and other nAChRs agonists have been known for many years, 
high toxicity has reduced the therapeutic potential of these drugs. The receptor, 
which seems to be involved with antinociception, is composed of α4β2 118. Selective 
compounds have been designed that show a separation of antinociception from toxic 
effects, which seems to be correlated with selectivity for the brain nACh receptors 
over the ganglionic and neuromuscular subtypes 158. One such example is ABT-594 
14, highly selective for α4β2* nAChRs. It has more than 5 fold greater separation 
between antinociceptive and lethal doses than epibatidine 118, 159. Due to its improved 
safety profile, ABT-594 14 is currently in Phase II clinical trials as analgesic. The role 
of nAChRs in analgesia is further supported by the discovery that nicotinic 
antinociception is reduced in α4 and β2 knockout mice. Marubio et al. identified the 
particular subunit involved in analgesic processes by generating mice with a 
deficiency of the α4 subunit and studying these together with previously generated 
mutant mice lacking the β2 nAChRs subunit 102. However, there is evidence that 
other subtypes may also be involved 102. 
I/1.9.10. Inflammation  
The immune system is responsible for the involuntary setting in motion of 
inflammatory responses 160. Excessive inflammation and the tumour-necrosis factor 
(TNF) synthesis cause morbidity and mortality in the form of several human 
diseases, including endotoxaemia, sepsis, rheumatoid arthritis and inflammatory 
bowel disease 160,161. Through a “cholinergic anti-inflammatory pathway”, 
acetylcholine can inhibit the release of macrophage TNF in the nervous system 
significantly and rapidly. The α7* nAChRs is the nAChR subtype considered to be 
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involved to attenuate systemic inflammatory responses inhibiting excessive 
inflammation and tumour-necrosis factor (TNF) release 162,163. 
I/1.9.11. Ulcerative colitis 
Several epidemiological studies report that smoking has predictable effects on 
inflammatory bowel disease (IBD) 164, 165. It is beneficial in ulcerative colitis (UC) but 
deleterious in Chron’s disease (CD) 164, 166. The positive effects of smoking have been 
attributed to nicotine, but the mechanisms that underlie the adverse effect are still 
under investigation 167. As nicotine delays the developing of ulcerative colitis and 
improves the clinical pattern, transdermal nicotine could be used therapeutically as a 
drug for this disease 161. In contrast, smoking and passive smoking increase the risk of 
developing CD. These effects could be due to the different influences of nicotine on 
the autonomic nervous system 167. 
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I/2. Modulators on nAChRs 
I/2.1. Nicotine and its pharmacological action in the ANS and CNS 
(S)(-)-Nicotine 3 is the natural ligand that gives the name to the receptor. (S)(-)-
Nicotine stimulates nicotinic receptors found on muscle cells, within autonomic 
ganglia and within the central nervous system 168.  
I/2.2.1. Nicotine as ganglionic stimulating drug 
In the peripheral nervous system and within autonomic ganglia, the pharmacological 
actions of (-)-nicotine 3 are complex. In fact, (-)-nicotine 3 acts on both sympathetic 
and parasympathetic ganglia and its stimulation is frequently followed by 
depolarisation blockade. The effects of (-)-nicotine 3 include: 
• Stimulation of the release of epinephrine from the adrenal medulla. 
• Excitation of the cardiorespiratory reflexes by a direct effect on the 
chemoreceptors of the carotid and aortic bodies. 
• Excitation of cardiovascular responses secondary to evoked blood pressure 
changes mediated by baroreceptors. 
• Stimulation and blocking of CNS cholinergic pathways in the medulla 
influencing heart rate. 
Activation of autonomic ganglia in the CNS causes tremors, which leads to 
convulsions as the dose is increased. Another nicotine effect in the central nervous 
system (CNS) is the stimulation of the area postrema i.e. the chemoreceptor trigger 
zone that induces vomiting 169.  
Nicotinic receptors in ganglia can be blocked by ganglionic blockers, such as 
hexamethonium 15, trimethapan 16 and mecamylamine 12 (Fig. I/2.1). These 
structures possess different mechanism of action. Hexamethonium 15 and related 
agents interfere with the ACh receptor directly, blocking the ion channel. 
Trimetaphan 16 and mecamylamine 12 are competitive antagonists. They block 
ganglionic transmission in ANS by competition with ACh 1. Trimethaphan 16 has 
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two direct effects: vasodilatation and histamine release, therefore it has been used to 
induce controlled hypotension (Fig. I/2.1). 
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Figure I/2.1: Structures of the ganglionic blockers: mecamylamine 12, hexamethonium 15 and 
trimethapan 16 
I/2.1.2.  Nicotine as CNS stimulating drug 
(-)-Nicotine 3 acts on nAChRs widely distributed in the brain. Low doses of (-)-
nicotine 3 (6-8 mg) facilitate relaxation and cause mild euphoria. (-)-Nicotine 3 also 
causes acetylcholine and norepinephrine levels to raise facilitating performance and 
memory ability, so improving attention as well as problem-solving skills. Its 
increasing dopamine level causes pleasure enhancement. The release of endorphins 
reduces anxiety and tension, whilst weights gain decrease by appetite reduction. 
I/2.1.3.  Potential therapeutic effects of nicotine 
In the past, nicotinic acetylcholine receptor ligands were used only as ganglioplegic, 
for the management of hypertension, or as neuromuscular blockers. Only the 
peripheral effect of nicotine stimulation was taken under consideration 170. The 
potential therapeutic actions of nicotine and its use as a drug are, like some other 
natural compounds, limited by some detrimental effect (neuromuscular paralysis, 
respiratory distress, hypertension, hypothermia, emesis and dependence). The 
collateral effect is due to the lack of nicotine’s ability in discriminating between 
activation of receptors in the ANS (sympathetic and parasympathetic ganglia) and 
neuromuscular junction. In recent years, interest in the field of neuronal nicotinic 
receptors has grown. The pharmacological effect elicited by (-)-nicotine 3 in the 
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central nervous system have been taken into consideration in view of the 
involvement of nicotine in many neurodegenerative diseases. Synthetic and semi-
synthetic new compounds, based mostly on the structure of natural products of 
plants and animals, have been synthesized and investigated in order to improve 
potency and selectivity and to reduce the toxicity.  
I/2.2. Modulators on nAChRs (small ligand based) 
Choline (Ch)  
Choline 4 is the precursor and metabolite of acetylcholine 1 (Fig. I/2.2). It is a full 
agonist for α7* nAChRs (EC50 = 1.6 mM) even if it presents very low affinities for 
α4β2* (Ki = 112 µM) and α7* nAChRs (Ki = 2.2 mM) in binding assays 171. Although its 
concentration in the brain is not exactly known, it is accepted that at concentrations 
above 200 µM, choline 4 activates α7* receptors 171. There are some speculations that 
choline 4 rather than acetylcholine 1 was the natural transmitter for α7*, and that the 
evolution to ACh 1 was in part caused by the need to have a “two step transmitter”, 
i.e. a rapidly acting, rapidly inactivable one (ACh) 1 and a more slowly removed one 
(choline) 4 172. 
Acetylcholine (ACh) 
The neurotransmitter acetylcholine (ACh) 1 is the endogenous agonist for nAChRs 
and mAChRs (Fig. I/2.2). Acetylcholine 1 binds with high affinity at α4β2* (Ki = 10 
nM) 173, α3β4* (Ki = 560 nM) 174 and muscle type (Ki = 15 nM, Torpedo californica, 
[3H]ACh) 175, but with lower affinity to α7* (Ki = 4,000 nM). Its utility as nicotinic 
ligand is limited by its lack of selectivity for nAChRs versus muscarinic and its 
susceptibility to hydrolysis. 
CH3
N
+
CH3
OH
CH3
CH3
N
+
CH3
O
CH3
CH3
O
4                                                          1  
Figure I/2.2: Structures of the endogenous ligands choline (Ch) 4 and acetylcholine (ACh) 1 
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 Structural analogues of Acetylcholine 
Modification of the ammonium group e.g. replacement of one N-methyl by an ethyl 
group permits retention of cholinergic activity, while a replacement by a longer 
substituent, such as a n-propyl or n-butyl group causes almost a complete loss of 
cholinergic activity. 176. The presence of a methyl in α-position (Fig. I/2.2) enhances 
the nicotinic activity versus the muscarinic. 
CCh, MCC, DMCC 
Stabilization of the ester group of ACh as a carbamate group gives the hydrolysis 
resistant analogue carbamylcholine 17 (carbachol, CCh). CCh has been widely used 
as a mAChR agonist although it possesses a moderate affinity to neuronal α4β2* 
nAChRs (Ki = 750 nM) 177. Introduction of one or two methyl groups at the carbamate 
nitrogen of CCh 17 gives N-methylcarbamoylcholine (MCC) 18 and N,N-
dimethylcarbamoylcholine (DMCC) 19 respectively (Fig. I/2.3), which display 
nanomolar binding affinities to nAChRs and a high degree of selectivity for nicotinic 
versus muscarinic ACh receptors (neuronal / muscarinic ratio is 7 for MCC 18 and 60 
for DMCC) 19 177. 
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Figure I/2.3: Analogues of acetylcholine: CCh 17, MCC 18 and DMCC 19. 
 
(S)(-)-AR-R17779 20 Spiro[1-azabicyclo[2.2.2]octane-3,5´-oxazolidin-2´-one] is a 
conformationally restricted analogue of acetylcholine (Fig. I/2.4). It is a full agonist 
for the α7* nicotinic receptor (efficacy = 96% compared to ACh). 178 and twice as 
potent as (-)-nicotine 3 in activating ion current at α7 receptor expressed in Xenopus 
oocytes. Its (S) enantiomer possesses selectivity for the α7* receptor versus the α4β2* 
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nicotinic receptor (Ki = 92 nM for α7* and Ki = 16,000 nM for α4β2*) 178. Introduction 
of a methyl group to the amide nitrogen reduces the affinity for α7* (Ki = 220 nM) 
increasing that for α4β2* (Ki = 200 nM) 178.  
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Figure I/2.4: (-) AR-R17779 20 
(-)-Nicotine 
(-)-Nicotine 3 (S)-3-(1-methyl-2-pyrrolidin-yl)-pyridin binds with high affinity to α4β2* 
nAChRs using (±)-[3H]epibatidine (Ki = 0.838 nM) in competition experiment 179. 
However, a lower affinity was shown towards the α7* nAChR (Ki = 127 nM) when 
tested in competition assays with [125I]α-Bgt and a micromolar affinity (Ki = 1 µM) 
was shown using [125I]α-Bgt and Torpedo californica 180. (-)-Nicotine 3 is widely used in 
behavioural studies because it can readily cross the blood brain barrier and its 
pharmacokinetics is well documented. But its utility as a tracer for in vivo imaging 
(PET and SPECT) of nAChRs in the human brain was hindered due to its rapid 
clearance and relatively low affinity 181,182.  (-)[3H]Nicotine is also used in radioligand 
binding assays to label primarily the α4β2* 74 but it has some negative aspects, due to 
its instability, high non-specific binding and light sensitivity 183. 
Structural analogues of nicotine  
Since the discovery of the potentially therapeutic use of (-)-nicotine 3 and nicotinic 
derivatives for treatments of a variety of cognitive disorders, different scientists have 
focused their attention on developing novel analogues of this alkaloid 3. Synthetic 
modifications at different positions of the skeletal structure of 3 have been carried 
out in order to improve the potency, selectivity, and stability as well as to reduce its 
toxicity (Fig. I/2.5) 184. The question was to find out the structural features required 
for the high affinity binding of nicotine related compounds. Four principal parts of 
the (-)-nicotine 3 structure were investigated:  
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Figure I/2.5: Structure of (S)(-)-nicotine 3 and its possible sites of substitution. 
Only small substituents in position 5 and 6 at the pyridine ring are tolerated and can 
even slightly improve the affinity in comparison to (-)-nicotine 3 185 (Fig. I/2.5 part a). 
Bromine and methoxy substitution at position C-5 of the pyridine moiety 186 despite 
their high affinity (Ki = 6.9 and 14.3 nM, (-)-[3H]nicotine, rat brain) do not show 
antinociceptive, hypolocomotor or hypothermic effects in mice. Introduction of a 
halogen at position C-6 markedly enhances α4β2* affinity, (6-Br > 6-Cl > 6-F) (Ki = 
0.45, 0.63, and 1.3 nM)187. Small aliphatic and alkyl moieties are accepted at this 
position, whereas a decrease in affinity is observed upon the introduction of a polar 
group, such as a hydroxyl moiety at position C-6 (Ki = 1062 nM) 187, 188. As far as 
substitutions at the pyrrolidine nitrogen are concerned, it has been demonstrated that 
both (R) and (S)-nornicotine 21 bind to the agonist site in the brain with 10- to 20-fold 
lower affinity than (-)-nicotine 3 (Fig. I/2.5 part b). N-alkyl substitutions on the 
cationic side are detrimental for the affinity to α4β2* 184, confirming that an N-methyl 
substituent might be optimal for the binding of (-)-nicotine 3 to the receptor. Since (-)-
nicotine 3 possesses a chiral atom, the ability of the two enantiomers to interact with 
the receptor has been investigated. It has been found that (S)-nicotine is 10-100 fold 
more potent than the (R)-enantiomer 13 (Fig. I/2.5 part c). With regard to the 
pyrrolidine ring, its aromatisation or opening has been proved to be detrimental to 
the affinity 189, 190. Damaj and co-workers found that an intact pyrrolidine ring would 
seem to be indispensable for nicotinic activity 184. Introduction of a large substituent 
at the R4’ and R5’ positions in the pyrrolidine ring is detrimental to the binding 
affinity (Fig. I/2.5 part d) 191. In the last years, some interesting analogues of (-)-
nicotine 3 have been synthesized and tested. 
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SIB-1508Y 11 3-ethynyl-5-(1-methyl-pyrrolidin-2-yl)-pyridine (Altinicline) 185, 192 is 
a 5-substituted nicotine derivative characterized by a 5-ethinyl group (Fig. I/2.6). It 
possesses high affinity (Ki = 3 nM) for (-)-[3H]nicotine binding sites in the rat brain. 
Given the ability to stimulate release of dopamine from rat striatum, it is under 
clinical evaluation for the treatment of Parkinson’s disease 193, 194.  
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Figure I/2.6: Structures of SIB-1508Y 11 and SIB-1663 22 
SIB-1663 22 7-methoxy-2,3,3a,4,5,9b-hexahydro-1-H-pyrrolo[3,2-h]isoquinoline is a 
novel conformational restricted analogue of nicotine, (IC 50 =1.9 µM) ((-)-[3H]nicotine 
in rat brain) 195 (Fig. 2.6). Mecamylamine 12, DHβE 36, atropine or naloxone do not 
block the analgesic activity of this constrained derivative. Therefore its pain-relieving 
function might be due to interactions with a different binding site which is not 
labelled by (-)-[3H]nicotine 184. 
SIB-1553A 23 4-[2-((S)1-methyl-pyrrolidin-2-yl)ethylsulfanyl]phenol is a derivative 
of (-)-nicotine 3. A thio-ethyl connector was introduced to separate the pyrrolidine 
ring from a phenol ring (Fig. I/2.7). SIB-1553A 23 represents a pharmacological tool to 
explore the function of specific nAChR subtypes, given the fact that it is presently one 
of the few β4 subunit-selective ligands described in literature 196. 
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Figure I/2. 7: Structures of SIB-1553A 23 and TC-2559 24 
TC-2559 24 4-(5-ethoxy-pyridin-3-yl]-but-3-enyl]methyl-amine is a metanicotine 
analogue described by the Targacept company (Fig. I/2.7). This compound is 
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reported to be markedly selective for neuronal nAChRs (Ki = 5 nM α4β2*, (-)-
[3H]nicotine, rat brain thalamic tissue) compared to ganglionic and peripheral 
nAChRs (selectivity ratio for central nervous system (CNS) to peripheral nervous 
system (PNS) > 4,000) 197.  
ABT-418 10 3-methyl-5- ((S)-1-methyl-pyrrolidin-2-yl)-isoxazole is an isoxazole 
isostere of nicotine (Fig. I/2.8) 198.  
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Figure I/2.8: Structure of ABT-418 10 
ABT-418 10 possesses improved functional selectivity for α4β2* (Ki = 4.2 nM) 199 over 
synaptic ganglionic-like nAChRs 13, 200. ABT-418 10 is effective in compensating 
cognitive deficits associated with lesions in the forebrain cholinergic system and in 
exerting anxiolytic activities with reduced side effects 201. Other substitutions than the 
methyl group of the heteroaromatic ring have shown that the ABT-418 10 almost 
loses affinity towards α4β2* nAChRs subtypes. Exchanging the isoxazole with an 
isothiazole moiety leads to compounds with lower affinity for α4β2* (12-54 fold 
lower) 185. 
Pyridyl Ethers 
Introducing a methyl ether moiety between the pyridyl and the pyrrolidinyl moiety 
of nicotine leads to pyridyl ether derivatives showing subnanomolar affinities for 
central neuronal nicotinic receptors (Fig. I/2.9) 202. 
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Figure I/2.9: Structures of the pyridyl ether derivatives, ABT-089 25, A-85380 26 and ABT-594 14 
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Among these, ABT-089 25 2-methyl-3-(S)-1-pyrrolidin-2-ylmethoxy)-pyridine is a 
cholinergic channel modulator (Fig. 2.9). In radioligand binding studies, ABT-089 25 
was shown to display selectivity towards the α4β2* nAChRs (Ki = 16.7 nM) relative to 
the α7* (Ki = 10000 nM) and (α1)2β1γδ nAChRs subtype (Ki = > 1000 nM) 203. It 
possesses a high oral bio-availability, excellent safety and behavioural efficacy 204. On 
the basis of its neuroprotective properties against an excitotoxic insult (glutamate 
and β-amyloid) and its cognitive enhancing activity in rodents and primates, it was 
selected for advanced preclinical evaluation.  
A-85380 26 3-((R)-1-azetidin-2-ylmethoxy)-pyridine (Fig. I/2.9) has been identified 
as a high-affinity nAChR ligand 202. In radioligand binding studies it has been shown 
to be a potent and selective ligand for the human α4β2* nAChR subtype (Ki = 0.05 
nM) relative to the human α7* (Ki = 148 nM) and the muscle (α1)2β1γδ subtype 
expressed in Torpedo electroplax (Ki = 314 nM)205. Functionally, A-85380 26 is a 
potent activator of cation efflux on the human α4β2* (EC50 = 0.7 µM) and ganglionic 
(EC50 = 0.8 µM) subtypes, effects that are attenuated by pre-treatment with 
mecamylamine (10 µM). In all cases, A-85380 26 is more potent than (-)-nicotine but 
less potent than (±)-epibatidine 202. 
ABT-594 14 5-((R)-1-azetidin-2-ylmethoxy)-2-chloro-pyridine is a chloro analogue 
of A-85380 158 (Fig. I/2.9) and a potent inhibitor of the binding of (-)-[3H]cytisine to 
α4β2* neuronal nAChRs (Ki = 37 pM, rat brain) 206. At the (α1)2β1γδ neuromuscular 
nAChR, ABT-594 (14) has a Ki value of 10,000 nM (labelled by [125I]α-Btx), resulting 
in a greater than 180,000-fold selectivity for the neuronal α4β2* over muscle type 
nAChR. It has been developed as a promising nonopioid analgesic having affinity for 
α4β2* nAChRs comparable to that of epibatidine, but lacking its toxicity 159. Like the 
parent compounds nicotine and epibatidine, ABT-594 14 establishes increased 
response latencies in the hot-plate test in rats (0.05 and 0.1 mg/kg s.c.) but causes 
hypothermia and dose-dependent increase in blood pressure 206. Both the 
antinociceptive and toxic effects (hypothermia and hypertension) were abolished by 
pre-treatment with the brain blood barrier (BBB) penetrating neuronal nAChR 
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antagonist mecamylamine 12, demonstrating that these actions of ABT-594 1 were 
mediated via activation of neuronal nicotinic receptors 118. At present, ABT-594 14 is 
in Phase II clinical trials as analgesic. 
Anabasine and Anabaseine 
Anabasine 27 like nicotine 3 is a natural alkaloid present in tobacco plants. On the 
other hand, anabaseine 28, whose structure resembles that of anabasine 27, is an 
alkaloid isolated from an animal toxin (a marine worm, and in certain species of ants) 
207(Fig. I/2.10). They differ structurally only at the 1,2 piperidine ring (anabaseine has 
a double bound) 208. Anabaseine 28, compared to (-)-nicotine 3 and anabasine 27, 
displays the greatest efficacy and affinity at α7* receptors (efficacy EC50 = 6.7 µM, Ki = 
58 nM rat brain, [125I]α-Bgt) 209. 
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Figure I/2.10: Structures of anabasine 27 anabaseine 28 and its derivatives GTS-21 29  
and 4OH-GTS 30207 
GTS-21 29 (DMXBA) 3-(2,4)-dimethoxybenzylidine)anabaseine (Fig. I/2.10) is an 
anabaseine derivative, also known as DMXBA. It shows nanomolar affinities for both 
α4β2* (Ki = 85 nM) and α7* nAChRs (Ki = 212 nM) 75, 209. GTS-21 29 and its main 
metabolite in primates, 4-OH-GTS-21 30 also known as HMBA 174 are both potent and 
selective agonists for the α7* type nicotinic acetylcholine receptor 174, 210, 211. They 
appear to be neuroprotective through the selective activation of the α7* subtype 
nAChR 86. GTS-21 29 has recently passed through Phase I clinical trial for use in 
Alzheimer’s disease as a cognition-enhancing agent 212. 
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(-)Lobeline  
(-)Lobeline (α-lobeline) 31 2-[6-((S)-2-Hydroxy-2-phenyl-ethyl)-1-methyl-piperidin-2-yl]-
1-phenyl-ethanone (Fig. I/2.11) is a lipophilic alkaloid from the Indian tobacco Lobelia 
inflata. In its structure (-)-Lobeline 31 contains a 2,5-disubstituted piperidine. It binds 
with high affinity to α4β2* nAChRs (Ki = 1.4 - 2 nM) and very low affinity to α7* 
nAChRs (Ki = 10,000 nM). In the past, it has been classified as an agonist at nAChRs. 
Despite its atypical structure, (-)-lobeline mimics some pharmacological effects of 
nicotine (self-administration by animals, antinociceptive effects and hypolocomotion) 
213, 214. There are indications that lobeline may be useful in memory and learning 
disorders and for the treatment of anxiety. Furthermore, (-)-lobeline 31 has been used 
in the treatment of smoking cessation 168,214. However, more recent studies indicate 
that lobeline inhibits nicotine-evoked dopamine release and (-)-[3H]nicotine binding, 
thus acting as a competitive, non-selective antagonist at α4β2* and α3β2* nAChRs 215 
(Fig. I/2.11). SAR studies have shown that both aromatic rings are required for 
optimal affinity. Analogues lacking one oxygen atom bind with lower affinity to (-)-
[3H]nicotine binding sites 213. The presence of the carbonyl oxygen, serving as a 
potential hydrogen bond acceptor, seems to be optimal for nACh receptor affinity 216. 
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Figure I/2.11: Structure of lobeline 31, a lipophilic alkaloid from the Indian tobacco Lobelia inflata. 
I/2.2.1. Azabicyclic compounds 
Epibatidine  
The discovery of (±)-epibatidine 13 (exo-2-(6-chloro-3-pyridyl)-7-azabicyclo-
[2.2.1]heptane) (Fig. /2.12) and its potent analgesic activity has had an enormous 
impact on research on nicotinic receptors and ligand development. However, (±)-
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epibatidine 13 shows significant side-effect liabilities associated with potent activity 
at the ganglionic and neuromuscular nAChR subtypes, which limits its potential as a 
clinical entity. The presence of this alkaloid was revealed accidentally during a 
routine toxicity assay. The methanolic extract from an Ecuadorean frog (Fig. I/2.12), 
collected during an exploratory trip to Western Ecuador in 1974 by Daly and Myers, 
injected into a mouse, showed a drug reaction known as the Straub tail. These first 
assays led to the isolation of this alkaloid whose structure was revealed in 1992 by 
NMR analysis 217. 
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Figure I/2.12: The Ecuadorian frog and the structure of (±)-epibatidine 13 and its stereoisomers. 
 
(±)-Epibatidine 13 is a potent nAChR modulator and possesses a 200-fold higher 
analgesic effect than morphine in the hot-plate test. The high analgesic activity is 
mediated through the nicotinic cholinergic receptor and was not due to an opioid or 
cholinergic muscarinic mechanism of action, as evidenced by the inability of 
naloxone and scopolamine to prevent it 218. (±)-Epibatidine 13 binds to the α4β2* 
nAChR subtype in rat brain membranes with high affinity (Ki = 8 pM) 179. In 1995, the 
binding of tritiated epibatidine was characterised. (±)-[3H]Epibatidine has proved to 
be a very useful radioligand for monitoring a variety of defined nAChR subtypes in 
heterologous expression systems 173. Zoli and colleagues identified, in a comparative 
analysis of nicotinic radioligand autoradiography, another high affinity (±)-
[3H]epibatidine binding site that persisted in mice lacking the β2 subunit, and 
assigned the subunit composition α3β4* 74. (±)-[125I]Epibatidine, in which the chlorine 
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atom of epibatidine is replaced by [125I], has become available and provides a higher 
specific activity ligand for labelling minor populations of binding sites 219. (±)-
[125I]Epibatidine possesses lower affinity in mouse brain homogenates when 
compared to (±)-[3H]epibatidine (KD = 50 and 8 pM, respectively) 179, 220. The slight 
reduction in affinity presumably reflects the effect of substituting a 125I for a chlorine 
atom. Nevertheless, the properties of the iodinate epibatidine in showing a slightly 
lower affinity than the tritiated form may be helpful in ameliorating ligand depletion 
problems associated with high affinity ligands 221. 
Epibatidine analogues  
Epiboxidine 32 (exo-2-(3-methyl-5-isoxazolyl)-7-azabicyclo[2.2.1]heptane) is an 
interesting synthetic analogue of the alkaloid (±)-epibatidine 13. It represents a 
hybrid between (±)-epibatidine 13 and ABT-418 10 222 (Fig. I/2.13). Although not as 
potent as (±)-epibatidine 13, epiboxidine has a higher affinity (Ki = 0.6 nM, 
α4β2*nAChRs) to nAChRs than nicotine (Ki = 0.838 nM, α4β2* nAChRs) 179 and ABT-
418 10 (Ki = 4.2 nM) 199. In a hot-plate antinociceptive assay with mice, epiboxidine 32 
was about 10-fold less potent but also 20-fold less toxic than (±)-epibatidine 13 222. 
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Figure I/2.13: Structure of epiboxidine 32, a potent nicotinic receptors agonist. 
 
Several analogues of (±)-epibatidine 13, in which the azabicycloheptane ring has been 
expanded, have been synthesized and tested. These include, for example 
homoepibatidine (33) 223 and the analogue 3-(6-chloro-3-pyridazinyl)-3,8-
diazabicyclo[3.2.1]octane 34 224,225 (Fig. I/2.14). Interestingly, compound 33 possesses 
analgesic potency comparable to that of (±)-epibatidine 13 at doses 4-fold higher 
(40µg/kg) 223, and its binding affinity is in the picomolar range (Ki = 0.23 nM) 226. 
Compounds 34, bearing a diazabicyclo[3.2.1]octane skeleton, showed high affinity (Ki 
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= 4 nM, [3H]cytisine, rat brain) for α4β2*nAChRs, an apparent high degree of 
selectivity (EC50 = > 1,000 µM, in muscle type cell line TE671) and also analgesic 
potency at low dose (1 mg/kg) 224. The idea of synthesizing this compound originated 
partly from research aimed at discovering analgesics agents. As a final point, this 
study verified that the 8-azabicyclo ring system can substitute the 7-azabicyclo-
heptane ring and can provide compounds with reduced binding affinities relative to 
(±)-epibatidine 13 but maintaining pharmacologically relevant potencies. 
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Figure I/2.14: Structure of epibatidine 13 and homoepibatidines 33 and 34. 
Ferruginine 
(+)-Ferruginine Fe 1 is a potent neurotoxin containing an 8-azabicyclo[3.2.1]octene 
skeleton (Fig. I/2.15). This alkaloid was isolated from the arboreal species Darlingiana 
ferruginea (J. F. Bailey) and Darlingiana darlingiana (F. Muell). The unnatural 
enantiomer (-)-ferruginine, an analogue of anatoxin-a An 1, was used as a new lead 
compound for structure-activity relationships on nAChR agonist binding site and to 
develop new potent nAChR ligands bearing diazine moieties 227, 228. 
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Figure I/2.15: Structures of ferruginine Fe 1 and its demethylated analogue, nor-ferruginine Fe 2. 
Anatoxin-a 
Anatoxin-a An 1 is a natural alkaloid; a toxin isolated from fresh-water 
cyanobacteria, Anabaena flos-aquae 198 (Fig. I/2.16). It is a small bicyclic compound, 
very soluble in water. Wright et al. developed an anatoxin-a/epibatidine hybrid UB-
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165 229, comprising the azabicyclononene bicycle of anatoxin-a An 1 and the 
chloropiridyl moiety of (±)-epibatidine 13.  
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Figure I/2.16: Structures of anatoxin-a An 1, (±)-epibatidine 13 and the anatoxin-a/epibatidine  
hybrid UB-165 229 
 
UB-165 is a potent neuronal nicotinic acetylcholine receptor (nAChR) ligand that 
displays functional selectivity between nAChR subtypes. It shows intermediate 
potency, compared with the parent molecules (±)-epibatidine 13 and anatoxin-a An 1, 
at α4β2* and α3-containing binding sites.  
I/2.2.2. Other nAChR ligands  
Cytisine 
(-)-Cytisine Cy 1 (1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one) is a 
chiral quinolizidine alkaloid composed of a tricyclic skeleton, including ring A und B 
forming a bispidine framework fused to a ring C representing a pyridin-2-one (Fig. 
I/2.17). In comparison with (-)-nicotine, (-)-cytisine Cy 1 is a more potent nAChR 
ligand, displaying higher selectivity toward the α4β2* nAChR subtype combined 
with subnanomolar affinity (Ki = 0.122 nM) 230. It has been found that the functional 
efficacy of (-)-cytisine Cy 1 is dependent on the identity of the β subunit present in 
the nAChRs. This fact underlines the importance of the β subunit in determining 
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agonist interactions with neuronal nAChRs 231. (-)-[3H]cytisine labels specific sites in 
the brain with an affinity and distribution comparable to (-)-[3H]nicotine 232. 
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Figure I/2.17: The structure of cytisine Cy 1  
 
Mecamylamine  
Mecamylamine 12 (N-2,3,3-tetramethyl-bicyclo[2.2.1]heptan-2-amine) is a competitive 
antagonist at nicotinic receptors in ganglia. It was introduced to the pharmaceutical 
market in 1956 as Inversene®, an antihypertensive agent. In early 1977, Merck, the 
company that owned the original patent, stopped producing mecamylamine 12 
because of postural hypotension (due to a broad parasympathetic inhibition) and 
probably also because of the presence of many new drugs that were more effective in 
treating high blood pressure. In 2000, Layton BioScience Inc. received approval from 
the United States Food and Drug Administration to reintroduce Inversine ® 
(mecamylamine HCl) to the U.S. market for use in treating symptoms of Tourette’s 
Syndrome, a condition which includes motor and vocal tics and mood disorders 233. 
Recently, Targacep acquired the drug Inversine ® (Mecamylamine HCl) from Layton 
BioScience, and mecamylamine 12 is currently marketed for the management of 
moderately severe to severe essential hypertension 234. 
 
Methyllycaconitine (MLA)  
Methyllycaconitine (MLA) 35 (Fig. I/2.18) is a tertiary norditerpenoid alkaloid 
isolated from "Delphinium” species brownie. MLA 35 is a competitive antagonist (Ki 
=1 nM) at [125I]α-Bgt binding site, in rat forebrain preparations 235. It produces a 
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potent reversible blockade of α7* and it is > 30 fold less potent at the α3β4* or α4β2* 
and inactive at the muscle nAChRs 236.  
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Figure I/2.18: Structure of the norditerpenoid alkaloid MLA 35. 
 
MLA 35 clearly differentiates between α-Bgt sensitive sites on neuronal and muscle 
nAChRs  235. The use of MLA as an α7* selective antagonist should be applied with 
caution, especially in studies of nAChRs in basal ganglia. Recently, it was observed 
that MLA is able to inhibit the binding of a [125I]α-CTx-MII binding site (a specific 
antagonist at nAChRs containing α3 and β2 subunits) 237 to striatum and nucleus 
accumbens with a Ki value of 33 nM 238. Actually, MLA concentrations between 1 and 
10 nM will reversibly block α7* type nAChRs, while at 100 nM it begins to block α3-
type receptors (e.g. α3/α6β2β3), present at presynaptic terminals on DA neurons 238. 
Since [3H]MLA displays rapid association and dissociation kinetics, it has been 
developed as an alternative to [125I]α-Bgt (slow dissociation kinetics) for labelling the 
α7 subtype. This radioligand labels a single population of binding sites in the rat 
brain with low nanomolar affinity (KD = 1-2 nM) 239. 
 
Dihydro-beta-erythroidine (DHβE)  
DHβE (36) (Fig. I/2.19) is an alkaloid found in seeds of plants of the genus Erythrina. 
In addition to its curare-like properties, it has been widely used as a classical, non-
selective, competitive antagonist at neuronal nicotinic acetylcholine receptors. DHβE 
has nanomolar affinity at both α4β2* (Ki = 35 nM) and α3β2* receptor subtypes, but is 
a relatively weak antagonist at α3β4* (ganglionic-like) and muscle subtype (Ki = > 
11,000 nM) 240,241. 
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Figure I/2.19: Structure of dihydro-β-erythroidine 36 
 
I/2.3. Peptide toxins 
I/2.3.1. Bungarotoxins 
Snake neurotoxins have a very high affinity to nAChRs, they produce a potent 
receptor functional blockade at neuromuscular junctions and have been extremely 
useful in the characterization of structure and function of the nicotinic receptors. 
Snake neurotoxins can be divided into two subfamilies, “short” (60-62 residues) and 
“long” (64-72 residues), which have sequence homology and share the same 3D-
structure 242. The best-established snake neurotoxin is the α-Bungarotoxin α-Bgt 5. It 
has been isolated from Bungarus multicinctus 239 (Fig. I/ 2.20). 
 
Figure I 2.20: Bungarus multicinctus. 
 
α-Bgt 5 is a 75 amino acid peptide, (8000 Da peptide), a highly potent and selective 
antagonist at α7* and muscle type nAChRs (Ki = 0.35 - 3.5 nM, respectively) 239,243. It 
was the instrumental compound in the isolation and purification of Torpedo nAChRs 
(muscle type nAChR) 239. Also avian α8* and the α9* subtype at cochlear hair cells 
interact with α-Bgt 5. All other neuronal nACh receptors formed by the assembly of 
α2-α4 and β2-β4 subunits are completely insensitive to α-Bgt 5 34. [125I]α-Bgt has been 
largely used for the exploration of the α7 channel structure and to investigate its 
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distribution in the PNS and CNS. 77,239. [125I]α-Bgt labels a single population of 
binding sites in the rat brain with low nanomolar affinity (KD 1 = nM) 239. However, 
[125I]α-Bgt is not an ideal ligand in equilibrium binding studies because of its slow 
kinetics 244.  
I/2.3.2. Conotoxins 
Conotoxins are short peptides isolated from the venom of cone snails a carnivorous 
mollusk from tropical marine environments (genus Conus). Many of these toxins are 
selective inhibitors of ligand- and voltage-gated ion channels and are classified 
according to the type of channel to which they bind (Table I/2.1). They are small 
peptide toxins (14-17 amino acids) with a highly conserved disulphide-bonding 
pattern. They are structurally simpler than α-bungarotoxin 5 and other snake venom 
α-neurotoxins (constituted by 60-70 residues plus four or five disulphide bridges). α-
Conotoxin MII, α-Conotoxin IMI and α-Conotoxin AuIB are important 
representatives of the neurotoxin family. α-Conotoxin MII is a potent, competitive 
antagonist, highly selective for neuronal nicotinic receptors containing α3β2* 
subunits 237. Also α6β2 nAChRs expressed in Xenopus oocytes are susceptible to 
inhibition by α-Conotoxin MII 237. Conotoxin IMI is a selective antagonist of α7* 
nAChRs and also blocks the α9* subtype with an affinity 8-fold less than at α7* 245. α-
Conotoxin AuIB 246 belongs to the family of conotoxins isolated from Conus aulicus, 
including α-Conotoxin AuIA, AuIB, and AuIC 247. Conotoxin AuIB partially inhibits 
nicotine-evoked [3H]noradrenaline and [3H]ACh release from rat brain and is a 
selective antagonist of α3β4* 246, 248. Other conotoxin peptides, e.g. PnIA, PnIB showed 
in table I/2.1 might be used for selective inhibition of other specific nAChR subtypes 
248. 
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Table I/2.1:Classification of selected α-Conotoxins 
α-Conotoxins Species Sequence nAChR Targets 
AuIA C. aulicus GCCSYPPCFATNSDYC* α3β4 
AuIB C. aulicus GCCSYPPCFATNPDC* α3β4 
AuIC C. aulicus GCCSYPPCFATNSGYC* α3β4 
GI C. geographus ECCNPACGRHYSC* muscle 
ImI C. imperialis GCCSDPRCAWRC* α7 
MI C. magus GRCCHPACGKNYSC* muscle 
MII C. magus GCCSNPVCHLEHSNLC* α3β2, α6 (chick), β3 
PnIA C. pennaceus GCCSLPPCAANNPDYC* α3β2 
PnIB C. pennaceus GCCSLPPCALSNPDYC α7 
SI C. striatus ICCNPACGPKYSC* muscle 
* C-terminal amidation 
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I/3. Pharmacophore models for nAChR ligands 
The elucidation of the three-dimensional structure of the nAChRs at atomic level by 
X-ray crystallography or by NMR is very complex. This is because integral 
membrane proteins are not suited for crystallization and nAChRs are too large 
(wide) for NMR studies. Given that the experimental knowledge about the particular 
three-dimensional structure of nAChRs is still unavailable, corresponding 
hypothetical pharmacophore models represent key sources for understanding drug-
receptor interaction on the molecular level and are useful tools that can be 
successfully employed in designing new nAChR modulators 249. Data and structure 
activity relationships from binding studies of different chemical classes of 
modulators will be used to optimize and refine the pharmacophore model.  
In the course of the pharmacophoric pattern identification process, the following 
limitations have to be taken into consideration: (1) The above reported inadequate 
characterization of the binding site on nAChRs, (2) the lack of a specific model for a 
subtype, despite the existence of ligands that interact with different receptor 
subtypes (3) and the existence of different pharmacophore models for every receptor 
state. In fact, the nAChR is an allosteric protein that exists in different conformational 
states 11. In radioligand binding studies, the presence of the agonist stabilizes the 
receptor in a desensitized (high affinity) state. It is difficult to match radioligand-
binding data coming from different laboratories. The use of different radioligands, 
the radioligand concentration, the buffer pH and composition and the method used 
to separate dissociated and bound ligand should be taken into account 188. 
Since 1970, several investigations have been performed to define a pharmacophore 
model 185, 187, 249-257. Beers and Reich developed the first model. It was characterized by 
two main structural elements: an onium group (N+) and a hydrogen bond acceptor 
(HBA) atom, with the optimal distance between the onium site and the HBA acceptor 
atom of 5.9 Å. 258(Fig. I/3.1). One of the limitations of this first model was the use of a 
miscellaneous set of agonists and antagonists ((-)-cytisine, (S)-nicotine, trimethaphan, 
dihydro-β-erythroidine (DHβE) and strychnine). 
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Figure I/3.1: Pharmacophore model of Beers and Reich, 1970.HBA can be an electronegative atom 
capable of accepting a hydrogen bond. 
 
In 1986, Sheridan and co-workers using only nicotinic agonists refined this model. 
They formulated a new model based on three salient features: a protonable nitrogen 
atom (corresponding to the pyrrolidine nitrogen of nicotine), a hydrogen bond 
acceptor atom (HBA) (e.g. the carbonyl oxygen of cytisine or the pyridine nitrogen of 
nicotine) and a third point, representing the centroid of the pyridine ring of nicotine 
or the carbonyl carbon atom of cytisine (Fig. I/3.2) 259. The optimal distances between 
the three points in the pharmacophore triangle were estimated to be (N+-HBA) 4.8 Å 
(N+-C) 4.0 Å (HBA-C) 1.2 Å (Fig. I/3.2). A limit is given by the fact that it was based 
on only four ligands, due to the paucity of ligands on nAChR at the time. 
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Figure I/3.2: Pharmacophore model of Sheridan (1986) 
 
Barlow and Johnson (1989), whose model was based on X-ray crystallographic data of 
two nicotinic ligands ((-)-cytisine and (S)-nicotine), suggested that the agonist activity 
might depend on a charged nitrogen atom and a planar area on the receptor that 
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accommodates an aromatic ring (Fig. I/3.3). Tyrosine or phenylalanine residues 250 
constitute this area. In some cases an unsaturated group, such as a carbonyl (ACh) or 
a double bond (anatoxin-a) can replace the aromatic ring. 
 
Figure I/3.3: Barlow and Johnson (1989) 255 
The elucidation of the structure of epibatidine and the discovery of its very high 
affinity at nicotinic acetylcholine receptors raised the issue of the role played by the 
internitrogen distance in binding affinity (See Table I/3.1). Glennon et al. 260 assumed 
that a relationship exists between N-N distance and affinity. They calculated that the 
internitrogen distance of the lowest energy conformation of epibatidine was 5.5 Å. 
Further studies demonstrated that other low-energy conformers of epibatidine were 
possible. Then the optimal internitrogen distance was considered to be 4 - 6 Å, 188, 202, 
259, 261, given that nicotine and epibatidine showed an N-N distance of 4.8 and 5.5 Å 
respectively 216, 260, 261.  
Table I/3.1: Different N-N distances found in literature 
Reference Compounds studied N-N distance 
1986 259 
(S)-nicotine,(-)- cytisine, (-)-ferruginine methiodide, 
(-)-muscarone, (±)-epibatidine 
4.8 Å 
1994 260 (±)-epibatidine 5.5 Å 
1996 202 A85380, (±)-epibatidine 4.6 - 6 Å 
1998 261 A85380, (±)-epibatidine 4.5 Å 
1999 257 (±)-epibatidine > 5.5 Å 
 
However, some high affinity nicotinic agents were identified, some of which were 
quite conformationally constrained, that possessed N-N distances > 5.5 Å 229, 257. To 
account for the high affinity of these compounds, Tonder et al. assumed that the 
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distance between specific features of the ligand and the receptor is a parameter 
which predicts the affinity of a ligand for the nAChRs better than the internitrogen 
(N-N) distance 257. 
Holladay et al. 13 extended the three-point model of Sheridan to a four-point 
pharmacophore model (Fig. I/3.4). In this model, the nitrogen atoms (1) and (2) are 
the pharmacophoric elements, while the elements presented in (3) and (4) are 
positions at the nAChR protein which optimally interact with (1) and (2). The 
optimal distance between the two N+-N is approx. 4.85 Å 13. 
 
 
 
N 
N
(1) 
(2) (3)
(4) 
 
Figure I/3.4: Pharmacophore model proposed by Holladay et al. (1997) 
Tonder et al. 257 proposed a vector model. They suggested that the distance between 
site point a and site point b define the binding to the nAChRs receptors (Fig. I/3.5 A), 
where a is a site selected to be 2.9 Å in length from a cationic head and b is a site 
selected to be 2.9 Å in length from a hydrogen bond acceptor moiety (Fig. I/3.5 A). 
An a-b distance of approximately 7-8 Å is thought to be optimal for the high affinity 
binding. Later, Tonder et al. modified the original model by the introduction of an 
aryl centroid (centre of a heteromatic ring or a carbonyl bond) 185, 256 (Fig. I/3.5 B). The 
authors assumed that a compound possesses high affinity for nAChRs if the 
following distances were present: (a-b) 7.3-8.0 Å and (a-c) 6.5-7.4 Å. The angle 
measured between the interatomic distance vectors should be 30°-35°. There is a 
certain appeal to the vector models because they account for the binding of agents 
with varying N-N distances, that is the distances between vectors and not the N-N 
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distances themselves 217. The limitation of this pharmacophore model is due to the 
use of a mixed set of nicotinic ligands.  
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Figure I/3.5 (A) Original vector pharmacophore model 257. (B) Improved vector model 256 
 
The assumption that nicotinic ligands must conform to three point pharmacophoric 
geometry cannot generally be accepted 188. This issue is based on the fact that 
acetylcholine itself only bears two pharmacophoric features, a cation and HBA, and 
is an extremely flexible molecule. Schmitt 188 subdivided the nAChRs ligands in five 
classes (See Table I/3.2): 
Class A: the cationic centre and the HBA/π are acyclic 
Class B: the cationic moiety is acyclic, while the HBA/π is cyclic 
Class C: the cationic and HBA/π are separated in non-fused rings 
Class D: the cation moiety is cyclic and the HBA/π is acyclic  
Class E: cationic and HBA/π sites are contained within a fused polycyclic or spiro 
ring system. 
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Table I/3.2: Schmitt’s classification of nAChRs ligands 
Class Example Reference
A 
Cationic centre acyclic HBA/π 
acyclic 
 
O CH3N+
CH3
CH3 CH3 O  
Acetylcholine 
174 
B 
Cationic moieties acyclic HBA/π 
cyclic 
 
N
N
+ R2
R4
R3
R1
 
3-Pyridyl-methylamines 
262 
C 
Cationic and HBA/π are within 
separate non-fused rings 
 
N
N R2
R1
 
Epibatidine-Derivatives 
157, 263 
D 
Cation moiety is cyclic 
HBA/π acyclic 
 
N
+
A R1
R3
R2
 
Anatoxin-a-Derivatives 
264 
E 
Cationic and HBA/π sites are in a 
fused polycyclic or spiro ring 
system 
 
NH
N
O
 
Cytisine 
232 
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I/4. Radioligand binding studies 
I/4.1. Introduction to in vitro pharmacology- Radioligand binding studies 
The radioligand binding technique is an important tool in pharmacology. 
Radioligand binding assays are used to obtain information about a receptor (e.g. 
distribution, concentration, structure and function) and to evaluate potential agents 
by assessing their ability to interfere with the specific binding of radioligands to its 
receptor. The radioligand is a radioactively labelled drug that can associate with a 
receptor of interest 265. Radioligand binding studies using both natively expressed 
and cloned receptors have been used extensively for the characterization of receptor 
modulators. There are two basic types of receptor binding experiments: saturation 
and competition 266. 
Saturation studies are used to determine the affinity of a radioactive ligand for a 
receptor, known as KD, as well as the Bmax of the receptor in a specific tissue or sample. 
The KD is the dissociation equilibrium constant of a drug for a receptor. The Bmax is 
the density of the receptor site in a particular preparation 267. 
Competition studies are used to determine the affinity of unlabelled ligands for a 
defined receptor. The Ki value, the equilibrium dissociation constant, for a 
competitive inhibitor of the receptor is a measure of how tightly a drug binds to a 
receptor. The higher the affinity (lower value of Ki) the tighter the drug binds to the 
receptor. 
Basic concepts in receptor binding studies 
Radioligand binding studies are based on a chemical equilibrium process (Fig. I/4.1) 
that is defined by the law of mass action (Eq. I/4.2).  
Receptor (R) +  Ligand (L) Ligand Receptor Complex (LR)
kon
koff  
Figure I/4.1: Radioligand binding experiments are based on the assumption that the receptor (R) 
interacts with a ligand (L) and forms a ligand-receptor complex (LR). This process is reversible. 
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The binding of a radioligand (L) to a receptor (R) to form a ligand-receptor complex 
(LR) is not a static process. It is viewed as a kinetic process of a ligand moving 
toward and away from receptors at different states. The equilibrium position is a 
position of minimum free energy within the force field of the receptors. It is reached 
when the rate constant of association equals the rate constant of dissociation.  
 
[LR] x kon = [L][R] x koff 
 
Equation I/4.1: Equation at equilibrium 
 
In biological chemistry this equilibrium is expressed in terms of the dissociation 
reaction KD rather than the association reaction Ka. The KD is obtained by a 
rearrangement of the law of mass action: 
KD = =
koff [L][R]
kon [LR] 
 
Equation I/4.2: The law of mass action, where KD is the dissociation equilibrium constant, [L] is the 
concentration of the unbound ligand, [R] the concentration of the unbound receptor and [LR] the 
concentration of bound receptor-ligand complex. kon  is the rate constant for association and koff is the 
rate constant of dissociation. 
 
KD is a measure of the affinity of a ligand for a receptor and is equal to koff / kon, where 
the kon is the rate constant for association and koff is the rate constant of dissociation, 
[L] is the concentration of the unbound ligand, [R] the concentration of the unbound 
receptor and [LR] the concentration of receptor-ligand complex. When the 
concentration of a ligand equals the KD, half the receptors will be occupied at 
equilibrium. If the receptors have a high affinity for the ligand, the KD will be low, as 
it will take a low concentration of ligand to bind half the receptors. The law of mass 
action is not useful in all situations. It can only be used in presence of certain 
conditions, that:  
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1. All receptors are equally accessible for the ligand; 
2. Receptors are either free or bound by the ligand; 
3. No more than one affinity state exists; 
4. Binding is reversible and does not alter the ligand or receptor. 
 
Basic steps in receptor binding studies  
Radioligand binding studies consist of four basic steps (Fig. I/4.2). 
 
a) Binding of radioactive / nonradioactive ligand to the receptor 
 
b) Separation of bound from free 
 
c) Measurement of the amount of radioactivity bound 
 
d) Analysis of the results 
 
Figure I/4.2: Basic steps in receptor binding studies 
a) Binding of radioactive / nonradioactive ligand to the receptor 
The parameters that need to be optimised are:  
1) radioligand (isotope, specific activity, stability),  
2) protein concentration, 
3) buffer (composition and pH), 
4) incubation time (duration and temperature). 
 
1) Radioligand 
Selection of isotope: The most commonly used radioactive isotope in in vitro 
pharmacological studies are 3H and 125I. They possess, as shown in Tab. 4.1, different 
physical properties. The Iodine-125 decays by electron capture, has a half-life of 60 
days and gamma-ray (35 keV) and x-ray emission (27 keV). Tritium decays by 
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electron emission (β-) with very low energy (18.6 keV) and has a half-life of 12.3 
years. Tritium has some advantages in comparison with the iodine-125. Tritium is 
chosen to label small molecules in order not to influence the interaction of the ligand 
with the receptor. Moreover, the radioligand can maintain the biological structure 
and function without alteration. A very important property of tritium is its longer 
half-life, which does not require a correction for decay during the duration of the 
experiment. Furthermore, due to the low energy of the radiation, a tritium labelled 
ligand is much easier to handle than a iodine-125 radioligand. The only disadvantage 
consists in the fact that the low energy of the radiation (β- particles) is responsible for 
the decomposition, by self-radiolysis of the radioligand. In fact, all the beta energy 
emitted is absorbed within the sample. On the other hand, iodinated radioligands 
have a higher specific activity (125I maximum specific activity = 2,200 Ci/mmol vs. 30 - 
100 Ci/mmol for 3H) that reduces the amount of the ligand that should be set in the 
assays and makes them particularly useful if the density of the receptor is low. 
Table I/4.1: Physical properties of the radionuclides 3H and 125I. 
Nuclide 3H Nuclide 125I 
Mode of decay :β- = 18,6 keV (100%)  
Half-life = 12,4 years 
maximum specific activity = 30 – 100 Ci/mmol 
Mode of decay: EC= γ (35 keV) and x-ray (27 keV) 
Half-life = 60 days  
maximum specific activity = 2,200 Ci/mmol  
 
Affinity, specific radioactivity and stability of the radioligand: The radioactive ligand used 
in radioligand assays should have a high affinity for the receptor being studied, low 
affinity for other receptors and a high specific radioactivity. The specific activity may 
be defined as the radioactivity per unit mass of a labelled compound. Usually, it is 
expressed as MBq/mmol (1 Bequerel, abbreviated Bq, equals one radioactive 
disintegration per second = 1 dps) or in Ci/mmol; Curies per mili mole (1 Curie = 3.17 
* 1010 disintegrations per second, dps, or 2.22 * 1012 disintegrations per minute, dpm). 
The higher the specific activity of the labelled compounds, the less mass needs to be 
used in assays. On the other hand, high specific activity can cause radiolysis in the 
solution of a compound. Certain steps may be taken into consideration to minimize 
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chemical instability and radiolysis. The radioactive ligands should be dissolved in a 
suitable solvent such as ethanol (which act as radical scavenger) and should be 
stored cold (- 20 C°). It should not be frozen, since freezing the solution tends to 
locally concentrate the radioligand and increase its radiolytic destruction 268. Further, 
exposure to UV light and rapidly changing temperature conditions should be 
avoided.  
2) Protein Concentration 
The right concentration of the receptor used in binding assays depends upon the 
amount, affinity and specific activity of the radioligand and on the density of the 
receptor in the tissue 269. Approximately 100 to 500 cpm should be bound to the 
receptor of interest at the lowest concentration of the radioligand used in the assays. 
However, the cpm counts are suitable for detecting and measuring the interaction 
ligand-receptor depends upon the counter efficiency. The concentration of the 
protein is a very crucial factor in saturation and competition binding experiments. 
Indeed, it can cause the phenomenon of ligand depletion, thereby affecting the result 
of the assays. Ligand depletion occurs when the concentration of the protein in the 
tissue is so large that the binding of ligand to the receptor depletes the free 
concentration of ligand for binding to the available receptors. Ideally, the free 
concentration of the ligand should be equal to the concentration of the ligand that 
was added. If the difference between both these concentrations becomes too high, the 
law of mass action becomes invalid. In saturation assays the depletion of the 
radioligand is a very frequent phenomenon. In this case, the results can be corrected 
directy using an appropriate equation. In competition assays, ligand depletion can 
cause an underestimation of the affinity of high potent ligand. This concept was 
demonstrated by experiments performed by Gundisch et al. 179. They investigated the 
effect of ligand depletion on the binding affinities of (-)-nicotine and (-)-epibatidine 
in competition assays with (-)-[3H]cytisine. Various concentrations of rat brain 
membranes were used while keeping the same amount of radioligand. An increase in 
protein concentration caused an increasing Ki value for the high affinity ligand (-)-
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epibatidine, whereas it had no effect on the binding affinity of (-)-nicotine (ligand 
with moderate affinity). The ligand depletion in competition assays can affect the 
results only if more than 10% of the radioligand binds. That is not true for the 
characterisation of ligands, which have higher affinities than the radioligands used in 
the assays 179. To compensate the effect of depletion, some pratical procedures are 
required 270: 
1. Increase the incubation volume without changing the amount of tissue. In this 
case, it is necessary to increase the amount of the radioligand.  
2. Reduce the amount of protein. 
3. Use a high concentration of both the radioligand and the compound being 
tested to reduce a depletion of nonradioactive ligand with high affinity to the 
receptor. 
4. Use an analysis procedure that can correct the difference between the 
concentration of the added ligand and the concentration of the free ligand. 
3) Buffer Composition and pH 
The choice of the buffer depends on the receptor type and the specific purpose of the 
experiments. The buffers usually used for binding studies are: HEPES or TRIS buffer 
at pH 7.4 (often used in the concentration of 20-50 mM) 269. They contain ions that are 
present in physiological fluids (e.g. Mg2+, Ca2+, Na+). Buffer solution containing heavy 
metal ions should be avoided because of the risk of reaction with sulphydryl groups 
in the receptors that may alter the structure-binding relationship 269. 
4) Duration and temperature of the incubation 
The tissue is incubated with the radioligand until the steady-state conditions are 
reached. The incubation time required is dependent upon the radioligand 
(concentration and affinity), receptors and temperature. The lowest concentration of 
radioligand will take the longest to equilibrate 267,271. The incubation can be done on 
ice (ca. 4°C), at room temperature (22-25°C) or at 37 °C, depending on the stability of 
the radioactive ligand and the tissue 269. The affinity of the radioligand may be 
temperature-dependent. In fact, in vitro binding affinity of some nAChR ligands is 
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affected by the change in incubation time and temperature 179,272. The influence of 
these two parameters on the KD value of (±)-[3H]epibatidine binding were 
investigated in saturation binding assays. The P2 membrane preparations of rat brain 
were incubated in the presence of various concentrations of radioligand at 4 °C, 22° 
C, and 37 °C for different periods of time. Results of kinetic studies demonstrated 
that (±)-[3H]epibatidine has a slow rate of dissociation (t/2 = 220 ± 5 min at 22 °C) and, 
consistent with this slow dissociation, it also has a slow association (t/2 = 110 ± 5 min 
at 22 °C for 8 pM (±)-[3H]epibatidine). Based on this data, it was found that 
incubation of ca. 2h are required to get a precise affinity determination at 22 °C and 
37 °C. In contrast, saturation assays carried out at 4 C° required more than 8 h 
incubation. Consequently, an insufficient incubation time may cause 
underestimation of the affinity of the radioligand 179. 
b) Separation of bound from free radioactive ligand 
Once the steady-state conditions have been reached, the bound radioactive ligand is 
separated from the free ligand using, for example filtration or centrifugation 
techniques. The suitable procedure is chosen upon the dissociation constant of the 
radioligand. Indeed, the filtration procedure is appropriate only for ligand receptor 
binding with KD of approximately 10–8 M or less (Tab. I/4.2).  
Table I/4.2: Relationship between allowable separation time and dissociation constant KD 269 
KD (M) Allowable separation time 
10-12 1-2 days 
10-10 2.9 hours 
10-11 17 min 
10-9 1.7 min 
10-8 10 sec 
10-7 0.1 sec 
10-6 0.01 sec 
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The filtration method works by trapping the receptor-ligand complex in the filter. 
The procedure has to be very rapid so that the bound ligand does not dissociate from 
the receptor during separation 273. Rapidity of the filtration depends on the KD of the 
radioligands, e.g. for a radioligand with a KD of 10 nM, the filtration time should be 
max. 10 sec (Tab. I/4.2). The rapid filtration technique presents some favourable 
aspects such as simplicity, rapidity, low non-specific binding and high 
reproducibility. Nevertheless, filtration possesses some disadvantages: 
1. Loss of small size membrane particles during filtration.  
2. Binding of the radioligand to the filter itself. 
3. The filter may become clogged. 
To solve the first problem, a suitable glass filter has to be used. Most of the particles 
will be captured by filter with pore size of 1 µm or pore size of 1.2 µm. The non-
specific binding of the radioligand to the filter during the filtration can be reduced 
using different types of filters pre-soaked, for instance in 0.1 % polyethylenimine 
(PEI) [CH3-(CH2-CH2)n- CH=NH] for a short time before filtration 271,274. The tissue 
concentration may be a critical factor in the filtration speed. In fact, in case of high 
concentrations of tissue homogenates (> 10 mg of tissue/tube), the filter may become 
clogged so that the filtration will be slow 269. As anticipated, in case of a rapidly 
dissociating ligand, the filtration method cannot be used because a significant loss of 
the ligand receptor complex can occur. A good alternative in this case is the 
centrifugation technique. This method works by using a desktop microcentrifuge. 
The limitation of this procedure is the incomplete separation of the free ligand 
trapped in the pellets, the fair specific to non-specific ratio and the poor 
reproducibility 270. 
c) Measurement of the amount of radioactivity bound 
The amount of receptor-ligand complex formed can be estimated by measuring the 
amount of radioactivity on the filter using a liquid scintillation counter or gamma 
counter, depending on the isotope.  
Liquid scintillation counter: The β- counter 
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A liquid scintillation counter is often used if the isotope being measured is tritium 
(low-energy β- emitting nuclide, efficiency about 40-50 %). When a tritium atom 
decays (Eq. I/4.3), a neutron converts to a proton and the reaction shoots off an 
electron and antineutrino (beta decay). 
 
                        n  p  +  e- + ∆E+ ῦ 
Equation I/4.3: A neutron (n) converts to a proton (p) and the reaction shoots off an electron (e-), an 
anti-neutrino (̃ῦ) and energy (∆E). 
Electrons emitted by tritium decay have very low energy, (β-emission = 0.0186 MeV). 
Thus this signal is received only if the electron has sufficient energy to travel far 
enough to encounter a flour molecule in the scintillation fluid, which amplifies the 
signal received and gives a flash of light detected by the scintillation counter. 
Solid scintillation counter: The γ-counter 
A gamma counter is suitable for detecting γ-rays emitted from isotopes such as 125I 
(efficiency ca. > 90%). The gamma counter is provided with a sodium iodide crystal 
dot with a very small amount of thallium. The sodium iodide crystal shows great 
likelihood of absorbing part of the received energy. The task of the thallium is to 
transform part of the energy absorbed by the NaI crystal in light with different 
wavelengths that can go through the crystal. The choice of NaI crystals for γ-rays 
detection is due to their reasonable density and high atomic number of iodine (Z=53) 
that results in efficient production of light photons. When a nuclide such as 125I 
decays (Eq. I/4.4), it emits energy in the form of high-energy photons (E = 35 keV for 
γ-rays and E = 27 keV for x-rays). The γ-rays hit the sodium iodide detector and light 
photons are re-emitted. 
 
p + e-     n + γ + ∆E 
Equation I/4.4: A proton (p) converts to a neutron (n) with emission of energy as electromagnetic 
radiation. 
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Light photons strike the photocathode of a photomultiplier (PM) tube. This 
photomultiplier (PM) amplifies the signal and generates an electric pulse that is 
proportional to the energy of the gamma rays. The resulting pulse will be measured 
in terms of counts/min (c.p.m.). The basic unit of radioactive emission is given 
variously as disintegrations per minute (d.p.m.), disintegrations per second (d.p.s.), 
or Curies (Ci). The ratio of measurement (c.p.m.) to emission (d.p.m.) is the counting 
efficiency (readily measured with the use of an external standard and quenched 
samples of known emission). 
d) Analysis of the results 
Receptor binding data can be analysed using different commercially available curve 
fitting programs, such as GraphPAD (supplied by GraphPAD software), CURVEFIT 
(supplied by IRL press software), LUNDON-1 and -2 KINETICS (supplied by 
Lundon software) 269. Moreover, self-made programs using Excel are suitable for 
analysis of ligand binding data.  
I/4.1.1. Saturation Binding Studies 
Saturation radioligand binding experiments measure specific radioligand binding at 
equilibrium at various concentrations of the radioligand. They are based on several 
assumptions: 
1. There is no cooperativity. 
2. Experiment has reached the equilibrium. 
3. Binding is reversible and follows the law of mass action. 
4. Small fraction of radioligand binds. The free concentration is almost identical 
to the concentration added. 
Such experiments are based on the one binding site equation (Eq. 4.5), where L is the 
free ligand, Bmax (plateau of the curve) is a measure of the density of the receptor in 
the tissue preparation and the KD is the concentration of radioactive ligand required 
to occupy 50% of the receptors.  
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RL = (L*Bmax)/(KD + L) 
Equation I/4.5: One site binding equation, where RL is the concentration of the drug-receptor 
complex, L is the concentration of the free radioactive ligand, KD is the affinity of the radioactive 
ligand for the receptor and Bmax  is a measure of the density of the receptor in that tissue.  
These experiments are called saturation experiments because at higher radioligand 
concentrations all the binding sites are occupied (saturated) by a radioactive ligand. 
In a typical saturation experiment, the radioligand concentration should be between 
1/10 and 10 times the possible KD (Fig. I/4.3) 267. 
[L]
[RL]
Specific binding
KD  
Figure I/4.3: Typical graph of a saturation hyperbole 
Unfortunately, radioactive ligand binds also other sites (non specific sites) than that 
of interest. The whole amount of the radioactive ligand bound is referred to as total 
binding, whereas the specific binding is the difference between the total binding and 
the non-specific binding  
Total binding (TB) –Non-Specific Binding (NS)  = Specific Binding (S) 
The non-specific sites may be other receptors from the same family or from a 
different class, other constituents of the tissue (they could be trapped in the lipid 
membrane) as well as the assay tools, such as glass fibre filters and test tubes. In 
order to distinguish specific and non-specific binding, a set of tubes containing a 
well-defined unlabelled ligand at a concentration sufficient to block the binding of 
the radioligand to the specific sites is conducted additionally. The inhibitory 
unlabelled ligand should be a competitive inhibitor, which is specific for the receptor 
and not the same ligand as the radioactive ligand 273. The non-specific binding has to 
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be determined in each experiment. If it exceeds 50%, the experiment cannot be 
considered reliable. An optimal result is between 10% and 30% 266,271. To reduce non-
specific binding, following instructions are useful: 
1. Achieve a very clean membrane homogenisation. 
2. Optimise the filtration time. 
3. Filter must be “pre-soaked” before the filtration. 
4. Use the right radioligand concentration, namely a concentration ranging from 
1/10 KD to 10 KD. 
Analysis of saturation assays 
The results of the saturation experiment are shown by plotting the “bound” vs. 
“free” as illustrated above (Fig. I/4.3). The resulting graph is a hyperbola. Since the 
equation I/4.5 is a nonlinear relationship, the binding parameters cannot be easily 
determined by graphical analysis. There are several linear transformations able to 
linearize binding data, including the methods of Lineweaver-Burk, Eadie-Hofstee 
(for enzyme kinetics), Scatchard and Rosenthal. All of them contain the same 
information given that they are achieved from the same equation (Eq. I/4.5). The 
prototype of a Rosenthal plot, the most popular linear transformation, is illustrated 
in figure 5 (Fig. I/4.4). In this plot, the X-axis presents the specific binding and the Y-
axis the specific binding divided by the free radioligand concentration (Eq. I/4.6). The 
slope of the line is equal to -1/KD (KD is the negative reciprocal of the slope). The Bmax 
value is the X-intercept 275. 
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[bound]
[bound]/[free]
Slope = -1/KD
Bmax  
Figure I/4.4: Evaluation of saturation experiment with a Rosenthal plot 275 
B/ L = -1/KD * B + Bmax / KD  
Equation I/4.6: Rosenthal equation 275, where B is the concentration of the bound radioactive ligand, L 
is the concentration of the free radioactive ligand, KD is the affinity of the radioactive ligand for the 
receptor, and Bmax  is a measure of the density of the receptor in that tissue.  
On the one hand, this graph permits a better and easier visualization of changes in 
KD and Bmax values 267. On the other hand, the Rosenthal plot evaluates data points 
improperly and can therefore lead to errors. For this reason, nonlinear regression 
programs should be preferred to analyse binding data.  
I/4.1.2 Competition Binding Studies 
Competition experiments are aimed at determining the affinity of an unlabelled 
ligand for the receptor. The affinity is measured as the ability of a ligand to compete 
with (thus inhibit) the binding of a known radioactive ligand to the receptor of 
interest. In competition experiments, the concentration of the radioligand is fixed, 
while various concentrations of the unlabelled drug compete with it for the binding 
to the receptor. The binding parameter obtained from this experiment is the 
concentration of the unlabelled ligand that inhibits the binding of the radioligand by 
50 %, namely the IC50  value. The IC50 is influenced by the concentration and the 
affinity of the radioligand for the receptor. The concentration of the radioactive 
ligand should be approximately 0.8-times the KD. If the concentration of the 
radioactive ligand is too high, higher concentrations of unlabelled ligand will be 
required to compete with it. At the same time, it cannot be too low, because there 
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may not be sufficient binding to obtain reliable data. The IC50 can be converted into 
Ki using the Cheng Prusoff equation (Eq. I/4.7) 276. 
Ki = IC50  / (1 + L / KD) 
Equation I/4.7: Cheng Prusoff equation 276 where IC50 is the concentration of the unlabelled ligand that 
inhibits the binding of the radioligand by 50%. L is the concentration of the radioactive ligand used, 
KD is the affinity of the radioactive ligand for the receptor. 
The Ki is defined as the equilibrium dissociation constant for a competitive inhibitor 
(agonist or antagonist) of the receptor. In simple terms, the Ki value for an unlabelled 
drug should be the same as the KD value obtained from the same drug in 
radiolabelled form. If the Ki value is low, the affinity of the receptor for the inhibitor 
is high.  
Affinity and efficacy of a ligand 
A limitation of the binding studies is that they are not able to determine if a 
substance is an agonist or antagonist at the receptor. With this method we can only 
calculate the affinity of the unlabelled ligand, but nothing is known about the ability 
of these substances to evoke a biological response. The “occupation theory” 
formulated by Clark 277 was the first attempt to apply a mathematical principle to the 
measurement of the drug action at receptors. It assumed that the effect of a drug is 
proportional to the fraction of receptors occupied by the drug itself and that the 
maximal effect results when all receptors are occupied. Ariens formulated a theory in 
order to separate the binding phenomenon to the activation phenomenon and 
introduced a new term, intrinsic activity, to describe the relationship existing 
between the effects elicited by a drug and the concentration of drug receptor 
complexes (Eq. I/4.8)278. 
E = α [LR] 
Equation I/4.8: Equation to determine the agonist or antagonist effect of a ligand 278 where E is the 
effect, α is the intrinsic activity and LR is the concentration of the drug-receptor complex. 
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The intrinsic activity is a molecular property of a ligand and is related to its efficacy. 
The α value of 1 tells us that the ligand is a full agonist. When the α value is 
comprised between 0 and 1, the drug is a partial agonist. This means that it does not 
elicit a maximal response even at apparently maximal receptor occupancies. For α 
values equal to zero, the ligand is an antagonist and is not able to elicit any biological 
effect 278. 
I/4.1.3. Protein Determination 
The exact determination of the protein concentration in membrane preparation is a 
very important parameter for the realization of saturation and competition 
experiments. The methods used most often in in vitro pharmacology are the Bradford 
279 and the Lowry test 280. Both procedures are based on the differential colour change 
of a dye in response to various concentrations of protein. The Bradford method uses 
an acidic solution of Coomassie Brillant Blue G 250 which absorbance maximum 
shifts from λ= 465 to 595 nm when binding of the protein occurs (Fig. I/4.5). The 
Coomassie blue dye binds to primarily basic and aromatic amino acids residues. The 
absorption is measured with a spectrophotometer. The quantification of protein 
concentration is realized by comparison with a standard curve (obtained using a 
standard bovine serum albumin). 
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Figure I/4.5: Reaction schematic for the Coomassie dye based protein assays 391 
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The Lowry’s method involves reaction of protein with cupric sulfate and tartrate 
(Fig. I/4.6). Under alkaline conditions, the divalent copper ion forms a complex with 
peptide bonds in which it is reduced to a monovalent ion. Monovalent copper ion 
and the radical groups of tyrosine, tryptophane, and cysteine react with Folin reagent 
to produce an unstable, water-soluble product that is reduced to 
molybdenum/tungsten blue which can be measured at 750 nm. The protein selected 
as reference standard is bovine serum albumin. The Lowry procedure is a reliable 
and satisfactory method for quantification of proteins.  
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Figure I/4.6: Reaction schematic for Lowry’s method 391 
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Over the past years, gradually interest is growing for the neuronal nicotinic 
acetylcholine receptors due to their involvement in a variety of brain functions, 
including neuronal development, learning and memory formation. (-)-Nicotine 3, the 
natural alkaloid ligand of this receptor has been proved to be a cognitive enhancing 
agent with additional anxiolytic, analgesic and neuroprotective effects. Further 
interest in nAChR agonists has emerged since the discovery of (±)-epibatidine 13 as 
potent antinociceptive ligand. Unfortunately, the potential therapeutic use of both 
ligands is limited by their toxicity. Numerous investigations have focused on the 
synthesis and pharmacological evaluation of (±)-epibatidine 13 and (-)-nicotine 3 
analogues in order to obtain novel ligands with low toxicity and improved 
selectivity. In the literature, the majority of in vitro SAR studies has been performed 
with the purpose to get information about the structural requirements for α4β2* 
nAChRs. On the contrary, less or nothing is known about pharmacophore models for 
other subtypes, such as α7*, α3β4* and (α1)2β1γδ. Other natural alkaloids, in 
addition to (-)-nicotine 3 and (±)-epibatidine 13, like (-)-cytisine Cy 1, (+)-ferruginine 
Fe 1, and (+)-anatoxin-a An 1 have been described as compounds with high affinity 
for α4β2* nAChRs. However, structure-activity relationship studies for these ligands 
are missing for α7*, α3β4* and (α1)2β1γδ. For this reason, in order to evaluate the 
affinities of the novel analogues of toxins, (-)-cytisine Cy 1, (+)-ferruginine Fe 1, and 
(+)-anatoxin-a An 1, in vitro radioligand binding studies are performed for four 
different nAChR subtypes: α4β2*, α7*, α3β4* and (α1)2β1γδ. The structure-activity 
relationships of these novel toxin analogues will be examined with the aim to obtain 
more information about the structural requirements to achieve α4β2* selectivity and 
at the same time to get insight into structural requirements for the α7*, α3β4* and 
(α1)2β1γδ nAChR. Beside the search and development of novel nAChRs ligands 
exhibiting selectivity for the α4β2* nAChR, interest is growing to develop ligands 
II. Objectives - 72 -  
which are selective for the α7* and α3-containing subtypes. Since the recent 
discovery of choline as a selective ligand for α7* 284, novel choline analogues will be 
evaluated in radioligand binding to gain more information towards an α7* 
pharmacophore model. 
The following items will be investigated: 
 
1. Systematic evaluation of known and novel ligands for four different   
nAChR subtypes using radioligand binding technique 
To address the issue of binding selectivity among nAChRs subtypes, affinities of 
known and novel toxin and choline analogues for α4β2*, α3β4*, α7*, and (α1)2β1γδ 
nAChR subtypes are measured in four different competition assays. Previously 
described competition assays are revaluated in order to screen compounds. The 
radioligand binding studies are performed under the same buffer conditions (buffer 
contains ions that are present in physiological fluids with a pH of 7.4).  
 
2. Establishment of a novel radioligand binding assay for α3β4* nAChR 
Structure-activity relationship studies carried out with regard to α3β4* nAChRs are 
missing. It is due to the absence of native tissue with a suitable density of α3β4* 
nAChR 281. In previous studies, it has been demonstrated that (±)-[3H]epibatidine is 
an appropriate radioligand to label α3β4* nAChR and that this receptor subtype is 
present in sufficient density in rat adrenal glands 180 . Nevertheless, the poor 
availability and the small size of rat adrenal glands represent a drawback for the 
intention of screening compounds via radioligand binding assays using native tissue. 
In this study, pig or calf adrenal glands, as a source for α3β4* rich tissue obtained 
from a local slaughterhouse, are used for the evaluation of the affinities of novel 
derivatives in competition assays. 
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3. Structure-activity relationships of novel analogues of the toxic alkaloids (-)-
cytisine Cy 1, (+)-ferruginine Fe 1, and (+)-anatoxin-a An 1 for different nAChRs 
(In cooperation with Prof. Seitz, Department of Pharmaceutical Chemistry, University of Marburg, 
synthesis of novel cytisine, ferruginine and anatoxin-a derivatives) 
 
Cytisine Cy 1, (+)-ferruginine Fe 1, and (+)-anatoxin-a An 1 bind with high affinity to 
α4β2* nAChRs, but also interact more or less selective with the multifarious nAChRs. 
A better understanding of the steric and electronic requirements via SAR studies 
might be useful to identify novel ligands with high affinity and selectivity towards 
the central, heteropentameric α4β2* neuronal nicotinic receptors, eliminating 
interactions with the ganglionic and muscular subtypes, which are believed to 
mediate the toxic effects of these natural ligands. 
Cytisine analogues 
In previous studies, cytisine-based compounds either substituted with halogen atoms 
at position C-3, C-5 or C-3 and C-5 of the 2-pyridone fragment or characterised by a 
bioisosteric thiolactam pharmacophore (thiocytisine) instead of the lactam moiety 
have been evaluated in vitro for their affinities for α4β2* and α7* nAChRs and have 
been proved to be highly potent α4β2* and α7* nAChRs ligands {Imming, 2001 #383}. 
In the present study, the previously reported halogenated cytisines and novel 
thiocytisine analogues are evaluated in in vitro radioligand binding assays in order to 
determine their binding affinities to the ganglionic and muscular nAChR subtypes.  
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Aim of this study is also to investigate the influence of a nitro group at position C-3 
or C-5 of the pyridine ring, the effect of hydrogenation of the pyridone ring or the 
introduction of a carbonyl moiety at position C-11 of the bispidine ring on the 
binding profile for α4β2*, α7*, α3β4* and (α1)2β1γδ nAChR subtypes. Another point 
is to investigate the influence of a methyl, benzyl or acetyl substituent on the 
secondary amine function on the binding affinity in comparison to the lead 
compound. 
Ferruginine and anatoxin-a analogues 
The natural alkaloids, (-)-ferruginine Fe 1 and (-)-anatoxin-a An 1 are important 
natural nicotinic agonists, which possess nanomolar affinity for the central α4β2* 
nAChR. Unfortunately, due to their poor selectivity for central versus peripheric 
nAChRs, they are proved to be too toxic to be useful therapeutic agents. Novel 
bioisosteric analogues might possess improved safety over the natural alkaloids, 
resulting from a higher discrimination between the multifarious receptor subtypes. 
In this study, the major structural modification, which is investigated, is the 
replacement of the acetyl moiety by heteroaromatic rings (diazines and pyridine 
moieties) in position C-2 as well as in position C-3 of the azabicyclic skeleton. N-
demethylation of the amine moiety of (-)-ferruginine provides (-)-norferrugine Fe 2. 
It is known that the absence of a N-methyl group in the pyrrolidine ring of (-)-
nicotine 3, giving (-)-nornicotine 21, 354 causes a decrease in binding affinity for 
nAChRs. On the contrary, replacement of the hydrogen on the NH group of (±)-
epibatidine 13, with a methyl group decreases by 2-fold the affinity 157. On the basis 
of this controversial finding, it will be of great interest to investigate the influence of 
the N-methylation. 
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A series of enantiopure 9-diazabicyclo[4.2.1]nonanes, bioisosters of (+)-anatoxin-a 
(An 1), will be evaluated for α4β2*, α7*, α3β4* and (α1)2β1γδ nAChR subtypes: The 
novel compounds bear one structural part similar to the azabicyclo[4.2.1]nonene 
moiety of anatoxin-a An 1 and a pyridine or diazine moiety (pyridazine, pyrimidine 
and pyrazine).  
R
N
N
CH3
N
H
CH3
O
R = pyridine or diazineAnatoxin-a An 1 
        basic structure of enantiopure 
9-diazabicyclo[4.2.1.]nonane derivatives  
 
The marine toxin, pinnamine Pin, can be regarded as a conformationally restricted 
variant of (+)-anatoxin-a An 1. Because of this evident similarity, it is used as a 
template to design novel structural analogues with probable similar affinity for the 
nAChRs. Two novel pinnamine derivatives cis-Pin 1 and trans-Pin 2 in which the 9-
azabicyclo[4.2.1]nonane moiety is bioisosterically replaced by the 8-
azabicyclo[3.2.1]octane moiety are evaluated in radioligand binding assays for their 
binding affinities to different nAChR subtypes. 
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Quinuclidin-2-ene derivatives 
Other interesting novel nicotinic AChR ligands can be obtained from compounds 
developed as muscarinic agonists or antagonists 282, 387. The quinuclidin-2-ene 
derivative with a 2–furanyl moiety M1 showed a moderate affinity for the cortical 
muscarinic receptor (Ki = 300 nM) 282. Interestingly, bioisosteric replacement of the 
furanyl moiety by a pyridine ring proved to be detrimental for the muscarinic 
activity of M1. The obvious structural relationship of this skeleton to the highly 
potent semirigid nAChRs agonists (±)-epibatidine 13 and UB-165 leads to the 
evaluation of these quinuclidine analogues as novel nicotinic ligands.  
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4.      Structure activity relationships for known and novel choline analogues as α7* 
selective ligands 
Ligands that are selective for the α7* subtype are gaining interest due to the 
implication of these latter subtypes in different diseases of the CNS and PNS. 
Recently, choline 4 has proved to be a selective ligand for the α7*, showing also 
neuroprotective actions 284. 
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Extending choline 4 with an amide moiety to obtain the carbamate function leads to 
carbacholine, MCC and DMCC, which were proved to be nicotinic agonists 177. 
Recently, compounds bearing a carbamate moiety showed a very selective 
interaction with the α7* nicotinic receptor versus α4β2* 178.  
In this study, the phenylether of choline is used as lead structure. Further 
modification concerns the insertion of an amide to get a carbamate fragment and the 
incorporation of the nitrogen of the quaternary amine group into a cyclic system. 
These latter modifications are introduced in order to permit the penetration through 
the blood-brain barrier and to study the influence of the azacyclic moiety for the 
different nAChR subtypes. SAR studies of phenylcarbamate derivatives could give 
us more information about the structural requirements to enhance the selectivity for 
α7* versus the α4β2* nicotinic receptor. 
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III. Results 
 
III/1. Radioligand binding studies for different nAChRs 
(Results and experimental conditions used in saturation and competition assays) 
III/1.1. α4β2* nAChR: Saturation and competition binding studies  
 
(±)-[3H]Epibatidine is a high affinity radioactive agonist able to label multiple 
nAChRs widely distributed in the brain as well as in the periphery. It is an excellent 
tool for studying neuronal nicotinic receptors and conceivably to distinguish 
between different subtypes that might exist in the central and peripheral nervous 
system 179, 261. Several previous studies support the idea that the high affinity binding 
sites of epibatidine in the brain represent interactions with the α4β2* nAChRs 
subtype 77, 157, 285, 286. Results of saturation experiments performed with (±)-
[3H]epibatidine in homogenates from rat forebrain and human cerebral cortex, in a 
concentration range of 1 pM to 15 nM, showed that this ligand bound with two 
binding sites in rat forebrain: a high affinity (KD values of 15 pM) and low affinity site 
(KD values 360 pM) 285. Further studies performed in a concentration range of 1-500 
pM permit a differentiation of the two binding sites. Indeed, over this concentration 
range, (±)-[3H]epibatidine bound a single population of sites in the rat brain with KD 
values of 8 pM and Bmax of 180 fmol/mg protein 179. This KD value is in agreement 
with previously measured KD (4-18 pM) for (±)-[3H]epibatidine binding in rat brain 
285, 286, human cerebral cortex 285, mouse brain 287 and M10 cells 173, 285. Several 
indications, such as the similar pattern of distribution of (±)-epibatidine 13, binding 
sites and the fact that the KD value found for (±)-[3H]epibatidine binding in M10 cells, 
stably expressing the α4β2 nAChRs 173, 285, similar to that found for (±)-[3H]epibatidine 
binding in rat brain, corroborate the idea that these high affinity binding sites 
correspond to the α4β2* nAChRs subtype. Therefore, (±)-[3H]epibatidine in an 
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optimal concentration between 1 and 500 pM with a KD of 8 pM 179 is the ideal 
radioligand for characterizing neuronal α4β2* nAChRs receptors.  
Saturation binding studies  
Based on these results, (±)-[3H]epibatidine was used as a radioligand in saturation 
and competition binding assays for the α4β2* nAChRs subtype. The concentration of 
(±)-[3H]epibatidine set up in saturation assays was between 1 and 500 pM. Non-
specific binding was determined using 300 µM (-)-nicotine hydrogen tartrate salt. 
The P2 membrane fraction was obtained from frozen Sprague-Dawley rat forebrain. 
To offset the effect of ligand depletion, 60-70 µg of protein pro vials were incubated 
at 22 °C for 4 h in a total volume of 4 ml HEPES-salt solution (HSS). A previous assay 
established for the α4β2* nAChRs subtype was carried out using P2 membrane 
fraction from rat brains. The intention of this experiment was to verify whether 
frozen P2 membrane fraction stored in the freezer at –80 °C has the same 
characteristic of Fischer-344 rat brain used in earlier assays. The binding parameters 
obtained were consistent with previously published data 179. 
Competition binding studies  
In competition binding studies, a previously developed assay with (±)-
[3H]epibatidine and P2 membrane fraction of Sprague-Dawley rat brains (except the 
medulla and the cerebellum) was utilized 261. Different concentrations of novel 
competitive ligands were incubated with 0.5 nM of (±)-[3H]epibatidine. Rat 
membrane preparations were incubated at 22 °C for 90 minutes in a total volume of 
0.5 ml of HSS. The concentration of the radioligand, the duration and temperature of 
incubation were established based on results obtained from kinetics studies 179.  
III/1.2. α7* nAChR: Saturation and competition binding studies 
Neuronal nicotinic receptors with high affinity for [125I]α-bungarotoxin ([125I]α-Bgt) 
are presumably composed of only α7* subunits and display a regional distribution 
distinct from that of the heteromeric nAChRs 86. [125I]α-bungarotoxin is recognised as 
a selective ligand for the homopentameric α7* nAChR (KD =1.5 ± 0.7 nM, and Bmax 63 
± 17 fmol/mg protein in rat brain) and has been widely used as a radioligand for 
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binding and autoradiographic studies of this receptor 76, 77 75. However, [125I]α-Bgt 
presents some drawbacks, e.g. slow kinetics properties that affect the incubation time 
of the assay, and difficulty in separation of free radioligand from the assay media, 
resulting in high and poorly reproducible non-specific values. Moreover, it does not 
cross the blood brain barrier, limiting its use for in vivo binding and imaging studies 
for the α7* nAChRs 244. A tritiated version of MLA, a selective antagonist at the α7* 
nAChRs subtype (affinity of unlabelled MLA for the α4β2* nAChRs subtype Ki =1.56 
µM in rat brain 288) has been developed as an alternative to [125I]α-Bgt in radioligand 
binding assays 239. Regional distribution of [3H]MLA binding sites in rat brain shares 
the pattern of that of [125I]α-Bgt 239. In saturation binding studies, [3H]MLA bound to a 
single population of binding sites exhibited a KD value of 1.2 ± 0.2 nM 239.  
Saturation binding studies  
To confirm the binding parameters (KD and Bmax) reported in previous studies, the 
saturation of [3H]MLA binding to α7* nAChR subtype in P2 membrane preparation 
of rat brain was re-evaluated. Saturation experiments were carried out in 
quadruplicates by incubating rat brain membranes (120 µg protein) at 22 °C for 2.5 h 
in HSS with concentrations of [3H]MLA ranging from 0.1 to 40 nM. Non-specific 
binding was determined in the presence of MLA (50 µM). The binding parameters 
obtained were Bmax = 147 fmol/mg protein and KD = 1 nM which are consistent with 
previously published data 239. 
Competition binding studies 
[3H]MLA is a tritium labelled ligand which is easier to handle than the iodine-125 
labelled α-Bgt. 239, 244. Therefore, [3H]MLA was used as an alternative radioligand to 
[125I]α-Bgt in competition binding assays. Membrane fractions isolated from the rat 
brain were incubated at 22 °C for 2 h in 250 µl HSS. 
III/1.3. α3β4*nAChR: Saturation and competition binding studies 
The affinity of novel ligands for the α3β4* nAChRs subtypes was assessed using a 
novel competition experiment procedure that involves the use of (±)-[3H]epibatidine 
and calf or pig adrenal glands 289-292. The specific binding of (±)-[3H]epibatidine to 
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crude synaptic membranes of pig adrenals is characterized by a single population of 
binding sites and exhibited a KD value of 54 pM (see Results III/2). 
III/1.4. (α1)2β1γδ nAChR: Saturation and competition binding studies 
In previous experiments, the radioligand of choice to determine Ki values of novel 
ligand for muscle type nAChR was [125I]α-Bgt. Unfortunately, [125I]α-Bgt presents 
some drawbacks (see III/1.2). The incubation process had to be carried out on 
borosilicate glass tubes, instead of polypropylene tubes, to avoid the adherence of the 
radioligand to the walls of the tubes. Furthermore, in order to reduce the non-specific 
binding to filter material, the rinse buffer should contain 1% of nonfatty dry milk 180. 
Based on the excellent properties of (±)-[3H]epibatidine in radioligand binding 
studies 179 a novel assay was established using (±)-[3H]epibatidine and membrane 
fractions isolated from the Torpedo californica electroplax 290, 291, 293, 294. In saturation 
assays, [3H]epibatidine binds to a single population of binding sites in Torpedo 
californica electroplax with a KD value of 2 ± 0.2 nM. 
III/1.5. Protein determination 
In order to decide which methods, between those of Bradford 279 or Lowry 280, were 
the most reliable and satisfactory for the present studies, protein concentrations of P2 
membrane fractions of rat brain and whole membranes of pig adrenal were 
determined following both procedures.  
Table III/1.1: Comparison of the two methods (Lowry and Bradford) for the quantitative 
measurement of protein content in P2 membrane fraction from rat brain and whole membrane from 
pig adrenal. 
 
Quantity of protein µg/ml 
Protein 
Bradford Lowry 
Ratio 
rat brain (P2 
fraction) 
1.629 ± 269 2.407 ± 47 1.4 
pig adrenal 1.112 ± 167 2.491 ± 260 2.2 
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The Bio-Rad Protein Assay, based on the method of Bradford, is a very simple 
procedure. It is rapid and also cheaper than the Lowry method. However, not every 
sample preparation is suitable for investigation with this method. Since the 
Coomassie dye reagent is highly acidic, a small number of proteins cannot be 
assayed with this reagent due to their poor solubility in the acidic reagent. In 
addition, Coomassie dye tinge the glass or quartz cuvettes used to hold the solution 
in the spectrophotometer. The Lowry method utilizes sodium dodecylsulfate (SDS) 
to facilitate the dissolution of relatively insoluble lipoproteins and to avoid a 
nonhomogeneous distribution of protein, responsible for errors in the protein 
determination 295. The values listed in table III/1.1 show that the quantity of protein 
(expressed in µg/ml) determined with the Lowry method is ca. twice as large as the 
quantity measured with the Bradford method. This means that the Lowry procedure 
allows us to obtain a more accurate measurement of the protein present in the tissue. 
On the basis of these considerations, the protein concentration of other membrane 
preparations used in this study (Torpedo Californica electroplax and calf adrenal) was 
determined using the Lowry procedure. 
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III/2. Characterization of α3β4* nAChRs  
III/2.1. Introduction  
III/2.1.1. Distribution of α3-containing nAChRs 
 
Nicotinic acetylcholine receptors containing α3 and β4 subunits are one of the major 
nicotinic receptor subtypes in post-synaptic neurons, in autonomic ganglia, sensory 
ganglia, and chromaffin cells of the adrenal medulla 40, 46, 296-299. They are involved in 
mediation of cholinergic actions on the autonomic nervous system (ANS). Nicotinic 
receptors containing α3 and β4 nAChRs subunits are thought to be potential nicotinic 
receptor subtype in rat intracardiac neurons mediating the nicotine induced heart 
rate increase 91. The α3-containing nAChRs are also present in several brain regions, 
in particular in the substantia nigra, the medial habenula and interpeduncular 
nucleus, hippocampus and ventral tegmental areas 113, 300, 301. Although the exact 
subunit composition of these receptors in the CNS have not been unravelled yet, it is 
believed to be α3β4*, probably in association with α5 299. In 1995, some studies 
revealed that the pineal gland also contains nAChRs subunit mRNAs 302. Recently, 
the pharmacological characteristic of nicotinic receptors present in rat pineal suggests 
that they are exclusively α3β4 nAChRs 312. With regard to the nicotinic receptors 
present in the mammalian medial habenula (MHb), the lack of sensitivity to α-Bgt 5 
and the high potency of (-)-cytisine Cy 1 indicate the absence of α7 and the presence 
of β4 subunits. Currently, studies performed by Quick et al. provide evidence that 
the majority of functional receptors in the mammalian medial habenula (MHb) 
contain α3 and β4 nAChRs subunits 300. The physiological role of α3β4* nAChR 
subtype in the CNS is not clear, but they seem to be involved in the control of 
norepinephrine and dopamine release 303, 304.  
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III/2.1.2. (±)-[3H]Epibatidine as radioligand to characterize α3β4* nAChRs 
 
(±)-[3H]Epibatidine, due to its high affinity and low nonspecific binding represents a 
very broad-spectrum ligand for studying different subtypes of nicotinic acetylcholine 
receptors that might exist in brain and peripheral tissue 111, 285, 287, 305. Currently, (±)-
[3H]epibatidine is a suitable radioligand to investigate nicotinic receptors in 
peripheral neuronal tissues, including neurons of mammalian sympathetic and 
parasympathetic ganglia 87, sensory neurons, such as the trigeminal ganglia 83 and 
adrenal chromaffin cells 298. Until the discovery of tritiated (±)-epibatidine 13 it was 
difficult to detect and measure the presence of nAChRs in such tissues. Indeed, 
compared to the α4β2* nAChR subtype in the CNS, receptors containing α3 subunits 
seem to possess a much lower affinity for other nicotinic ligands. In competition 
assays against (±)-[3H]epibatidine, the affinities of (-)-cytisine Cy 1 and (-)-nicotine 3 
for nAChRs in the adrenal gland, superior cervical ganglia and pineal, were between 
85 nM and 325 nM 306. Their low affinity limits the use of (-)-[3H]nicotine and (-)-
[3H]cytisine as radioligands. In fact, in saturation assays, the binding of (-)-
[3H]nicotine and (-)-[3H]cytisine in such tissues was characterized by a high non-
specific binding 306, so that neither of these can be used to obtain reliable 
measurements of the density of these peripheric neuronal tissues. On the contrary, 
(±)-[3H]epibatidine binds with high affinity ganglionic-type receptors 83, 157, 219, 221, 286, 287 
and is an appropriate radioligand for studying and characterizing α3β4* neuronal 
nAChRs in stably transfected cell lines 240, 281, 307as well as receptors in rat adrenal 
glands 180, 285 and trigeminal ganglia 83. Given that the α3β4* nAChRs subtypes are 
supposed to possess a lower affinity for (±)-[3H]epibatidine if compared to α4β2* 
nAChRs, a radioligand concentration higher than 500 pM is required to detect and 
measure the ganglionic nAChRs subtypes. In previous studies, epibatidine 
radiolabelled with tritium was replaced by its radioiodinate analogue, namely 
[125I]IPH 111, 220, 221, 306. The high specific radioactivity of [125I]IPH greatly facilitated 
measurements in tissue with relatively low receptor density. However, the problem 
regarding the limited supply of the tissue still subsists. 
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III/2.1.3. Membrane preparations used to characterize α3β4* nAChRs 
 
There are some difficulties which make the characterization of the pharmacology of 
α3β4* nAChR subtype complicated 281. Firstly, the low density of nAChRs subtypes 
containing α3 subunits in peripheral neuronal tissue (autonomic ganglia and adrenal 
gland). A second critical aspect concerns the peripheral neuronal tissue that may 
contain more than one nAChR subtype. The novel recombinant technique permitted 
to study the pharmacological properties of recombinant rat, bovine and human α3β4 
stably expressed in human embryonic kidney (HEK 293) cells. This technique has the 
advantage of working with nAChR of known subunit composition; on the other 
hand, is limited in that functional properties of recombinant receptors may not fully 
match those of the native AChRs. Nevertheless, it has proved to be useful in 
unravelling the pharmacological and functional characteristics of α3β4* receptors 
subtype located in the CNS as well as in the peripheral nervous system. In 1998, Xiao 
et al. 281 stably transfected human kidney embryonic 293 cell with the rat neuronal 
nicotinic acetylcholine receptor α3 and β4 subunit genes 281. They found that this cell 
line contains a high level of the α3β4 receptor subtype and (±)-[3H]epibatidine binds 
with a KD value of 304 pM and a BMAX value of 8942 fmol/mg protein (Tab. III/2.1). 
Staudermann et al. 308 also performed saturation binding experiments for the α3β4 
nAChR receptor, but they preferred to use human recombinant α3β4 receptors stably 
transfected in embryonic kidney cells (HEK 293) and (±)-[3H]epibatidine to determine 
the binding parameters (KD = 236 pM and BMAX = 2010 fmol/mg protein). Compared 
to Xiao et al., they found a lower receptor density. In 2002 and 2003, Free et al. made 
saturation and kinetics studies using both native bovine chromaffine cells (KD = 52 
pM and BMAX =34 fmol/mg protein) 309 and recombinant bovine α3β4 nAChR 
expressed in HEK 293 cells (KD = 66 pM and BMAX =3500 fmol/mg protein) 310 in order 
to compare the difference in the pharmacological profile that might exist (based on 
difference in the subunit) (Tab. III/2.1). They found that the KD values at BMα3β4 
HEK cell and bovine adrenal medulla are nearly identical. On the other hand, the 
BMAX value for (±)-[3H]epibatidine to BMα3β4 HEK cell is > 100- fold higher than that 
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reported for (±)-[3H]epibatidine binding to membranes from bovine adrenal cells 309, 
310. Only a few studies on native neuronal α3-containing nAChRs have been reported 
285, 311 due to the lack of a specific native membrane preparation containing a high 
density of the α3β4* receptors subtype. The iodinated analogue of epibatidine, 
[125I]IPH), due to its high specificy radioactivity, has been used to label α3β4 
receptors in the superior cervical ganglia (KD values of 443 pM and a BMAX value of 
272 fmol/mg protein 220 and in adrenal glands with a KD value of 155 pM and a BMAX 
value of 83 fmol/mg protein 306. Like (±)-epibatidine 13, the drawback of using 
[125I]IPH is that it is not able to distinguish α4β2* nAChRs and the nicotinic receptors 
containing α3 and β4 subunit 83. However, the KD value found for the membrane 
preparation of rat adrenal glands using [125I]IPH is 3-fold higher than that found by 
Mukhin et al. for (±)-[3H]epibatidine using the same native tissue (KD value of 55 pM, 
single population of binding sites) 180 (Tab. III/2.1). To exclude any possible 
interaction with the α7* subtype (also found in the adrenal gland), they proved that 
(±)-[3H]epibatidine binding was not blocked (data not shown) by α-bungarotoxin (Ki 
= 1 nM) at concentrations as high as 10,000-times its affinity at α7* nAChRs 309 300. 
These data are consistent with the view that (±)-[3H]epibatidine binds nAChRs 
containing the α3 and β4 subunits. Nevertheless, these results do not exclude 
possible interactions with other subunits (e.g. α5) 83, 88, 89.  
Table III/2.1: Comparison of KD and BMAX values obtained from different saturation binding 
experiments for α3β4*, using different membrane preparations and radioligands 
Tissue used in radioligand binding 
assays (saturation assays) 
KD (pM) 
(epibatidine 
radiolabelled) 
Bmax 
(fmol/mg protein) 
References 
Rat brain α3β4 nAChR expressed in HEK 
293 cells 
304 
(±)-[3H]EPI 
8942 281 
human recombinant α3β4 nAChR 
expressed in HEK 293 cells 
236 
(±)-[3H]EPI 
2010 308 
α3β4* nAChRs in native bovine 
chromaffine cells 
52 
(±)-[3H]EPI 
34 309 
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recombinant bovine α3β4 nAChRs 
(BMα3β4) expressed in HEK 293 cells 
66 
(±)-[3H]EPI 
3500 310 
α3β4* nAChRs in the superior cervical 
ganglia 
443 
[125I]IPH 
272 220 
α3β4* nAChRs in native rat adrenal gland 
155 
[125I]IPH 
83 306 
α3β4* nAChRs in native rat adrenal gland 
55 
(±)-[3H]EPI 
Data not shown 180 
α3β4* nAChRs in native pineal gland 
100 
(±)-[3H]EPI 
300 312 
 
In 2004, Hernandez et al. 312 studied the nicotinic receptors expressed in the rat pineal 
gland. The pharmacology of these receptors and their function correspond to the 
defined α3β4 nAChRs subtype heterologously expressed in HEK 293 cells. They 
performed saturation studies for pineal glands and found that (±)-[3H]epibatidine 
(concentration range: 5 – 3,000 pM) fits a model for a single binding site with a KD 
value of 100 pM and a high density (BMAX = 300 fmol/mg protein). Moreover, they 
performed immunoprecipitation studies with subunit-specific antibodies in order to 
definitively clarify the subunit composition of receptors in the pineal gland. These 
assays also corroborate the finding that the nAChRs receptor is apparently 
exclusively a α3β4 subtype. Previous mRNA analysis also indicated the presence of 
β2 subunits, but via western plot they did not find any evidence for the presence of 
such a subunit. Furthermore, autoradiographic studies of [125I]α-Bgt binding in the 
pineal did not exceed the background level, indicating that the pineal gland does not 
express α7* or other subtype that binds [125I]α-Bgt 312. In future, the rat pineal glands 
may provide a suitable native tissue to perform studies about the channel properties, 
regulation and turnover of this subtype in native cells 312.  
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III/2.2.  Project: establishment of a radioligand binding assay for 
α3β4*nAChRs using pig/calf adrenal glands 
Saturation assays: Analysis of (±)-[3H]epibatidine binding to α3β4* receptors in native 
adrenal glands 
Bovine adrenal chromaffin cells are supposed to contain at least two subtypes of 
neuronal nAChRs. One is thought to be the α7* nAChRs subtype, which binds α-Bgt 
5 313 and is present in the adrenal glands only in limited amounts. The precise subunit 
composition of the second neuronal nAChR is unknown so far, but it is likely to be 
composed of α3, α5 and β4 subunits. In fact, mRNAs for such subunits have been 
found in bovine adrenal cells 297-299. Further studies with bovine adrenals confirmed 
that such glands were rich in nAChRs containing the α3 and β4 309 subunits. Given 
that only limited amounts of tissue were available to carry out radioligand binding 
experiments, only few studies on native neuronal α3-containing nAChRs have been 
performed 180, 285, 309. The use of a radio-iodinated version of (±)-epibatidine 13, 
thought to give an acceptable numbers of counts, was not able to overcome the 
problem of a limited supply of tissue containing α3β4* nAChRs. On the other hand, 
the positive results obtained by Mukhin et al 180  using (±)-[3H]epibatidine and rat 
adrenal glands suggest that tritiated epibatidine, due to its high affinity to the 
ganglionic-type nAChRs, is a suitable radioligand to detect α3β4* nAChRs in adrenal 
glands. Based on these considerations, larger and more easily obtainable pig or calf 
adrenal glands were used in this study to perform radioligand-binding assays. The 
intention of saturation binding assays was to determine the KD and Bmax of (±)-
[3H]epibatidine for the α3β4* nAChRs contained in pig or calf adrenal glands.  
Competition assays 
In order to validate a novel procedure for radioligand binding competition assays 
using α3β4* nAChRs in native adrenal glands, affinities of some standard ligands, 
such as (±)-epibatidine 13, (-)-cytisine (Cy1) and (-)-nicotine 3 are assessed for the 
subtype under investigation. The results obtained in assays performed with known 
cholinergic drugs should confirm the utility of this novel protocol for screening the 
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affinities of novel ligands for the α3β4* nAChR. Moreover, for the first time, the 
affinities of the two enantiomers of epibatidine, (-)- and (+)-epibatidine are evaluated 
at the α3β4* nAChRs subtype (in the present study, (-)- and (+)-epibatidine refer to 
rotation of the salts). 
III/2.3. Results 
III/2.3.1. Analysis of (±)-[3H]epibatidine binding to α3β4* receptors in pig adrenal glands 
Saturation experiments were carried out by incubating 60-90 µg protein of pig 
adrenal whole membranes at 22 °C for 4 h in a total volume of 2.2 ml of HSS with 
concentrations of (±)-[3H]epibatidine ranging between 2 and 2400 pM. The results of 
saturation studies are shown in Fig. III/2.1. The binding parameters obtained from 
four independent experiments were: KD = 54 ± 4.6 pM and Bmax = 99 ± 11 fmol/mg 
protein. The nonspecific binding was determined in the presence of 600 µM (-) 
nicotine hydrogen tartrate salt. 
Kd = 54 pM                           
Bmax = 99 fmol/mg protein
0,0
0,5
1,0
1,5
2,0
2,5
0 50 100 150
Bound (fmol/mg protein)
B
/F
 (f
m
ol
/m
g 
pr
ot
ei
n/
pM
)
0
20
40
60
80
100
120
0 1000 2000 3000 4000
[3H] Epibatidine, pM
Sp
ec
ifi
c 
bi
nd
in
g,
 fm
ol
/m
g 
pr
ot
ei
n
 
Figure III/2.1: Each graphs represents results of a single experiment performed in quadruplicates 
(S.E.M. < 10%). Similar results were obtained in three additional experiments. 
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III/2.3.2. Analysis of (±)-[3H]epibatidine binding to α3β4* receptors in calf adrenal glands 
Saturation experiments were carried out by incubating whole membrane fractions of 
calf adrenals (60-90 µg protein) with different concentrations of (±)-[3H]epibatidine 
(2-2400 pM) at 22 °C for 4 h in a total volume of 2.2 ml (HSS). Nonspecific binding 
was determined in the presence of 600 µM (-)-nicotine hydrogen tartrate salt. The 
results of saturation studies are shown in Fig. III/2.2. The Scatchard plot was linear in 
conformity with the presence of a single population of binding sites. The binding 
parameters obtained from two independent experiments were: KD = 39 ± 5.3 pM and 
Bmax = 91 ± 10 fmol/mg protein. These studies demonstrated that calf adrenal provides 
a simple and convenient model system to study native α3β4* nAChRs subtype. 
Kd = 39 pM                           
Bmax = 91 fmol/mg protein
0,0
0,5
1,0
1,5
2,0
2,5
0 50 100 150
Bound (fmol/mg protein)
B
/F
 (f
m
ol
/m
g 
pr
ot
ei
n/
pM
)
0
20
40
60
80
100
120
0 1000 2000 3000 4000
[3H] Epibatidine, pM
Sp
ec
ifi
c 
bi
nd
in
g,
 fm
ol
/m
g 
pr
ot
ei
 
Figure III/2.2: Each graphs represents results of a single experiment performed in quadruplicates 
(S.E.M. < 10%). Similar results were obtained in three additional experiments. 
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III/2.3.3. A novel competition binding assay with (±)-[3H]epibatidine and calf/pig adrenal 
glands  
In competition assays with (±)-[3H]epibatidine and pig adrenal glands the affinity of 
standard cholinergic ligands, such as (±)-epibatidine 13, (+) and (-)-epibatidine, (-)-
cytisine Cy1 and (-)-nicotine 3 was assessed for α3β4* nAChRs 289-292. (±)-
[3H]Epibatidine binds to crude synaptic membranes of pig adrenals with a KD value 
of KD = 54 ± 4.6 pM. Different concentrations of a competing drug were incubated in 
the presence of 0.5 nM of (±)-[3H]epibatidine, at 22 °C for 90 min using whole 
membrane fractions of pig adrenal glands (60-90 µg). The rank order of potency of 
the agonists was (±)-epibatidine 13 >> (-)-cytisine Cy 1 > (-)-nicotine 3 (Tab. III/2.2). 
(±)-Epibatidine 13 was by far the most potent drug in competing for α3β4* nAChRs 
(Ki = 0.03 nM). Among these ligands, (±)-epibatidine 13 was > 600 times more potent 
than (-)-cytisine Cy 1 and 2200 times more potent than (-)-nicotine 3. In the present 
study, the interaction of the two epibatidine enantiomers with the α3β4* nAChRs 
subtype was investigated for the first time. Results of competition binding assays 
carried out with (±)-[3H]epibatidine in pig adrenal glands, revealed that (+)-
epibatidine (Ki = 0.124 ± 0.02 nM) has a 3-fold lower affinity compared to the (-)-
epibatidine (Ki = 0.042 ± 0.06 nM). Therefore, these values demonstrated that (-)-
epibatidine binds to the α3β4* nAChRs subtypes with a certain degree of 
enantiomeric selectivity.  
Table III/2.2: Comparison of binding affinities (Ki values) of nicotine 3, (-)-cytisine Cy1, (±)-epibatidine 
13 derived from binding competition studies against (±)-[3H]epibatidine,using different tissue sources 
Competing 
drugs 
(±)-[3H]EPI 
pig adrenal glands 
α3β4* nAChRs 
Ki  (nM) 
(±)-[3H]EPI 
bovine adrenal 
medulla 
α3β4* nAChRs 
Ki  (nM) 
309 
(±)-[3H]EPI 
recombinant 
bovine adrenal 
medulla 
expressed in HEK 
293 cells 
Ki  (nM) 
310 
(±)-[125I]EPI 
rat adrenal glands 
α3β4* nAChRs 
Ki  (nM) 
Davila 2003 
(±)-[3H]EPI 
rat adrenal glands 
α3β4* nAChRs 
Ki  (nM) 
180 
(+)-EPI 0.124 ± 0.02  n.d. n.d. n.d. n.d. 
(-)-EPI 0.042 ± 0.06  n.d. n.d. n.d. n.d. 
(±)-EPI  0.03 0.3 ± 0.1 0.3 ± 0.02 0.30 ± 0.14 0.049 ± 0.02 
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(-)-
Nicotine  
67 215 ± 69 517 ± 9 236 ± 45 100 ± 20 
(-)-
Cytisine 
18 401 ± 37 517 ± 27 325 ± 24 54 ± 9 
 
III/2.4. Discussion  
 
Neuronal nicotinic receptors in the brain can be labelled and studied with different 
radioactive agonists, including [3H]ACh 75, 314, (-)-[3H]nicotine 75, and (-)-[3H]cytisine 
232, 315. However, these radiolabelled agonists, due to their low affinities towards non-
α4β2* nAChRs, are not useful in detecting receptor subtypes in the adrenal glands or 
autonomic ganglia. The present study shows that (±)-[3H]epibatidine, in addition to 
being an excellent radioligand for studying nAChRs present in rat brains (CNS)179, 285, 
286, is also a suitable ligand to characterize α3β4* nAChRs present in the peripheral 
neuronal tissues. This conclusion is based on results of saturation studies performed 
with (±)-[3H]epibatidine and pi/calf adrenal glands. (±)-[3H]Epibatidine 
(concentration range of 2-2400 pM) was shown to combine with a KD = 54 ± 4.6 pM to 
nAChRs in pig adrenals (Bmax of 99 ± 11 fmol/mg protein) and with a KD of 39pM to 
nAChRs in calf adrenals (Bmax of 91 ± 10 fmol/mg protein). The KD values are 
consistent with the previously measured KD value of 55 pM for (±)-[3H]epibatidine 
binding with nAChRs in the rat adrenal gland membranes 180 and in native bovine 
adrenal α3β4* nAChRs (KD = 52 pM and BMAX =34 fmol/mg protein) 309, 310. Pig and calf 
adrenal glands possess some advantages in comparison to rat adrenal glands, such as 
the large size and easy availability from a local slaughterhouse. Such characteristics 
make the preparation of whole membrane fraction from pig and calf adrenal glands 
uncomplicated and permit having enough native tissue, with a suitable density of 
α3β4* nAChRs at one´s disposal. Such considerations underlined that pig/calf 
adrenal glands represent a better tool for research purpose than other native tissue 
and sustain the classification of adrenal nAChRs as α3β4* nAChRs. In order to 
validate the experimental conditions for a novel competition binding assays for 
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α3β4* nAChRs subtypes, the binding affinities of standard cholinergic agonists were 
determined using (±)-[3H]epibatidine and pig/calf adrenal glands 289-292. In the present 
study, the binding affinity of (±)-epibatidine 13 for nAChRs in pig adrenal glands (Ki 
= 0.03 nM) was in accordance with the value found by Mukhin et al. 180 in 
competition binding assays using (±)-[3H]epibatidine and rat adrenal glands (Ki = 
0.049 nM). On the contrary, it is not possible to compare Ki values found in this 
project for (±)-epibatidine 13, (-)-cytisine Cy 1 and (-)-nicotine 3 for α3β4* nAChRs 
with previous values obtained from competition assays using (±)-[3H]epibatidine and 
cultured bovine chromaffin cells or native bovine chromaffin cells (Tab. III/2.2) 309, 310. 
The discrepancies may be related to the different protein concentration (10-fold 
higher) used by other research groups in radioligand assays 309,310. Once the protocol 
of this novel competition assay had been validated, a series of experiments have been 
carried out, for the first time, to investigate the ability of the α3β4* nAChRs subtype 
to interact with a certain degree of enantiomeric selectivity. It has been previously 
reported that binding sites on the α4β2* nAChRs do not distinguish between the 
stereoisomers of (±)-epibaditine 13 285. In fact, competition assays using (-)-
[3H]nicotine and P2 membrane fraction of rat brain nAChRs showed that the natural 
enantiomer, (+)-epibaditine 13 (Ki = 0.045 nM) has nearly the same binding affinity of 
the synthetic enantiomer, (-)-epibaditine (Ki = 0.058 nM) for α4β2* nAChRs 157. In 
order to determine whether the α3β4* nAChRs subtype is able to distinguish 
between the two isomers of (±)-epibatidine 13, competition binding studies using (±)-
[3H]epibatidine and (+)-epibatidine, (-)-epibatidine in pig adrenal glands have been 
performed. The rank order of potency was (-)-epibatidine > (+)-epibatidine. 
Surprisingly, the (1R,2R,4S)-(-)-epibatidine (Ki =0.042 ± 0.06 nM) showed 3-fold 
higher affinity than the (+)-isomer of epibatidine (Ki =0.124 ± 0.02 nM) for the α3β4* 
nAChRs subtypes. This presence of stereospecificity probably indicates that a chiral 
centre of (±)-epibatidine 13 participates in a decisive way to its binding to α3β4* 
nAChRs. 
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III/3. Cytisine as a lead compound for novel nAChR ligands 
III/3.1. Introduction 
III/3.1.1. Cytisine: Structure and Origin 
(-)-Cytisine Cy 1 (1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one) is a 
quinolizidine alkaloid composed of a tricyclic skeleton with a bispidine framework 
fused to a pyridone moiety (Fig. III/3.1). The absolute configuration of the two chiral 
centres was established by Okuda et al. to be 7R and 9S 316.  
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Figure III/3.1: Structure of cytisine Cy 1, composed of a bispidine framework fused to a pyridone 
moiety (an alternative numbering of atoms is used: 7,9,10,11,12,13-hexahydro-7,9-methano-
pyrido[7,8][7,9]diazocin-2-one). 
(-)-Cytisine Cy 1 is easily accessible by extracting seeds from Laburnum anagyroides 
medicus (Fabaceae) (Fig. III/3.2) 317, 318. This plant is poisonous with the greatest 
amount of the highly poisonous alkaloid found in the black seeds (up to 3%) 319. They 
are toxic after ingestion (LD50 = 101 mg/kg p.o. in mouse) 319 and the symptoms are 
similar to those of (S)-(-)-nicotine 3 intoxication (LD50 = 25 mg/kg p.o in mouse) 319. In 
fact, (-)-cytisine Cy 1, like (-)-nicotine 3, can cause convulsions and death by 
respiratory failure 320, 321. 
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Figure III/3.2: Laburnum anagyroides medicus (Fabaceae). 322 
Barlow and Johnson determined the X-ray crystal structure of (-)-cytisine Cy 1. They 
noted that although Cy 1 has a rigid structure, it occurs in the crystal in two distinct 
but very similar conformations. A comparison of the structure of (-)-cytisine Cy 1 and 
(-)-nicotine 3 (Fig. III/3.3) shows that the quasi-aromatic ring in the (-)-cytisine Cy 1 
and the pyridine ring of (-)-nicotine 3 are tilted in a similar extent in relationship to 
the nitrogen atom in the bispidine ring and the nitrogen atom in the pyrrolidine ring, 
respectively 250 (Fig. III/3.3). 
N
O
NH
N
CH3
N
(7R,9S)(-)-cytisine Cy1 (S)(-)-nicotine (3)  
Figure III/3.3: Structure of (-)-nicotine 3 and (-)-cytisine Cy1. 
(-)-Cytisine Cy 1 represents an important nAChR ligand, which could disclose new 
opportunities for developing new agonists or antagonists in this receptor family. In 
radioligand binding studies, (-)-cytisine Cy 1 has demonstrated a very high affinity 
to neuronal nicotinic receptors (KD = 0.15 - 0.98 nM) 43, 183, 231, 232, 315, 323 and a very high 
selectivity for nicotinic compared to muscarinic receptors (Ki = 0.16 nM (nAChRs) 
and Ki > 400,000 nM (mAChRs)) 183. Recent studies showed that compared to (-)-
nicotine 3, (-)-cytisine Cy 1 has a 7-fold higher affinity (Ki = 0.124 nM) 230 for the α4β2* 
subtype and only a 2-fold lower affinity for the α7* nAChR (Ki = 261 nM) 230. 
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Functional data showed that the effects of (-)-cytisine Cy 1 on nAChRs are sensitive 
to receptor subunit composition. (-)-Cytisine Cy 1 is a full and potent agonist at hα7 
(EC50 = 83 µM) 324, 325 in the Xenopus oocytes expression system and an agonist at 
hα4β4 receptors. But it appears to be only a partial agonist when the α subunits are 
co-expressed with β2 instead of β4, constituting the hα4β2 subtype 183, 231, 325, 326. (-)-
Cytisine Cy 1 has also been proved to be a relatively potent agonist at the α3β4* 
receptor but a poor agonist at the α3β2* 231. In bovine adrenal chromaffin cells 
expressing the β4 subunit, (-)-cytisine Cy 1 stimulates adrenal catecholamine release 
(EC50 = 41 µM), being less efficacious than either (-)-nicotine 3 or (±)epibatidine 13 
(EC50 = 4 µM and 8.5 nM, respectively) 299. These results are consistent with a partial 
agonist action of (-)-cytisine Cy 1 on adrenal nAChRs. Tritiated (-)-cytisine Cy 1 was 
used as radioligand largely due to its high affinity for α4β2* nAChRs (KD = 0.15 - 0.98 
nM) 183, 232. The binding characteristics of (-)-[3H]cytisine were investigated in whole 
rat brains as well as in different regions of the human brain (cortex, hippocampus, 
thalamus and cingulate). The highest density of cytisine binding sites was found in 
the thalamus (KD = 0.147 nM and Bmax = 48 fmol/mg protein) 315. (-)-[3H]Cytisine has 
the advantage to show a high selectivity for nicotinic over muscarinic receptors 
(eliminating the need to mask muscarinic receptors), a slow rate of dissociation and a 
chemical stability (it is not subject to hydrolysis, as ACh is) 183. These features make it 
a suitable tool for studying neuronal nAChRs 315. 
III/3.1.2. Cytisine: Potential Clinical Utility 
(-)-Cytisine Cy 1 has a remarkable combination of properties and shares various 
physiological effects with (-)-nicotine 3. (-)-Cytisine Cy 1 acts mainly at the 
ganglionic level where it exhibits more stimulating than blocking effects 327. (-)-
Cytisine Cy 1 stimulates the nAChRs located on the postsynaptic membranes in the 
autonomic ganglia, chromaffins cells and sinocarotid reflexogenic zone. This results 
in an excitation of the respiratory centre, release of adrenaline by the suprarenal 
glands and a rise in the blood pressure.  
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Currently, (-)-cytisine Cy 1 is on the market in Bulgaria as the main compound in a 
pharmaceutical preparation called Tabex®, intended for the treatment of tobacco 
dependence 319. The mechanism of action of (-)-cytisine Cy 1 is that of a nicotine-
substitute able to reduce the smoker’s mental and physical dependency on nicotine 3 
319. The daily therapeutic saturating dose of Tabex® is from 1.5 to 9 mg. Each tablet 
contains 1.5 mg cytisine 319. In the former Soviet Union, (-)-cytisine Cy 1 was used as 
a respiratory analeptic for its stimulating activity on respiratory centres 328. Japanese 
patents proposed (-)-cytisine Cy 1 and its methyl derivative as hypoglycaemic and 
antinflammatory agents 329, 330. Due to its high affinity to neuronal nicotinic receptors 
and its pharmacological similarities to (-)-nicotine 3, (-)-cytisine Cy 1 and some 
derivatives were patented in 1994 by Reynolds Tobacco CO (U.S.A.) for use in the 
treatment of neurodegenerative diseases 331. More recently, Pfizer Company have 
filed patent applications that focus on the partial agonist profile of (-)-cytisine 
derivatives and their potential use in treating addiction and obesity (in conjunction 
with an anti-obesity agent) 332, 333. In 2000, a Russian patent claimed phosphorus-
containing derivatives of (-)-cytisine Cy 1 as hepatoprotecting agents 334. Moreover,  
(-)-cytisine Cy 1 shows antinociceptive activity and is able to modulate locomotor 
activities 335, 336.  
III/3.1.3. Cytisine: Previous Studies and Structural Modification  
(-)-Cytisine Cy 1 provides an interesting template for the design of novel nicotinic 
ligands 232. Due to its semi-rigid structure, its high affinity towards neuronal nAChRs 
and its ability to discriminate among different receptor subtypes, it has been chosen 
as a lead compound for investigating the influence of various substituents on the 
affinity for different nAChR subtypes 230, 325, 327. In the past, structural modifications of 
(-)-cytisine Cy 1 were made to improve its respiratory analeptic property 337 or to 
develop new local anaesthetic agents 338. In the past few years, structural 
modifications of (-)-cytisine Cy 1 have been performed in order to obtain compounds 
of potential therapeutic interest in the central nervous system, with a particular focus 
on neurodegenerative disease 327. One of the first chemical modifications on (-)-
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cytisine Cy 1 concerned the basic nitrogen atom of the bispidine ring. Boido et al. 327 
investigated the effects of the introduction of saturated or unsaturated alkyl or 
arylalkyl residues and more complex moieties at the secondary amino group. 
Moreover, they prepared a set of compounds possessing two cytisine units connected 
by a polymethylene chain 327. All these compounds were subjected to a broad 
pharmacological evaluation in order to clarify their affinities for a number of 
receptors (α1-adrenergic, dopaminergic (D2), serotonin (5HT3), histamine (H3), 
kainate, muscarinic (M1 and M2), N-methyl-D-aspartic acid (NMDA), cholecystokinin 
A, vasoactive intestinal polypeptide (VIP)). The cytisine derivatives tested in binding 
experiments with (-)-[3H]cytisine using brain cerebral cortices exhibited an affinity 
significantly lower than that of cytisine itself to the nAChRs. The Ki values are in the 
nanomolar range (between 30 and 4100 nM). The most active compound was the 
cytisine dimer 1,3-bis-(N-cytisinyl)-propane (Ki = 30 nM) 327. The other compounds 
showed other biological effects such as anti-hypertensive, cardioionotropic, anti-
inflammatory and hypoglycemic effects 327. Recently, Boido et al. 339 studied structural 
modifications of (-)-cytisine Cy 1 with the intention of reducing its affinity for 
ganglionic receptors. The chemical modification investigated in this work concerned 
mainly the secondary amino function rather than the pyridone ring (Fig. III/3.4.) 339. 
These compounds were tested for their ability to displace (-)-[3H]cytisine from rat 
brain membranes. 
NH
N
O
secondary amino function 
pyridone ring 
Figure III/3.4: Chemical modifications investigated in the structure of (-)-cytisine Cy 1 
In 2003, Carbonelle et al. synthesized some cytisine derivatives whose amine 
function was substituted by aliphatic, alicyclic or chloroheteroaryl groups 340. These 
cytisine derivatives were tested in competition binding studies using (±)-
[3H]epibatidine and [125I]α-Bgt, respectively, and native neuronal nicotinic receptor 
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subtypes present in the rat central and peripheral nervous system. Furthermore, in 
order to assess the functional profile, all compounds were tested on the Ca2+ flux of 
native or transfected cell lines expressing the rat α7 or human α3β4 or α4β2 (using 
Ca2+ dynamics with a fluorescence image plate reader, FLIPR) 340. Some derivatives 
were also electrophysiologically tested on Xenopus oocytes expressing rat α4β2; α3β4 
and α7 subtypes. N-3-oxobutylcytisine was found being a partial agonist for α4β2 
and α3β4 and only a weak antagonist at the α7 subtype. This derivative had the 
highest affinity for all three subtypes examined (Ki = 0.87 nM for α4β2, Ki = 552 nM 
for α3β4 and Ki = 1,240 nM for α7 nAChRs). The compound with an adamantin 
moiety at the bispidine nitrogen had the lowest affinity for all subtypes. Pfizer 
Company focused its interest on cytisine derivatives containing a halogen substituent 
at the pyridone ring. Data concerning biological evaluation has not been published 
333. In 2001, Imming et al. developed a new and simple synthetic method for 
preparing halogenated cytisine derivatives 230 and investigated the influence of 
halogen substituents, such as chlorine, bromine and iodine in position C-3, C-5 or C-3 
and C-5 on the affinity for α4β2* and α7* nAChRs. They found that several of these 
halogenated cytisines proved to be highly potent nAChR ligands 230. In addition, they 
reported the first synthesis and biological evaluation of the previously unknown 
thiocytisine, characterized by a bioisosteric replacement of the lactam moiety by a 
thiolactam 230. In 2003, Slater et al. resynthesized and investigated the effects of 
bromination or iodination of the pyridone ring of (-)-cytisine Cy 1 and N-methyl-
cytisine Cy 3 on recombinant human α7, hα4β2 and hα4β4 nAChRs expressed in 
Xenopus oocytes and clonal cell lines 341. They found that halogenation at C-3 of the 
pyridone ring of (-)-cytisine Cy 1 or N-methyl-cytisine Cy 3 improves the binding 
affinities and efficacies of (-)-cytisine Cy 1 on hα7 as well as on hα4β2 and hα4β4. 
The opposite effect was shown if (-)-cytisine Cy 1 is halogenated at position C-5 or 
position C-3 and C-5 of the pyridone ring 341.  
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III/3.2. Project 
(In cooperation with Prof. Seitz, Department of Pharmaceutical Chemistry, University of Marburg: synthesis of 
novel cytisine analogues) 
(-)-Cytisine Cy 1 has been chosen as a template to synthesize novel analogues due to 
its semi-rigid conformation and high affinity for the α4β2* neuronal nicotinic 
receptor. Although several derivatives have already been synthesized, there is still a 
need for other novel ligands that would interact with greater selectivity and more 
potency with different neuronal nAChRs. The focus of this project was to find out 
which steric and electronic requirements are necessary to obtain selective ligands for 
the α4β2* nAChR. The affinities of the novel (-)-cytisine derivatives were also 
assessed through radioligand binding assays for α7*, α3β4* and muscle nAChRs. The 
purpose of this study was to identify which moieties are responsible for the binding 
to ganglionic and muscular subtypes which are thought to mediate potential side 
effects on the cardiovascular and gastrointestinal systems. In order to gain further 
insight into the structure activity relationship (SAR) of    (-)-cytisine derivatives, (Fig. 
III/3.5) a large number of structural modifications have been introduced such as: 
1. The introduction of the following substituents on the secondary amine 
function: a methyl, benzyl or acetyl group. 
2. The introduction of halogens (chlorine, bromine and iodine) in position C-3, 
position C-5 and in both positions C-3 and C-5 of the pyridone ring. 
3. Variation of the pyridone ring by the introduction of the nitro group in 
position C-3 and in position C-5. 
4. Conformationally constrained analogue. 
5. Hydrogenation of the pyridone ring. 
6. A carbonyl group in position C-11 of the bispidine ring. 
7. The introduction of multiple oxygen functionalities in position N-12, in 
position C-6 of the bispidine moiety and in position C-3 of the pyridone ring.  
8. Bioioisosteric replacement of the oxygen by sulphur: thiocytisine. 
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9. The introduction of halogens (chlorine, bromine and iodine) in position C-3, 
position C-5 and in both positions C-3 and C-5 of thiocytisine. 
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Figure III/3.5: Modifications on the structure of the natural alkaloid (-)-cytisine Cy 1 
III/3.3. Determination of affinities and structure-activity relationships (SAR) 
Cytisine 
The affinities of (-)-cytisine Cy 1 for the two major nAChR subtypes presumably 
present in the rat and human brain, α4β2* nAChRs and the α7* nAChRs, were 
previously determined by Imming et al. in radioligand binding studies on P2 
membrane fraction of rat brain, using (±)-[3H]epibatidine and [3H]MLA, respectively 
230. In order to study the binding profile of (-)-cytisine Cy 1 on receptors present in 
the autonomic nervous system (ANS) and neuromuscular junction (NMJ), its ability 
to displace binding of (±)-[3H]epibatidine in α3β4* and (α1)2β1γδ nAChRs was 
examined using whole membrane fractions from native pig adrenals and Torpedo 
californica electroplax, respectively. In competition binding experiments, (-)-cytisine 
Cy 1 bound to the ganglionic receptor subtype with a Ki value of 18 nM which means 
a 145-fold lower affinity compared with α4β2* nAChR (Ki = 0.124 nM) 230. The Ki value 
of (-)-cytisine Cy 1 for the (α1)2β1γδ subtypes was in the low micromolar range (Ki = 
1,300 nM). Based on these results, the rank order of affinity of (-)-cytisine Cy 1 for 
four nAChRs was: α4β2* > α3β4* > α7* > (α1)2β1γδ.  
 
 
III. Results 102 SAR of cytisine analogues 
Influence of substituents at the secondary amine function 
In previous studies, N–methylation of Cy 1 (Ki = 0.124 nM) to caulophylline Cy 3 
caused a dramatic loss in affinity for α4β2* dropping into the nanomolar range (Ki = 
5.7 nM) in comparison to the parent alkaloid Cy 1 230. The dimethylated compound 
caulophylline-methiodide Cy 5 disclosed only a two-fold lower affinity (Ki = 0.238 
nM) for α4β2* nAChRs in comparison to (-)-cytisine Cy 1 230. The introduction of a 
methyl moiety Cy 3 or dimethyl moiety Cy 5 at the secondary amine function proved 
to be unfavourable for the binding at α7* nAChRs (Ki = 15,000 nM and 1,100 nM, 
respectively) 230. In the present study, N-methylation of (-)-cytisine Cy 3 also proved 
to be detrimental for the binding affinity at the α3β4* nAChRs (83-fold lower in 
comparison with Cy 1) (Tab. III/3.1). The affinity of the N,N-dimethylated cytisine Cy 
5 for α3β4* nAChRs was not determined due to an insufficient amount of this 
compound. The influence of a voluminous group was investigated by the 
introduction of a benzyl group Cy 8 on the bispidine nitrogen. Binding experiments 
demonstrated that this bulky moiety at N-position has a detrimental effect on the 
binding affinity for α4β2* nAChRs (11,000 fold decrease), α7* nAChRs (190 fold 
decrease) and also for α3β4* nAChRs (305 fold decrease) (Tab. III/3.1). Cytisine 
derivatives tested in this series do not possess affinity for the muscle type.  
Tetrahydrocytisine and analogues  
The hydrogenation of the pyridone ring of (-)-cytisine Cy 1 leads to 
tetrahydrocytisine Cy 2 (Tab. III/3.1). From the Ki value obtained is evident that 
tetrahydrocytisine Cy 2 has a very low affinity for α4β2* nAChRs (170-fold lower 
than Cy 1), a 21-fold lower affinity for the α3β4* nAChRs (Ki = 385 nM), and a 14-fold 
lower affinity for the muscle type (Ki = 18,000 nM). Both N-methylation Cy 4 and N-
acetylation Cy 7 of the secondary amino function of the tetrahydrocytisine Cy 2 
caused a further loss in affinity for α4β2* nAChRs (Ki = 10,000 and 20,000 nM, 
respectively). On the contrary, quaternization of the bispidine nitrogen gives 
compound Cy 6 which shows a marked increase in affinity for α4β2* nAChRs (Ki = 
35 nM) in comparison with Cy 4 (Ki = 10,000 nM). The Ki value of Cy 6 for α4β2* 
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nAChRs was also 2-fold higher than the affinity of tetrahydrocytisine Cy 2 for this 
subtype (Ki = 17 nM) (Tab. III/3.1). A similar trend was observed for N-methylcytisine 
Cy 3 and N,N-dimethylcytisine Cy 5 compared to (-)-cytisine Cy 1. Interestingly, 
compound Cy 6 showed a dramatic reduction for the α7* nAChR (Ki = 17,000 nM). In 
these series, the N-methyl-tetrahydrocytisine Cy 4 is the only compound which 
maintains a modest affinity for α7* nAChRs (Ki = 2,450 nM). Its Ki value (Ki = 2,450 
nM), is similar to the lead compound Cy 2 (Ki = 2,000 nM), even if 7-fold lower 
compared to (-)-cytisine Cy 1 (Ki = 250 nM). However, Cy 4 showed only a weak 
interaction with α4β2* nAChRs (Ki = 10,000 nM) and no reasonable affinity for α3β4* 
nAChRs subtypes (Ki = > 50,000 nM) (Tab. III/3.1). 
A carbonyl group in position C-11 of the bispidine ring 
A carbonyl group in position C-11 of the pyridone moiety leads to a cytisine 
analogue Cy 9 with an affinity 1,000-fold lower (Ki = 125 nM) than the lead 
compound for α4β2* nAChRs (Tab. III/3.1). The presence of the carbonyl group in 
position C-11 of the pyridone moiety is also detrimental to the affinity for α7* (Ki = 
52,500 nM), α3β4* and muscle nAChRs (Tab. III/3.1).  
Cytisine derivatives with multiple oxygen functionalities 
The introduction of an acetyl substituent at position N-12, a carbonyl function in 
position C-3 of the pyridone ring and an ethoxy group in position C-6 of the 
bispidine moiety (Cy 10, 12-acetyl-6-ethoxy-3-oxo-dihydrocytisine) (Tab. III/3.1) 
result in a weak ligand for the nicotinic receptors, with Ki values in the micromolar 
range. It is difficult to predict which of these substituents are responsible for the loss 
of affinity because of the lack of analogues with similar moieties (Tab. III/3.1). 
Variation at the pyridone ring by the introduction of a nitro group  
in positions C-3 and C-5 
Interesting results were obtained with cytisine analogues bearing a nitro group in 
position C-3 and C-5 of the pyridone moiety. The compound containing a nitro 
group in position C-3 (Cy 12) presented a Ki value for the α4β2* nAChR in the 
picomolar range (Ki = 0.42 nM). On the contrary, introduction of the same moiety in 
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position C-5 led to a compound (Cy 13) 100-fold less potent than Cy 12 for this 
subtype. The affinity of Cy 12 for the α7* subtype was 65-fold higher than the lead 
compound Cy 1. The nitro group in position C-5 on the pyridine ring Cy 13 is not 
well tolerated and is particularly detrimental to the affinity for the α7* subtype (300-
fold decrease). The affinity of the analogue Cy 12 for the α3β4* is similar to that of 
the lead compound (-)-cytisine Cy 1 (Tab. III/3.1). Compound Cy 13 showed only low 
affinity for α3β4* and (α1)2β1γδ nAChRs. 
Constrained analogues 
A conformationally constrained analogue Cy 11 possesses a low affinity for α4β2* 
nAChRs (Ki = 5,333 nM) (Tab. III/3.1), whereas it is not able to interact with α7* 
nAChRs subtypes. 
Table III/3.1: Radioligand binding affinities of cytisine analogues for α4β2*, α7*, α3β4*and (α1)2β1γδ 
nAChRs. 
Structure No. 
α4β2* 
[3H]EPI 
rat brain 
Ki ( nM) 
α7* 
[3H]MLA 
rat brain 
Ki ( nM) 
α3β4* 
[3H]EPI 
pig adrenals 
Ki ( nM) 
(α1)2β1γδ 
[3H]EPI 
Torpedo calif. 
Electroplax 
Ki ( nM) 
NH
N
O
 
Cy 1 0.124 ± 0.014 a 
261 ± 24 b  
250 n=1 
54 ± 9 c  
(rat adrenal) 
18 
(pig adrenal) 
1,300 
NH
N
O
 
Cy 2 17 2,000 385 ± 6 19,000 
NCH3
N
O
 
Cy 3 5.7 ± 1.5 a 15,000 a 1,500 n.d. 
NCH3
N
O
 
Cy 4 34 10,000 2,450 ± 420 > 50,000 
N
+
N
O
CH3
CH3
I
 
Cy 5 0.238 ± 0.046 a 1,100a  n.d. >20,000 
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N
+
N
O
CH3
CH3
NH
N
O
CH3O
> 50,000 > 50,000 > 50,000 
NH
N
O
 
Cy 8 1,448 n=1 > 50,000e 5,500e > 50,000 
NH
N
O
O
 
Cy 9 125 ± 17 52,500 ± 707e 1,600e > 50,000  
NH
N
O
O
O CH3
O
 
Cy 10 9,400 95,000e 50,000e 20,000  
N
N
NH
N
O
CF3
F3C  
Cy 11 5,333 > 50,000 n.d. n.d. 
NH
N
O
NO2
 
Cy 12 0.42 ± 0.07 40.7 ± 4.3 e  12 e 10,000 d 
NH
N
O
O2N  
Cy 13 65.6 ± 0.28 12,000 e 1,000e 20,000 d 
a =230 
b = [125I]-α-Bgt  
c = 180 
d = 342 
e = 343 
n.d.= not determined 
 
Cy 6 35 17,000 2,855 ± 6 > 50,000 
 
Cy 7 >20,000 
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Halogen substitution 
Halogen substitution at position C-3 
In previous studies, halogenation at C-3 of (-)-cytisine Cy 1 resulted in a marked 
improvement of affinity for α4β2* (Ki values from 0.01 to 0.022 nM) and for α7* 
nAChRs (Ki values from 1.5 to 2.5 nM) 230. The most potent molecule of this series for 
α4β2* nAChRs was 3-bromocytisine Cy 13 (Ki = 0.01 nM) which displayed a 10-fold 
higher affinity than the parent alkaloid (-)-cytisine Cy 1 (Ki = 0.124 nM), similar to 
that of (±)epibatidine 13 (Ki = 0.008 nM) (Tab. III/3.2). Slater et al. 341 suggested that 
the favourable effects on affinity of halogenation of (-)-cytisine Cy 1 at position C-3 
might be due to the existence of a hypothetical hydrophobic-binding pocket located 
close to the hydrogen bond donor moiety which is thought to interact with the 
carbonyl oxygen of (-)-cytisine Cy 1. Within the halo-series, the size of the halogen 
atoms does not cause a significant influence on the binding affinity for α4β2* and the 
electronegativity of the halogens seems to possess small relevance too (Ki = 0.010 (Br) 
≅ 0.017 (I) > 0.022 (Cl). However, when the halo-cytisine are compared to the lead 
compound (-)-cytisine Cy 1, the improvements in affinity are noteworthy. The 
presence of bromine in position C-3 is promising for a better interaction with the 
α4β2* nAChR. The size of the chlorine atom is smaller than that of bromine and, 
moreover, chlorine possesses a higher electronegativity. This causes a reduction of 
the negative charge on the carbonyl and thus a minor probability of hydrogen bond 
formation. Therefore, bromine emerges as the favourite halogen atom next to the 
carbonyl group. These considerations are also appropriate for α7* nAChRs. The 
affinity increases with an enhancement of the size of the halo substituent and with a 
diminution of the electronegativity. In fact, the 3-iodocytisine Cy 22 possesses the 
highest affinity for the α7* nAChRs (Ki = 1.5 nM) 230 within the 3-halogenated 
analogues and shows a 174-fold higher affinity compared to the lead compound (-)-
cytisine Cy 1 (Ki = 261 nM). The halogenated analogues in position C-3 (Cy 14, Cy 19 
and Cy 22) were tested for their in vitro affinity at the α3β4* and (α1)2βγδ nAChRs 
(Tab. III/3.2). Compared to the parent alkaloid Cy 1 (Ki = 18 nM) they showed a 
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higher affinity for the α3β4* nAChRs (Ki values from 0.35 -1.1 nM). The 3-
iodocytisine Cy 22 possesses the highest affinity, displacing (±)[3H]epibatidine with a 
Ki value of 0.35 nM. The rank order of potency at α3β4* nAChR is: 3-I > 3-Br > 3-Cl 
(Tab. III/3.2). The same trend was found for the ability of the halogenated 
compounds to inhibit the binding of (±)[3H]epibatidine at (α1)2β1γδ nAChRs (Ki 
value from 413 to 1,332 nM). Actually, halogenation in position C-3 only slightly 
improves the binding affinity for the muscle type in comparison with the high 
influence on the binding affinity for the α4β2*, α7* and α3β4* nAChRs. Compared to 
(-)-cytisine Cy 1, the affinity of the halogenated analogues in position C-3 (Cy 14, Cy 
19 and Cy 22) for the α4β2* nAChRs is higher, but the selectivity to α7* nAChRs is 
lower. Halogenation in position C-3 provides a marked increase in affinity for the 
affinity for α7* nAChRs compared to α4β2* nAChRs, so that the selectivity for α4β2* 
over the α7* is lower than that for (-)-cytisine Cy 1.  
Halogen substitution at position C-5 
Compared with halogenation in position C-3, halogen substitution in position C-5 of 
the pyridone moiety exerts a smaller impact on the binding affinity for all subtypes 
under consideration. Nevertheless, the Ki values for α4β2* of compounds Cy 16, Cy 
20 and Cy 24 are in the higher picomolar (5-iodocytisine Cy 24) and nanomolar 
ranges (5-chlorocytisine Cy 20) 230 (Tab. III/3.2). The 5-iodocytisine Cy 24 shows the 
highest affinity (Ki= 0.23 nM) for α4β2* nAChRs. The potency scale is 5-I > 5-Br > 5-Cl. 
The 5-chlorocytisine (Cy 20) possesses the lowest affinity, with a Ki value being 10-
fold lower (Ki= 2.5 nM) than the halogenated parent compounds Cy 16 and Cy 24. 
Compared to the parent alkaloid Cy 1 (Ki = 0.124 nM), the 5-iodocytisine and 5-
bromocytisine (Cy 24 and Cy 16, respectively) showed a similar affinity for the α4β2* 
nAChR (Ki values 0.23 nM and 0.38 nM, respectively). Even if the presence of a 
halogen at position C-5 of the pyridone fragment slightly reduces the affinity for 
α4β2* nAChR, it increases the affinity for the α7* nAChR subtype. The highest 
affinity was determined for the 5-iodocytisine Cy 24 with a Ki value of 21 nM being 
two-fold higher than (-)-cytisine Cy 1. Surprisingly, the affinity of the 5-
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chlorocytisine Cy 20 for the α7* nAChRs subtype drops in the low micromolar range 
(Ki= 1,000 nM). The rank order of affinities is: 5-I > 5-Br > 5-Cl. The introduction of 
halogen substituents at position C-5 of the pyridone moiety proves to be favourable 
for α7* as well as for the interaction with the α3β4* nAChRs. It results in a 5-fold 
affinity increase compared to (-)-cytisine Cy 1. The ligand with the best affinity is 
again the 5-iodocytisine Cy 24 with a Ki value in the low nanomolar range (Ki = 3.2 
nM). In this series, although the 5-chloro analogue Cy 20 possesses the lowest affinity 
for the ganglionic subtypes (Ki = 14.3 nM), it shows the highest Ki ratio between the 
α3β4* and α7* nAChR subtype. Interestingly, halogenation in position C-5 does not 
improve the affinity of cytisine derivatives for the muscle type. The Ki values are in 
the micromolar range (between 12,500 and 40,000 nM), thus 10 to 30-fold lower than 
that of (-)-cytisine Cy 1 (Ki = 1,300 nM). 
Halogen substitution at position C-3 and C-5 
Given that a bulkier substituent at position C-5 of the pyridone fragment reduces the 
affinity for α4β2*, it is expected that the 3,5-dihalocytisine derivatives (Cy 17, Cy 21 
and Cy 25) also possesses a reduced affinity towards the four subtypes of the 
nicotinic receptors under investigation. Indeed, the Ki values of Cy 17, Cy 21 and Cy 
25 ranged from 0.520 to 10.8 nM 230 (Tab. III/3.2). The 3,5-dichloro-cytisine Cy 21 has 
the higher subtype selectivity for α4β2* nAChRs over α3β4* nAChRs (1:114). The 
introduction of two chlorine halogens in position C-3 and C-5 (Cy 21) causes a drastic 
reduction in affinity for the α3β4* nAChR (Ki = 287 nM), whereas disubstitution with 
iodine (Cy 25) leads to a marked affinity increase for the same nAChR subtype (Ki = 
4.8 nM). Interestingly, the Ki value of Cy 25 at the α3β4* nAChRs is 3-fold lower than 
that of (-)-cytisine Cy 1 (Ki = 18 nM). The dihalogenation at position C-3 and C-5 
causes a considerable decrease in affinity for (α1)2βγδ nAChRs (Ki = 8,000 to 15,000 
nM) compared to (-)-cytisine Cy 1 (Ki = 1,300 nM). The structure-affinity relationship 
of the dihalogenated cytisine derivatives indicates that introducing iodine at position 
C-3 and C-5 increases the affinity for the α3β4* nAChRs subtypes, whereas it has 
little impact on the affinity for (α1)2βγδ nAChRs. The disubstitution at positions C-3 
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and C-5 with two different types of halogen atoms (chlorine and bromine) leads to 
compounds Cy 27 and Cy 28, with an even lower affinity for α4β2* in comparison to 
the previously tested dihalogenated derivatives (Cy 17, Cy21 and Cy 25) (Tab. 
III/3.2). The Ki values of compound Cy 27 and Cy 28 for α4β2* nAChRs, clearly shows 
the positive influence on binding affinities of a bromine in position C-3. The 
electronic properties and the size of the halogen in position C-3 also appear to be 
important for the affinity at the α3β4* nAChRs. Compound Cy 28 (3-Cl, 5-Br) (Ki = 
869 nM) shows 3-fold lower affinity for the α3β4* nAChRs in comparison with the 
3,5-dichlorocytisine derivative Cy 21 (Ki = 287 nM), whereas the Cy 27 (3-Br, 5-Cl) 
possesses 2-fold higher affinity than Cy 21. From these results we could hypothesize 
that an increase in size of the halogen atoms in position C-3, in combination with a 
reduced electronegativity, can have a positive influence on the affinity towards the 
α4β2*, α7* as well as α3β4* nAChRs subtype.  
N-Methyl-halo-cytisines 
N–methylation of 3-bromocytisine Cy 14 (Ki = 0.010 nM) to Cy 15 causes a dramatic 
loss in affinity Cy 15 (Tab. III/3.2). In relation to Cy 14, the Cy 15 has a 137-fold lower 
affinity for α4β2*, a 65-fold lower affinity for α7* and a 7.5-fold lower affinity for 
α3β4* nAChRs. Interestingly, compared to cytisine Cy 1 (Ki = 260 nM), Cy 15 retains 
a high affinity for the α7* nAChRs (Ki = 131 nM). It was observed that whilst N-
methylation of the bispidine ring seems to encumber the binding to the α4β2* and 
with some less extent to α7*, it is not detrimental to the interaction with α3β4* 
nAChR. Indeed, the N-methyl-3-iodocytisine Cy 23 shows subtype selectivity for 
α3β4* nAChR over α7* nAChR of a factor of 130 (Tab. III/3.2). N-methylation of 3,5-
dibromocytisine Cy 17 (Ki = 10.5 nM) to Cy 18 causes a further loss of affinity for 
α4β2*, dropping it into the high nanomolar range (Ki = 485 nM). The same trend can 
also be observed for the N-methyl-3,5-iodo-derivative Cy 26 (Ki = 656 nM). In fact, its 
binding affinity for the α4β2* is 1,300-fold lower than that of the 3,5-iodo-derivative 
Cy 25 (Ki = 0.520 nM). The structure activity relationship (SAR) of these N-methyl 
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analogues shows that introducing a methyl moiety on the secondary nitrogen is 
detrimental to the affinity towards all subtypes under investigation.  
Table III/3.2: Radioligand binding affinities of halo-cytisine analogues for α4β2*, α7*, α3β4* and 
(α1)2β1γδ nAChRs. 
N
N
O
R2
R1
R3
 
R1 R2 R3 No 
α4β2* 
[3H]EPI 
rat brain 
Ki ( nM) 
α7* 
[3H]MLA 
rat brain 
Ki ( nM) 
α3β4* 
[3H]EPI 
pig 
adrenals 
Ki ( nM) 
(α1)2β1γδ 
[3H]EPI 
Torpedo calif. 
electroplax 
Ki ( nM) 
Br H H Cy 14 0.010 ± 0.001a 2 ± 0.3a 0.61 ± 0.8 627 ± 49 
Br H CH3 Cy 15 1.37 ± 0.28 131 c 4.5 c n.d. 
H Br H Cy 16 0.308 ± 0.014a 28 ± 2a 5 ± 1.1 14,900 ± 2.3 
Br Br H Cy 17 10.8 ± 0.4a 1,500a n.d. n.d. 
Br Br CH3 Cy 18 485 n=1 > 10,000 n.d. n.d. 
Cl H H Cy 19 0.022 ± 0.005 a 2.5 ± 0.3a 1.1 ± 0.06 1,332 ± 108 
H Cl H Cy 20 2.5 ± 0.3 a 1,000a 14.3 ± 2.5 40,000 n=1 
Cl Cl H Cy 21 2.5 ± 0.4 a 1,000a 287 ± 6.3 >15,000 
I H H Cy 22 0.017 ± 0.002 a 1.5 ± 0.1a 0.35 413 ± 22 
I H CH3 Cy 23 0.988 ± 0.008 260c 2 c n.d. 
H I H Cy 24 0.230 ± 0.02a 21 ± 2a 3.25 ± 0.7 12,500 ± 4.43 
I I H Cy 25 0.520 ± 0.015a 41 ± 2a 4.8 ± 0.1 8,032 ± 2.09 
I I CH3 Cy 26 656 ± 85 6,000c 1,568c n.d. 
Br Cl H Cy 27 10.5 ± 0.5 420 c 174c 2,744b 
Cl Br H Cy 28 27 n=1 1,328 c 869 c 15,000b 
a = 230 
b = 342 
c = 343 
n.d. = not determined 
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Thiocytisine derivatives 
The bioisosteric thioanalog of (-)-cytisine Cy 1, named thiocytisine, showed a seven-
fold lower affinity compared with the parent alkaloid and subnanomolar binding 
affinity for the α4β2* receptor (Ki = 0.832 nM) (Cy 29) 230. (Tab. III/3.3). Remarkably, 
the novel thiocytisine showed the best affinity-selectivity profile for α4β2* nAChRs 
with an affinity for the α7* in the µM range (Ki = 4,000 nM) 230. In the present study, 
the affinity of thiocytisine Cy 29 for the ganglionic nicotinic receptors α3β4* was in 
the nanomolar range (Ki = 632 nM), approximately 35-fold lower than that of the 
parent compound (-)-cytisine Cy 1 (Ki = 18 nM). However, thiocytisine Cy 29 shows 
the best Ki ratio between the α4β2* receptors and the α3β4* nAChRs (α4β2* / α3β4* = 
1:790). Introduction of bromine or chlorine substituents at position C-3 of the 
pyridone moiety of thiocytisine Cy 29 gives analogues Cy 34 (Ki = 0.603 nM) and Cy 
32 (Ki = 1.48 nM) displaying affinities for α4β2* in the pico- and low nano-molar 
range. Compared to (-)-cytisine Cy 1 and thiocytisine Cy 29, the improvement of the 
binding affinity of Cy 34 was of great relevance towards all the neuronal nicotinic 
receptor subtypes under consideration. Indeed, the 3-bromothiocytisine Cy 34 
showed the highest affinity for α4β2* (Ki = 0.603 nM) as well as for α7* (Ki = 48 nM) 
and α3β4* (Ki= 11.8 nM) nAChRs. From these results it is evident that the 
introduction of a bromine or chlorine atom in position C-3 (Cy 32 and Cy 34, 
respectively) adjacent to the hydrogen-bonding centre enhances the affinity of the 
ligand. The electronic effect of bromine on the pyridine ring, and more specifically on 
the hydrogen bond accepting oxygen atom, appears to be ideal for the interaction of 
Cy 34 with the neuronal nicotinic receptor subtypes. The introduction of chlorine and 
bromine substituents at position C-5 of thiocytisine Cy 29 gives analogues Cy 33 and 
Cy 36, respectively. Compared to the thiocytisine Cy 29, both analogues possess 
lower affinity for α4β2* nAChRs. However, the 5-bromothiocytisine Cy 33 displays a 
better affinity for α4β2* (Ki = 8.1 nM) compared to the 5-chlorothiocytisine Cy 36 (Ki = 
55 nM). Halogenation in position C-5 of the thiocytisine Cy 29 slightly improves the 
binding affinity for the α7* nAChRs compared to the lead compound Cy 29. The 5-
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halogenated thiocytisines were also tested for the ganglionic and the muscular type. 
The affinity of the 5-bromo derivative Cy 36 (Ki = 141 nM) for the ganglionic type 
(α3β4*) is 8-fold higher than that for the α7* nAChRs and 4-fold higher than 
thiocytisine Cy 29 (Ki = 3,390 nM) (Tab. III/3.3). The affinity towards the muscle type 
is in the high micromolar range and is similar for both 5-halogenated derivatives (Cy 
33 and Cy 36). Studying the influence of a methyl or acetyl moiety on the bispidine 
ring of thiocytisine, it was observed that the affinities of these derivatives follow the 
same trend of the cytisine derivatives. N-methylation of thiocytisine Cy 30 caused a 
dramatic reduction in affinity, in particular towards α4β2* (Ki = 6,000 nM, which is 
7000-fold lower than (-)-cytisine Cy 1). The affinity of Cy 30 for the α7* and α3β4* 
nAChRs decreases by 10-and 5-fold respectively. N-acetylation of thiocytisine Cy 29 
leads to compound Cy 31. This substitution proved to be detrimental to the affinity 
towards α7*, α3β4* and muscle nAChRs. Interestingly, the introduction of an acetyl 
moiety on the byspidine ring Cy 31 causes an enhancement of the affinity towards 
α4β2* compared to the N-methyl analogue Cy 30. Compound Cy 35, N-acetyl-3-
bromo-thiocytisine, shows an increase in binding affinity for α4β2*, α7*, α3β4* 
subtypes with the exception of the muscle type (Tab. III/3.3). The Cy 35 possesses a Ki 
value for α4β2* in the low nanomolar range (Ki = 2.4 nM), namely 357 times higher 
than the affinity measured for the N-acetyl-thiocytisine Cy 31, but almost 3-fold 
lower than the affinity of thiocytisine Cy 29. From these values it is evident that the 
affinity of Cy 35 for the α4β2* is increased in comparison with the Cy 31, but not in 
comparison with the thiocytisine Cy 29. The opposite trend is observed for the 
affinities towards the other subtypes, namely the α7* and α3β4* nAChRs. Compared 
to thiocytisine Cy 29, Cy 35 shows 10-fold higher binding affinity for α7* and 2-fold 
higher for α3β4* nAChRs. 
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Table III/3.3: Radioligand binding affinities of thiocytisine analogues for α4β2*, α7*, α3β4* and 
(α1)2β1γδ nAChRs 
N
N
S
R2
R1
R3
 
R1 R2 R3 No. 
α4β2* 
[3H]EPI 
rat brain 
Ki ( nM) 
α7* 
[3H]MLA 
rat brain 
Ki ( nM) 
α3β4* 
[3H]EPI 
pig adrenals 
Ki ( nM) 
(α1)2β1γδ 
[3H]EPI 
Torpedo 
calif. 
electroplax 
Ki ( nM) 
H H H Cy 29 0.832a 4,000a 632 ± 62 95,000 
H H CH3 Cy 30 6,000 40,000 2,390 > 50,000 
H H COCH3 Cy 31 857 > 50,000 > 50,000 > 50,000 
Cl H H Cy 32 1.48 ± 0.4 50 n=1 248 ± 52 21,000 n=1 
H Cl H Cy 33 55 n=1 2,200 n=1 2,900 ± 208 > 50,000 
Br H H Cy 34 0.603 48 n=1 11.8 ± 0.35 11,150 ± 777 
Br H COCH3 Cy 35 2.4 412 307 ± 25 > 50,000 
H Br H Cy 36 8.1 1,400 141± 7 > 50,000 
H Br CH3 Cy 37 4,800 13,000 23,000 n.d. 
NH
N
S
 
Cy 38 2,900 8,000 4,300 ± 458 > 50,000 
NCH3
N
S
 
Cy 39 7,800 n =1 > 50,000 > 50,000 > 50,000 
a= 230 
n= number of experiments 
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Structure-activity relationship (SAR) for α4β2* (Fig. III/3.6) 
• The introduction of an acetyl or benzyl moiety at the secondary nitrogen of 
the bispidine ring of (-)-cytisine Cy 1 results in a dramatic loss of affinity. A 
moderate loss of affinity was observed with the introduction of a methyl 
group. Interestingly, a dimethylation, determining the formation of a 
quaternary amino function, gives a compound with an affinity similar to the 
lead compound Cy 1. 
• Bioisosteric thiolactam pharmacophore was found to retain much of the 
biological activity of the parent alkaloid with a subnanomolar affinity for the 
α4β2* subtype and displayed the best affinity-selectivity profile for α4β2* 
over α7* and α3β4*. 
NH
N
O
CH3 (CH3)2
OCH2CH3
NO2
NO2
S
acetyl>benzyl 
>
Cl >I > Br
hydrogenation
Br > I > Cl
carbonyl function
 
Figure III/3.6: Cytisine derivatives: structure activity relationship for the α4β2*nAChR 
• Halogenation at position C-3 of the pyridone ring of (-)-cytisine Cy 1 and 
thiocytisine Cy 29 significantly increases the affinity. 
• A nitro group in position C-3 as well as in position C-5 decreases the affinity. 
In particular, the nitro group in position C-5 causes a marked drop off in 
affinity compared to cytisine Cy 1.  
•  Hydrogenation of the pyridone ring reduces the affinity. 
• Halogenation at position C-5 of the pyridone ring of (-)-cytisine Cy 1 and 
thiocytisine Cy 29 moderately decreases the affinity. 
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• Dihalogenation at position C-3 and C-5 of the pyridone ring of (-)-cytisine Cy 
1 and thiocytisine Cy 29 decrease the affinity. 
• Introduction of an ethyl moiety at position C-6 is detrimental to the affinity. 
Structure-activity relationship (SAR) for α7* (Fig. III/3.7) 
• The bulkiness of the N-substituent greatly reduces the affinity of the 
compounds for α7* nAChRs. The introduction of a methyl, acetyl or benzyl 
moiety on the secondary amine function results in a dramatic loss of affinity. 
• A nitro group in position C-3 of the pyridone ring leads to a significant 
improvement of the affinity towards α7*, whereas in position C-5 it has a 
detrimental effect (binding affinity drops into the micromolar range). 
NH
N
O
CH3 (CH3)2
OCH2CH3
NO2
NO2
S
benzyl > acetyl 
>
I > Br
hydrogenation
I > Br > Cl
Cl
carbonyl function 
 
Figure III/3.7: Cytisine derivatives: structure activity relationship for the α7*nAChR 
• 3-chlorine, 3-bromine, 3-iodine derivatives possess an appreciably higher 
affinity relative to (-)-cytisine Cy 1. The Ki values range from 1.5 to 2.5 nM. 
• The introduction of a halogen in position C-5 of the pyridone ring may exert 
different effects, depending upon the nature of the halogen introduced. The 5-
chlorocytisine has a Ki value in the micromolar range, whilst 5-bromine and 5-
iodine possess an affinity for the α7* nAChRs of 21 and 28 nM, respectively. 
These latter compounds are more potent at α7* nAChRs than (-)-cytisine Cy 1 
(Ki value of 261 nM). 
• The dihalogenation in positions C-3 and C-5 is detrimental for the affinity. 
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Structure-activity relationship (SAR) for α3β4*nAChR (Fig. III/3.8) 
• The bulkiness of the N-substituent greatly decreases the affinity of the 
compounds. 
• The introduction of halogens on the pyridone ring in position C-3 or in 
position C-5 causes a marked increase in affinity. The rank order was for both 
positions: I > Br > Cl. 
NH
N
O
CH3 (CH3)2
OCH2CH3
NO2
NO2
S
acetyl>benzyl 
>
Cl >I > Br
hydrogenation
I > Br > Cl
carbonyl group
 
Figure III/3.8: Cytisine derivatives: structure activity relationship for the α3β4* nAChR 
• A nitro group in position C-3 or C-5 of the pyridone ring shows different 
effects: the 3-nitro derivative has an affinity similar to the lead compound (-)-
cytisine Cy 1. In contrast, the 5-nitro derivative shows reduced affinity 
compared to (-)-cytisine Cy 1. 
• The hydrogenation, as well as the bioisosteric replacement of oxygen by 
sulphur, in the pyridone ring leads to compounds with very low affinity. 
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Structure-activity relationship (SAR) for muscle type (Fig. III/3.9) 
• All modifications introduced at the structure of the lead compound resulted in 
being detrimental to the affinity to muscle type. 
 
NH
N
O
CH3 (CH3)2
OCH2CH3
NO2
NO2
S
acetyl>benzyl 
>
Cl >I > Br
hydrogenation
I > Br > Cl
carbonyl group
 
Figure III/3.9: Cytisine derivatives: structure activity relationship for the (α1)2β1γδ nAChR 
 
• The 3-iodo derivative with a Ki value of 413 nM (2-fold lower than cytisine Cy 
1) was the compound with the best affinity in this series. 
Summary of structure-activity relationschips (SAR) 
9 Substituents in the secondary amine function of cytisine decrease the affinity 
towards the nAChRs under consideration (Cy 3). 
9 Cytisine and thiocytisine analogues with a bromine atom as a substituent at 
position C-3 are the most potent nAChR ligands for the α4β2* (Cy 14-Cy 34). 
9 Bioisosteric replacement of oxygen by sulphur resulted in thiocytisine, a very 
selective ligand for α4β2* nAChRs (Cy 29). 
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III/3.4. Discussion 
(-)-Cytisine Cy 1, due to its structural rigidity and its high affinity for the nAChRs, 
has been chosen as a reference compound to design and synthesize new ligands for 
nAChRs 231. In preliminary studies, it was found that (-)-cytisine Cy 1 exhibited a 
high affinity (Ki = 0.124 nM) for the α4β2* subtype and a moderate affinity for the α7* 
subtype (Ki = 261 nM) 230.  
The binding affinity of (-)-cytisine Cy 1 has been evaluated for the muscle type 
(α1)2β1γδ and the ganglionic type α3β4* nAChRs. The Ki value of (-)-cytisine Cy 1 for 
the (α1)2β1γδ nAChRs was in the high nanomolar range (Ki = 1,300 nM). The binding 
affinity at α3β4* nAChRs, using (±) [3H]epibatidine and pig adrenals (Ki = 18 nM) was 
slightly higher than that assessed in a competition experiment performed with 
(±)[3H]epibatidine and rat adrenals (Ki = 54 nM) (Tab. III/3.1) resulting in a moderate 
species dependency. On the basis of these data, (-)-cytisine Cy 1 shows a high 
subtype selectivity for α4β2* nAChRs over the α7*, α3β4* and (α1)2β1γδ nAChRs. 
To evaluate the affinity of a high affinity ligand such as (-)-cytisine Cy 1, it is 
necessary to take into account the conditions used in the assays. There are some 
parameters that are essential to prevent the underestimation of the affinity of the 
competitors. Such parameters are: radioligand concentration, protein concentration, 
temperature and duration of the incubation time. For example, an increase in protein 
concentration can result in an increase of the Ki value of a high affinity ligand. In 
studies of Boido et al. 339, the use in assays of too high protein concentration (i.e. 600 
mg of protein in contrast to 60 mg 179) could give incorrect values (ligand depletion, 
Ki = 2.3 nM using (-)[3H]cytisine in rat brain, 339). In addition, Ki values found by 
Gündisch et al. 179 are not even comparable to the other Ki values that have been 
found in literature, due to the fact that the latter ones were determined using 
different membrane preparations, such as human recombinant α4β2 expressed in 
SHSY5Y cells 325 or in Xenopus oocytes 341. Binding studies 230, 251, 325, 327, 339 
demonstrated that halogenation of (-)-cytisine Cy 1 in position C-3 provides a higher 
affinity for nAChRs. In 2001, Imming et al.230 performed a further structural 
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modification of (-)-cytisine Cy 1 by replacement of a hydrogen atom of the pyridine 
moiety with a halogen (such as a chlorine, bromine and iodine) in one or more 
positions (C-3 and/or C-5) and investigated the influence of these substitutions on in 
vitro affinity for α4β2* and α7* nAChR. They found 3-bromocytisine Cy 14 to be the 
most potent molecule of this series (for α4β2* nAChRs) (Ki = 0.01 nM) with an affinity 
10-fold higher than the parent alkaloid (-)-cytisine Cy 1 (Ki = 0.124 nM). Furthermore, 
performing binding assays for the α7* nAChR using [3H]MLA and native α7* nAChR 
230, they also found that the introduction of a halogen in position C-3 causes a 
remarkable increase in affinity compared to (-)-cytisine Cy 1 with the following order 
of potency: I > Br > Cl. These results are in agreement with the ones performed by 
Houlihan 325 who compared the binding affinity of brominated cytisine analogues in 
position C-3, position C-5 and in both position C-3 and C-5 using human 
recombinant hα4β2 and hα7 expressed in SH-EP1 and SH-SY5Y cells as well as the 
ones from Slater et al. 341 who also tested the 3-iodocytisine and 5-iodocytisine using 
recombinant hα4β2 and hα7 nAChR 325. 
In the present study, the binding affinities of the halogenated compounds were 
determined for the naturally expressed α3β4* and (α1)2β1γδ nAChRs. The 
introduction of a halogen substituent in position C-3 of the pyridine ring improves 
the ability of the (-)-cytisine Cy 1 derivatives to interact with the ganglionic nicotinic 
receptors α3β4* nAChRs. Interestingly, the ability of 3-halogenated cytisine to 
interact with the nicotinic neuromuscular receptors is only slightly enhanced. 
Halogenation (bromine, chlorine and iodine) of cytisine at position C-5 reduces 
affinity for (±)-[3H]epibatidine binding site for α4β2* nAChRs 230, whereas 5-iodine 
and 5-bromine have an affinity higher than that of (-)-cytisine Cy 1 for α7* nAChRs 
230. Again, 5-halogenation on the pyridone ring of (-)-cytisine Cy 1 resulted 
favourably for the interaction with the α3β4* nAChRs naturally expressed in pig 
adrenals, whereas is unable to improve the affinity for the muscle type.  
Furthermore, the effects of the simultaneous halogenation either in position C-3 and 
position C-5 on the affinity for α3β4* and muscle nAChRs were investigated. The 
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introduction of two chlorine atoms in position C-3 and C-5 causes a drastic reduction 
in affinity for the α3β4* nAChRs, while disubstitution with iodine leads to a notable 
increase in affinity. The large size of the halogen atom may be favourable for the 
interaction with the α3β4* nAChR subtype. This trend does not subsist for (α1)2βγδ 
nAChRs. The disubstitution in positions C-3 and in C-5 with two different types of 
halogen atoms (chlorine and bromine) showed that a bromine halogen in position C-
3 rather than a chlorine halogen at the same position have a preference for a higher 
interaction at α4β2*, α3β4* and α7* nAChRs. From these results it follows that the 
halogen atom has different effects at the different receptor subtypes. In particular, the 
increase of the size of the halogen atom and the decrease of its electronegativity can 
enhance the affinity toward the ganglionic nicotine receptors subtype. Thus, the size 
of the halogen substituent may be a limiting factor at α4 subunit containing 
receptors, but not for α7* and α3β4* nAChRs.  
In literature, the influence of a variety of substituents on the amine nitrogen of (-)-
cytisine Cy 1 have been deeply investigated 327,340,339. In 2001, it was demonstrated that 
the introduction of a methyl group on the secondary nitrogen of (-)-cytisine Cy 1 is 
generally unfavourable for the affinity to all the nAChRs subtypes 230. Moreover, the 
introduction of a pentyl moiety leads to a compound showing a lower affinity for the 
neuronal nAChRs (Ki = 43.4 nM, using (-)[3H]cytisine and rat brain preparation) 339. 
Slater et al. 341 tested on α4β2 and α7 nAChRs expressed in human recombinant 
Xenopus oocytes, the N-methyl-3-bromocytisine and the N-methyl-5-bromocytisine 
341, demonstrating that halogenation of the N-methylcytisine in position C-3 as well 
as in position C-5 is favourable to the interaction with the α4β2 and α7 nAChRs. A 
similar trend has been observed in our binding experiments performed on native 
α4β2* and α7* nAChRs. Interestingly, a quaternization of the bispidine nitrogen 
improves the affinity for the α4β2* and α7* nAChRs, except for the muscle type (Ki 
value for α3β4* was not determined). In addition, in the course of this study it has 
been demonstrated that N-substitution (e.g. with a methyl, acetyl, benzyl, or 
carbonyl moiety) dramatically decreases the affinity for all nAChRs subtypes under 
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investigation. Such tendency is also corroborated from binding studies carried out by 
Slater et al. on α4β2 and α7 nAChRs expressed in human recombinant Xenopus 
oocytes 341. Furthermore, in order to unravel the influence of halogenation in the N-
methylcytisine skeleton on the affinities for other subtypes, the Ki values of these 
novel analogues have been evaluated for α3β4* and muscle nAChRs. Compared to 
the N-methyl analogue (Ki = 5.7 nM), the introduction of a bromine or an iodine atom 
at position C-3 of the N-methylcytisine produces an increase in the affinity for α4β2* 
nAChRs (Ki = 1.37 (Br) and Ki = 0.959 nM (I)). Moreover, the introduction of a bromine 
or an iodine atom at position C-3 of the N-methylcytisine is responsible for a 
significant increase in the affinity for native α3β4* (333- and 750–fold higher affinity, 
respectively) and α7* nAChRs (114- and 57–fold higher affinity, respectively). The 
binding affinity of N-methyl-3-bromocytisine and N-methyl-3-iodocytisine for the 
α7* is similar to that of (-)-cytisine Cy 1 (Ki = 131 and 260 nM, respectively), whereas 
it was observed as an improvement, in comparison to the lead compound, for their 
ability to displace (±)[3H]epibatidine on α3β4* nAChRs (4 and 9-fold, respectively). 
The affinity decreases remarkably for all the subtypes under investigation when the 
iodine or the bromine atoms are introduced at both positions C-3 and C-5 at the 
pyridone ring of N-methyl-cytisine. 
Interesting results have been obtained with compounds derived from the 
introduction of a nitro group in position C-3 or C-5 of the pyridone moiety of (-)-
cytisine Cy 1. The replacement of hydrogen in position C-3 by a nitro group 
enhanced the affinity for all types of nAChRs. On the contrary, the introduction of 
the same group in position C-5 strongly reduced the affinity. Bodio et al. 339 reported 
a similar pattern in a radioligand binding experiment using (-)-[3H]cytisine and 
whole membrane preparation from rat brain.  
The thiocytisine analogues representing a novel series of (-)-cytisine Cy 1 which have 
not been investigated so far. Here, for the first time, the affinity of these analogues 
was determined for four different nAChRs subtypes, namely: α4β2*, α7*, α3β4* and 
muscle type nAChRs. Bioisosteric replacement of the carbonyl oxygen by sulphur 
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resulted in a drastic decrease of affinity for the α7* subtype. On the basis of this 
finding, the novel thiocytisine may be used as a very selective ligand for α4β2* 
nAChRs. Unfortunately, none of the structural modifications of the thiocytisine were 
able to enhance the selectivity for subtypes under investigation. Furthermore, the 
influence of hydrogenation of the pyridine moiety was investigated. The 
tetrahydrocytisine Cy 2 showed affinity in the nanomolar range for α4β2* nAChR. 
Binding studies performed in our laboratory showed that structural modifications of 
the skeleton of the tetrahydrocytisine, such as N-methylation or N-acetylation are 
detrimental to the binding to α3β4*, α7* and muscle nAChRs. In a successive study, 
Boido et al. also tested the affinity of tetrahydrocytisine for the central neurons in the 
brain, finding a value (Ki = 138 nM) notably higher than the value found in the 
present study (Ki = 17 nM). This difference is probably due to the different conditions 
used in the competition radioligand binding assays. 
Such chemical modifications were of particular importance for unravelling the 
characteristics of the binding site and the development of a pharmacophore model 
(I/3). 
In conclusion, it would be interesting to discover which kind of substituent in the 
cytisine and thiocytisine template would be able to improve the selectivity towards 
α4β2* nAChRs and reduce or abolish the affinity towards the ganglionic and 
peripheral subtype. At the same time further modifications could lead to analogues 
with an improved selectivity for other nAChR subtypes. 
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III/4. Ferruginine as a lead compound for novel nAChRs ligands 
III/4.1. Introduction 
(+)-Ferruginine, a potent neurotoxin, is a natural alkaloid isolated from the arboreal 
species Darlingia ferruginea (J. F. Bailey) 344 and darlingiana (F. Muell) 345. The Darlingia 
darlingiana and ferruginea (common name Silky Oak) belong to the family of the 
Proteaceae (Fig. III/4.1) and contain (+)-ferruginine as their major alkaloid.  
 
 
Figure III/4.1: Flowers of the trees of Darlingia darlingiana and ferruginea 346 
 
The unnatural enantiomer of (+)-ferruginine, (-)-ferruginine Fe 1 as well as the 
demethylated analogue (-)-norferruginine Fe 2 347 (Fig. III/4.2), characterized by an 8-
azabicyclo[3.2.1.]octene-skeleton, have attracted considerable attention as potential 
modulators of the nicotinic acetylcholine receptors 348. The structure of (-)-ferruginine 
Fe 1 is similar to that of (+)-anatoxin-a An 1, a potent ligand on nAChRs. They differ 
only in the number of carbon atoms constituting the azabicyclic skeleton.  
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Figure III/4.2: Structures of (-)-ferruginine Fe 1, its demethylated analogue (-)-norferruginine Fe 2 and 
(+)-anatoxin-a An 1 
As shown in Fig. III/4.2, (+)-anatoxin-a An 1, (-)-ferruginine Fe 1 and (-)-
norferruginine Fe 2 have common structural characteristics. All of them possess a 
protonable nitrogen function and an acetyl side chain. Despite their similar structure, 
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(-)-ferruginine Fe 1 and its demethylated analogue Fe 2 possess a lower affinity for 
the central α4β2* nAChRs subtypes (Ki = 110 and 94 nM, respectively) compared to 
anatoxin-a An 1 (Ki = 1.1 nM) 228. In addition, (-)-norferruginine Fe 2 shows 
remarkably low affinity for the α7* nAChRs subtypes (Ki = 110,000 nM) 228. On the 
basis of the structural correlation of (-)-norferruginine Fe 2 to (+)-anatoxin-a An 1 as 
well as of the discovery of the racemic pyrido[3.4b]homotropane PHT, which is a 
bioisosteric and conformationally constrained variation of (+)-anatoxin-a An 1, the 
conformationally restricted pyrido[3.4-b]tropane P1, a bioisosteric variant of (-)-
norferruginine Fe 2, has been synthesized 349 (Fig. III/4.3). 
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Figure III/4.3: Structure of anatoxin-a An 1, its conformationally restricted analogue PHT, (-)-
norferruginine Fe 2 and its conformationally restricted analogue P1 
In order to obtain more information about the SAR of this structure for the nAChRs, 
the pyridino[3.4-b]tropane P1 has been used as lead compound to synthesize new 
variants, whereas the pyridine element is bioisosterically replaced by other nitrogens 
containing heteroarenes such as 1,2 and 1,3 diazines 349 (Fig. III/4.4). These 
constrained analogues were tested for their in vitro affinity for α4β2* and α7* 
nAChRs using (±)-[3H]epibatidine and [3H]MLA in P2 membrane fraction from rat 
brains.  
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pyrimidino[4.5-b]tropane    pyridazino[4.5-b]tropane   pyrimidino[5.4-b]tropane
P2                                              P3                                          P4  
Figure III/4.4: Conformationally restricted diazine bioisosteres of pyrido[3.4-b]tropane. 
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The pyridazino[4.5-b]tropane P3 (Ki = 76 nM) 349 has the highest affinity for α4β2* 
nAChRs. The dramatic decrease in affinity observed for the pyrimidine annulated 
isomer P2 (Ki value higher than 10,000 nM) is considered due to the less favourable 
orientation of the nitrogen atoms in position C-3. In contrast, the isomeric racemic 
pyrimidino[5.4-b]tropane P4 binds with a significantly higher affinity than P2 
(although it is 9-fold lower in comparison with the pyridazine annulated species P3). 
As observed for (-)-norferruginine Fe 2, none of these pyridazine or pyrimidine 
annulated ligands possess any affinity for the α7*, demonstrating an increased 
selectivity for the α4β2* over the α7* nAChRs. The structural modifications 
introduced on the skeleton of (±)-epibatidine 13, the potent agonist at α4β2* nAChR 
subtype, were taken as a model in order to improve the binding affinity of the lead 
compound (-)-ferruginine Fe 1. In previous studies, the bioisosteric replacement of 
the chloropyridyl moiety of (±)-epibatidine 13 350(with e.g. methylisoxazole, 222 
pyrimidine 351 or pyridazine 352) produced novel agonists which retained a good or 
improved affinity towards neuronal nAChRs receptors. Hence, novel diazine 
analogues of (-)-ferruginine Fe 1 were synthesized and tested in radioligand assays in 
order to examine the limits of the nicotinic pharmacophore 228, 258, 224, 260, 353, 259. These 
novel ligands are characterized by the azabicyclo[3.2.1]octane moiety of (-)-
ferruginine Fe 1 and by the replacement of the acetyl moiety in position C-2 with a 
diazine, such as pyridazine, pyrimidine and pyrazine. They were tested for in vitro 
affinity to central nAChRs such as α4β2* and α7* subtype 228. Interestingly, the 
pyrimidine analogue was revealed to be the most active compound with a Ki value of 
3.7 nM (Fe 20). The structure of this analogue was verified by X-ray crystallography, 
revealing an internitrogen distance close to that of (±)-epibatidine 13 228. In general, 
both the pyridazine and pyrimidine derivatives proved to be more efficacious to the 
α4β2* compared to the lead compound (-)-ferruginine Fe 1. Moreover, it was 
discovered that these ligands have only a weak binding affinity for the α7* subtype 
228. 
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III/4.2. Project 
(In cooperation with Prof. Seitz, Department of Pharmaceutical Chemistry, University of Marburg: synthesis of 
the novel ferruginine analogues) 
Only few structure-activity relationship (SAR) studies have been carried out with 
regard to the (-)-ferruginine-type nAChRs ligands so far. In 2001, an initial study was 
performed to determine the binding affinities of some diazine derivatives of (-)-
norferruginine (P2, P3, P4) for α4β2* and α7* nAChRs 228 (see above, introduction). In 
order to gain more information about the SAR of (-)-ferruginine Fe 1, some structural 
modifications have been introduced in the azabicyclic skeleton of (-)-ferruginine Fe 1 
by varying the nature of the two main elements of the general nAChR 
pharmacophore: the positively charged sp3 hybridised nitrogen in the azabicycle and 
the hydrogen bond acceptor group (HBA) 257-259,261. The (-)-ferruginine analogues are 
structurally similar to the (-)-norferruginine series recently published 228. In a 
previous study, it has been seen that the introduction of a N-methyl group, as in the 
case of (-)-nicotine/(-)-nornicotine 354 could increase affinity to the nAChRs. Therefore, 
it was of interest to study the influence of this modification on an 8-
azabicyclo[3.2.1.]octene-skeleton. To address the topic of binding selectivity among 
the nAChR subtypes, the affinities of these novel (-)-ferruginine and (-)-
norferruginine analogues will be measured in competition-binding assays for four 
different nAChRs. Below, (Fig. III/ 4.5) a list of the structural variations of the (-)-
ferruginine Fe 1 which have been developed is enumerated: 
CONH2, CON(CH3)2, CSN(CH3)2
H
N
CH3
COOCH3
H
N
CH3
CH3
O
pyridine or diazine group
1
5
1
5
(1R,5S)-ferruginine                                                                        ent-form
pyridine or diazine group
pyridine or diazine group
 
Figure III/4.5: Structural modifications of (1R,5S)(-)-ferruginine Fe 1 and the corresponding (1S,5R)(-)-
ent-form. 
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9 Replacement of the acetyl group of (1R,5S)(-)-ferruginine Fe 1 with an amide, 
dimethylamide, or thioamide moiety 
9 Replacement of the acetyl group of (-)-ferruginine Fe 1 with a pyridine or diazine 
group at position C-2 of the azabicycle. 
9 Introduction of a pyridine or diazine group at position C-3 of the azabicycle. 
9 Novel analogues of (-)-norferruginine with similar structural modifications 
performed on the (-)-ferruginine structure. 
9 Novel enantiopure ent-(-)-ferrugininoids (1S,5R) with a pyridine or diazine group  
9 Double substitution of the ent-azabicyclic skeleton with an ester and a diazine 
group. 
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III/4.3. Determination of affinities and structure-activity relationships (SAR) 
The (-)-norferruginine derivatives were evaluated in previously described 
competition assays for their possible interaction with different nAChR subtypes 
using (±)-[3H]epibatidine and [3H]MLA as radioligands and P2 membrane fractions 
of Sprague-Dawley rat forebrain (α4β2* and α7* nAChRs) 179,294,349,355. To estimate the 
binding affinities of the novel (-)-ferruginine and (-)-norferruginine analogues for the 
α3β4* nAChRs, a novel assay using pig adrenals and (±)-[3H]epibatidine was 
established 290, 292, 294. To characterize binding of each of the ferrugininoids to the 
(α1)2β1γδ nAChRs, (±)-[3H]epibatidine and Torpedo californica electroplax were used. 
(±)-[3H]Epibatidine bound to a single population of binding sites with KD = 2 ± 0.3 nM 
289, 290. 
Replacement of the acetyl moiety by an amide or thioamide group 
The replacement of the methyl group next to the carbonyl function with an amine, 
methylamine or dimethylamine moiety leads to compounds Fe 3, Fe 4 and Fe 5. 
These modifications have been performed based on the hypothesis that an increase of 
the hydrogen bond acceptor (HBA) capability of (-)-ferruginine Fe 1 might enhance 
the binding affinity for α4β2* nAChRs. In contrast, each of the amides Fe 3, Fe 4 and 
Fe 5 were weaker ligands for the nAChRs than the lead compound Fe 1. These 
derivatives (Fe 3, Fe 4, Fe 5) exhibited low affinity for α4β2* nAChRs (Ki values in the 
µM range) and no interaction with α7*, α3β4* and (α1)2β1γδ nAChRs (Tab. III/4.1). 
Furthermore, the exchange of the oxygen atom with a sulphur led to weaker ligands 
for the α4β2* nAChR, with Ki values in the higher µM range (Fe 6, Fe 7) (Tab. III/4.1). 
The derivatives Fe 6 and Fe 7 showed no interaction with other nAChR subtypes 
examined.  
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Table III/4.1: Radioligand binding affinities of (-)-ferruginine Fe 1 and (-)-norferruginine Fe 2 
analogues bearing an amide moiety for α4β2*, α7*, α3β4* and (α1)2β1γδ nAChRs. 
N O
R1
R2
 
R1 R2 No α4β2* 
[3H]EPI 
rat brain 
Ki ( nM) 
α7* 
[3H]MLA 
rat brain 
Ki ( nM) 
α3β4* 
[3H]EPI 
pig adrenals 
Ki ( nM) 
(α1)2β1γδ 
[3H]EPI 
Torpedo calif. 
electroplax 
Ki ( nM) 
CH3 CH3 Fe 1 120 ± 2 a 330 ± 23 a 1,455 ± 319 > 50,000 
H CH3 Fe 2 94 ± 5 a > 100,000 2,300 n=1 5,300 n=1 
CH3 NH2 Fe 3 3,790 > 50,000 > 50,000 > 50,000 
CH3 NHCH3 Fe 4 1,490 ± 252 > 10,000 > 50,000 > 50,000 
CH3 N(CH3)2 Fe 5 2,027 ± 40 7,500 n=1 n.d. n.d. 
 
N S
R2
R1
 
CH3 N(CH3)2 Fe 6 20,000 50,000 n.d. n.d. 
H N(CH3)2 Fe 7 2460 n=1 39,000 ± 1414 13,650 ± 3323 n.d. 
n.d. = not determined 
n = number of experiments 
a = 228 
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Pyridine analogues 
The substitution of the 2-acetyl moiety with a 3-pyridyl moiety seems to be of 
particular interest in the search for compounds with an improved affinity for 
neuronal nAChRs 202 203 356,357. Hence, in these series, the acetyl moiety of Fe 1 and Fe 2 
was substituted with a 3-pyridyl moiety, giving the analogues Fe 8 and Fe 10, 
respectively. The introduction of a 5-chloro-pyridyl moiety at position C-2, according 
to the structure of (±)-epibatidine 13, led to the ferruginine analogue Fe 11 (Tab. 
III/4.2). In addition, in order to obtain more information about the 
stereodiscrimination, ent-Fe 8, ent-Fe 9 and ent-Fe 10 were investigated for the 
multifarious nAChRs subtypes  
Substitution at position C-2 
The azine analogues Fe 8-Fe 11 proved to be very high affinity bioisosters of Fe 1 
with a significant influence of the heteroaryl moiety on the binding affinity and 
selectivity towards the nAChRs examined. The novel ferrugininoids proved to be 
more potent than the lead Fe 1 and the analogue Fe 2. The (-)-norferruginine 
derivative Fe 8 showed the highest affinity for the α4β2* nAChR subtype with a Ki 
value of 1.6 nM being twice as potent as (1S,5R) ent-Fe 8 (Ki = 3.8 nM). Interestingly, 
the stereodiscrimination found for Fe 8/ent-Fe 8 towards the α4β2* nAChRs subtype 
was not observed towards the α7* and α3β4* nAChRs subtypes. The 5-iodo-pyridyl-
containing modification (1S,5R) ent-Fe 9, exhibited a ca. 6-fold lower affinity (Ki = 
1,724 nM) for the α7* nAChRs compared to both Fe 8 and ent-Fe 8 (Ki = 396 and 365 
nM, respectively). Probably, the presence of a bulky substituent distorts the 
molecular conformation of the ligands and also affects the intramolecular N-N 
distance that seems to be important for the binding to neuronal nAChRs. On the 
contrary, the introduction of the iodine atom does not seem to disturb the interaction 
of (1S,5R) ent-Fe 9 with the α3β4* nAChRs, given that its affinity (Ki = 224 nM) is 
similar to that of the pyridyl analogue ent-Fe 8 (Ki = 198 nM). With regard to the 
ferruginine analogues, Fe 10, Fe 11 and their corresponding compounds ent-Fe 10 
and ent-Fe 11, the most active ligand at the α4β2* and α3β4* nAChRs (Tab. III/4.2) 
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was the 5-chloropyridyl-containing ligand Fe 11. The binding affinity of this 
compound for the α4β2* nAChRs (Ki = 1.1 nM) is 100-fold higher than the affinity of 
the lead Fe 1. Further, Fe 11 is able to differentiate between different nAChRs 
subtypes. In fact, it binds to the ganglionic α3β4* subtype with a 18-fold lower 
affinity than to the α4β2* nAChRs. One aspect that should be highlighted is the 
influence of the N-methyl moiety on the binding affinity of these ferrugininoids 
towards α7* nAChRs. On the one hand, N-methylation decreases (even if slightly) 
the affinity for the α4β2*, on the other hand it has been shown to increase 
significantly the affinity for α7* nAChRs. The results listed in the Table III/4.2 show 
that the ferruginine analogues, Fe 10 and Fe 11, exhibited the highest affinity for the 
α7* nAChRs in this series (Ki = 53 and 56 nM, respectively), which is ca. 7- to 30-fold 
higher than the affinities of its demethylated analogues (Fe 8, ent-Fe 8). The novel 
compounds Fe 10 and Fe 11 possess an even greater affinity for the α7* nAChR than 
the lead compound  (-)-ferruginine Fe 1 (Ki = 330 nM). Interestingly, both 
correspondent analogues ent-Fe 10 and ent-Fe 11 showed reduced affinity for the α7* 
nAChRs (Ki =237 and 371 nM, for the ent-Fe 10 and ent-Fe 11, respectively). The same 
tendency is observed for the α3β4* nAChRs. The ferruginine analogues Fe 10 and Fe 
11 bind with 3- and 7-fold higher affinity to the ganglionic α3β4* nAChRs (Ki = 44 
and 20 nM, respectively) compared to the (-)-norferruginine analogue Fe 8 (Ki =139 
nM). Both analogues ent-Fe 10 and ent-Fe 11 lose their affinities towards α3β4* 
nAChRs compared to the corresponding form Fe 10 and Fe 11. Whereas the α7* and 
α3β4* nAChRs are affected by the stereodiscrimination, the muscle type nAChRs 
does not seem to be influenced by the stereospecificity of the compounds. The Ki 
values found for Fe 10 and its corresponding analogue for muscle type nAChRs are 
nearly similar, as well as the affinities of Fe 11 and ent-Fe 11. It is interesting to notice 
that the introduction of a chlorine atom on the pyridine ring is correlated to an 
increase of 4-6 fold of the affinity of Fe 11 in comparison to Fe 10 for the muscle type 
nAChRs (Tab. III/4.2). 
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Influence of the methylisoxazole group 
It is known that the replacement of the pyridine ring of (S)(-)-nicotine 3 by an 
methylisoxazolyl moiety leads to a potent nicotinic ligand (ABT-418) 10 which 
possesses a high affinity binding for α4β2* nAChRs receptors 200. The replacement of 
the 2-chloro-pyridinyl unit of (±)-epibatidine 13 with a methylisoxazolyl moiety 
results in epiboxidine 32, an (±)-epibatidine 13 analogue also with very potent 
antinociceptive activity and a very high affinity for the neuronal nAChRs 222. Based 
on these results, the methylisoxazole ring appears to be a useful bioisosteric moiety, 
and it was used for the synthesis of the ferruginine analogue, Fe 12. Interestingly, 
this analogue possesses ca. 4-fold higher affinity for the α4β2* receptor compared to 
the lead compound Fe 1. Moreover, it is slightly more potent at the α7* receptor in 
comparison to the (-)-ferruginine Fe 1 (Tab. III/4.2). 
Table III/4.2: Radioligand binding affinities of ferruginine analogues bearing different pyridine 
moieties or a methylisoxazole for α42β23, α7*, α3β4*and (α1)2β1γδ nAChRs. 
Pyridine moieties (substitution at position C-2) 
N
R1
R2
 
N
R1
R2
ent-form
 
R1 R2 No. 
α4β2* 
[3H]EPI 
rat brain 
Ki ( nM) 
α7* 
[3H]MLA 
rat brain 
Ki ( nM) 
α3β4* 
[3H]EPI 
pig adrenals 
Ki ( nM) 
(α1)2β1γδ 
[3H]EPI 
Torpedo 
californica 
electroplax 
Ki ( nM) 
H N
 
Fe 8 1.6 ± 0.2 396 n=1 139 ± 16 n.d. 
H 
N  
ent-Fe 8 3.8 ± 0.8 365 ± 45 198 ± 72 n.d. 
H 
N
I  
ent-Fe 9 6.3 ± 0.9 1,724 ± 189 224 ± 45 n.d. 
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CH3 N
 
Fe 10 3.4 ± 1.4 53.3 ± 9.3 44 ± 5.7 4,390 ± 50 
CH3 
N  
ent-Fe 10 9.6 n=1 273 n=1 305 ± 7 6,323 n=1 
CH3 N Cl
 
Fe 11 1.1 ± 0.2 56.6 ± 3 20.7 ± 2 1,361 n=1 
CH3 
N
Cl  
ent-Fe 11 13.2 ± 3.7 371 ± 31 156 ± 3.5 1,430 ± 24 
Methylisoxazole analogue of (-)-ferruginine 
 
O NN
CH3
CH3
 
Fe 12 30 ± 1.2 234 n.d. n.d. 
n.d. = not determined 
n = number of experiments 
Substitution at position C-3 
The introduction of a pyridine or chloropyridine ring at the position C-3 of the 8- 
azabicyclo[3.2.1.]octene-skeleton leads to (-)-ferruginine/(-)-norferruginine analogues 
Fe 13, Fe 14 and Fe 15 bearing a structure similar to (±)-epibatidine 13. In previous 
studies, it has been shown that the 3-pyridyl unit is an important requisite for high 
affinity binding. As expected, these analogues showed an improved affinity for 
α4β2*, α7*, α3β4* and muscle nAChRs compared to the lead compounds Fe 1 and Fe 
2. The SAR observed for Fe 13, Fe 14 and Fe 15 confirmed the importance of an 
optimal distance between the cationic nitrogen of the azabicyclic skeleton and the 
pyridyl nitrogen for the binding affinity at α4β2* nAChRs. In this series, the (-)-
norferruginine derivative Fe 13 showed the highest affinity for α4β2* (Ki = 0.257 nM), 
being 376- and 466-fold more potent than (-)-norferruginine Fe 2 (Ki = 94 nM) and (-)-
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ferruginine Fe 1 (Ki = 120 nM), respectively. Fe 13 also showed a moderate selectivity 
for α4β2* over α3β4* nAChR subtypes (1:54). With regard to the (-)-ferruginine 
analogues, Fe 14 is slightly less potent than Fe 13 with respective decrease in binding 
affinities of 4.5 and 2-fold at α4β2* and α3β4*nAChRs. Chlorination of the pyridyl 
ring, as in compound Fe 15, exerts different effects on the binding affinity depending 
upon the subtype under consideration: it slightly decreases the affinity for α4β2* 
nAChR, whereas it has a detrimental effect for the affinity to α7* nAChRs (4-fold 
lower). An opposite tendency is observed for the ability of Fe 14 and Fe 15 to interact 
with the α3β4* nAChRs. Actually, analogue Fe 15 turned out to be the most active 
ligand at α3β4* nAChRs (Ki = 5.5 nM). The 5-chloropyridine moiety in position C-3, 
has been shown to improve the binding affinity toward α3β4* and muscle type to a 
similar extent (4-fold). This observation suggests that a chlorine atom on the pyridine 
ring improves the affinities for α3β4* and muscle type nAChRs (Tab. III/4.3). 
Influence of a double substitution at the azabicyclic skeleton 
The drop in affinity observed for the (-)-ferruginine analogues (ent-Fe 16 and ent-Fe 
17) (Tab. III/4.3) clearly indicates that a double substitution, such as an introduction 
of an ester moiety in position C-2 and a pyridine or chloropyridyl moiety at position 
C-3 of the (1S,5R)-8-azabicyclo-[3.2.1]octene-skeleton is significantly detrimental to 
the affinity for all subtypes examined. The Ki values have been detected in the 
micromolar range (Tab. III/4.3). The presence of bulkier substituents close to the HBA 
moiety appears to dramatically influence the affinities for neuronal nAChR. This 
observation inspires a hypothesis, namely that the ester group at position C-2 
orientates the substituent in a disfavoured region. In addition, the loss of affinity 
could be attributed not only to steric effects but also to the reduced electron density 
of the aromatic chloropyridine moiety. 
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Table III/4.3: Radioligand binding affinities of pyridine analogues of (-)-ferruginine, ent-(-)-
ferruginine and (-)-norferruginine for α4β2*, α7*, α3β4* and (α1)2β1γδ nAChRs. 
Pyridine moieties at position C-3 
N
R1
R2  
N
R1
R2R3
ent-form
 
R1 R2 R3 No. 
α4β2* 
[3H]EPI 
rat brain 
Ki ( nM) 
α7* 
[3H]MLA 
rat brain 
Ki ( nM) 
α3β4* 
[3H]EPI 
pig 
adrenals 
Ki ( nM) 
(α1)2β1γδ 
[3H]EPI 
Torpedo 
calif. 
electropla
x 
Ki ( nM) 
H 
N
 
H Fe 13 0.257 ± 0.06 n.d. 14 ± 3.5 n.d. 
CH3 
N
 
H Fe 14 0.96 ± 0.14 73.6 ± 7.7 24 ± 3.5 341n=1 
CH3 
N
Cl
 
H Fe 15 1.54 ± 0.02 256 ± 26 5.5 ± 0.9 80.3 ± 10 
CH3 
N
 
COOCH
3 
ent-Fe 16 4,931 ± 144a > 50,000 > 30,000 > 50,000 
CH3 
N
Cl
 
COOCH
3 
ent-Fe 17 1,659 ± 354 
20,311 ± 
185 
13,340 ± 
58 
> 50,000 
n.d.= not determined 
n= number of experiments 
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Diazine analogues 
The bioisosteric potential of diazine moieties on binding affinities was investigated in 
the field of (-)-ferruginine/(-)-norferruginine type structures. The novel ligands Fe 18-
Fe 34 are characterized by the azabicyclo[3.2.1]octene pharmacophore and by the 
replacement of the acetyl group of Fe 1 and Fe 2 with a diazine nucleus such as 
pyridazine, pyrimidine and pyrazine. The diazine moiety was introduced at position 
C-2 as well as positions C-3 of the azabicyclic skeleton. All these novel analogues 
were analysed for their in vitro affinity for α4β2*, α7*, α3β4* and (α1)2β1γδ nAChRs. 
Generally, the incorporation of an additional nitrogen atom into the heteroaromatic 
HBA pharmacophoric element has a deleterious effect on the binding affinity. This 
effect is well-known in literature, e.g. for the diazine substituted variants of (±)-
epibatidine 13 and anatoxin-a An 1 352. In the present study, the diazine substituted 
ferrugininoids and norferrugininoids are approximately 10-times less potent than the 
chloropyridyl/pyridyl substituted ligands Fe 8 and Fe 11 and Fe 13 and Fe 15 for the 
neuronal nAChRs subtypes.  
Influence of diazine substituents at position C-2 
The binding affinities (Ki values) of compounds Fe 18, Fe 20 and 21 for α4β2* and α7* 
have already been reported 228. It was demonstrated that the three isomeric diazine 
heterocycles are suitable bioisosteres of the acetyl moiety of Fe 1 228. Although the 
inter-nitrogen distance for the three bioisosteres is approximately equal, the presence 
of another nitrogen in the heteroaryl moiety obviously results in modifications of the 
electronic density in the diazine ring. As a consequence, the hydrogen bond acceptor 
ability, which is crucial for nAChR affinity, decreases. The most potent analogue for 
α4β2* was the chloro-pyrimidine derivative of (-)-norferruginine Fe 19 with a Ki 
value of 2 nM. Compounds Fe 18 and Fe 19 differ by the presence of a chlorine atom 
in the pyridine ring. This halogenation has small influence on the binding potency of 
Fe 18 and Fe 19 at α4β2* nAChRs. On the contrary, it seems to be favourable for the 
binding to the α7* nAChRs. Compound Fe 19 exhibited a 5-fold higher affinity at the 
α7* nAChRs compared to the deschloro analogue Fe 18. The Fe 19 shows the highest 
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affinity in these series for the α3β4* nAChRs (Ki= 71 nM) (Tab. III/4.4). Compound Fe 
22, bearing chloropyrazine moiety displays the lowest affinity for α4β2* nAChRs 
within the (-)-norferruginine derivatives (Ki = 4,100 nM). In this case, the marked 
decrease in affinity could be caused by steric interactions between the chloro-
substituent and the bicyclic ring system that leads to an unfavourable orientation of 
the pyrazine ring 358. The Fe 18 and Fe 20 possess no affinity for the α7* nAChR. It is 
of interest to notice that for the (-)-ferruginine analogues Fe 24 and Fe 25 the 
influence of the diazine moiety on binding affinities is similar to that observed in the 
(-)-norferruginine series. The order of potency is the following: 5-pyrimidinyl > 4-
pyridazinyl > 2-pyrazinyl. Among the series of diazine containing compounds, the 
favourable influence of the pyrimidine moiety is due to its electrostatic properties. In 
fact, pyrimidine has been shown to possess by far the most negative atomic density 
compared to pyridazine or pyrazine substituents 358. Thus, the analogue Fe 23, having 
a pyrimidine moiety as a substituent, has turned out to be the most active ligand 
among the ferrugininoids (Tab. III/4.4). However, in comparison to its (-)-
norferruginine analogue Fe 18, it possesses a 4-fold lower affinity for the α4β2* 
nAChR. On the contrary, the presence of a methyl moiety in compound Fe 23 results 
in an increase of affinity for the α7* nAChRs (Ki = 500 nM). The analogue Fe 25, 
bearing a pyridazine moiety proved to be the weakest ligand in the series of diazine 
analogues (C2-substitution at the (-)-ferruginine skeleton). Probing the issue of 
enantioselectivity, an investigation was made whether the pyridazine substituted 
ferruginine analogues Fe 24/ent-Fe 24 and Fe 23/ent-Fe 23 have the same 
stereochemical bias observed with Fe 10/ent-Fe10 and Fe 11/ent-Fe11 ferruginine 
analogues. Surprisingly, the analogues Fe 24/ent-Fe 24 showed no stereo-
discrimination toward the α4β2*. A certain degree of stereoselectivity was observed 
for their interaction with the ganglionic type. Indeed, the binding potency of ent-Fe 
24 (Ki= 305 nM) was 5-fold better than the corresponding analogue Fe 24 (Ki= 1,559 
nM). On the contrary, the ligands Fe 23/ent-Fe 23 (Tab. III/4.4) interact in a 
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stereoselective manner with α4β2*, α7* and α3β4* nAChRs subtypes, but not with 
the (α1)2β1γδ nAChRs. 
Table III/4.4: Radioligand binding affinities of diazine analogues (substituted at position C-2) of (-)-
ferruginine Fe 1, its ent-form and (-)-norferruginine Fe 2 for α4β2*,  α7*, α3β4*and (α1)2β1γδ nAChRs. 
Diazine analogues (substitution at position C-2) 
N
R1
R2
 
N
R1
R2
ent
 
R1 R2 No 
α4β2* 
[3H]EPI 
rat brain 
Ki ( nM) 
α7* 
[3H]MLA 
rat brain 
Ki ( nM) 
α3β4* 
[3H] EPI 
pig adrenals 
Ki ( nM) 
(α1)2β1γδ 
[3H] EPI 
Torpedo 
calif. 
electroplax 
Ki ( nM) 
H 
N
N
 
Fe 18 3.7 ± 0.6 a 5,000 ± 230 n.d. n.d. 
H N
N Cl
 
Fe 19 2 ± 0.5 1,000 71.6 n.d 
H 
N
N
 
Fe 20 113 ± 4.7 a > 50,000 n.d. n.d. 
H 
N
N
 
Fe 21 400 ± 17 a 13,500 ± 244 n.d. n.d. 
H 
N
NCl
 
Fe 22 4,100 ± 300 > 50,000 n.d. n.d. 
CH3 
N
N
 
Fe 23 12.6 ± 0.07  500 ± 28 234 ± 16 15,269 n=1 
CH3 N
N  
ent-Fe 23 43.2 n=1 4,215 ± 90 906 n=1 25,300 n=1 
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CH3 
N
N
 
Fe 24 29.7 ± 0.7 1,300 n=1 1,559 ± 297 > 50,000 
CH3 N
N  
ent-Fe 24 29.5 ± 4.7 2,862 ± 353 305 ± 14.8 > 50,000 
CH3 
N
N
 
Fe 25 713 ± 49 10,000 n=1 6,444 ± 50 n.d. 
a =228 
 
Influence of diazine substituents at position C-3 
In this series, the influence on the binding affinity of an introduction of a diazine 
moiety at position C-3 of the azabicyclic system of (-)-ferruginine Fe 1 and (-)-
norferrugine Fe 2 was investigated. The results of radioligand binding studies for 
these novel analogues are listed in Tab. III/4.5. As already observed in the pyridine 
series, the introduction of a diazine moiety at the same position would be expected to 
have a positive influence on the binding affinity for the central nAChRs. Indeed, Fe 
26 and Fe 27 showed affinity values for the α4β2* nAChRs in the picomolar range (Ki 
value of 0.66 and 0.70 nM, respectively). Thus, having an affinity ca. 140-fold higher 
than that of ferruginine Fe 1, they represent the more potent analogues tested for 
α4β2* nAChRs. The introduction of a chlorine atom into the pyrimidine moiety, as in 
compound Fe 27, does not influence the affinity towards the α4β2* nAChRs. On the 
other hand, it increases the selectivity for α4β2* over α7* (1/5100). The analogues Fe 
28 and Fe 29, bearing a pyridazinyl and pyrazinyl moiety at position C-3 of the (-)-
norferruginine skeleton, are 15- and 46-fold less potent at the α4β2* nAChRs 
respectively (Ki value of 10 and 31 nM, respectively) than the pyrimidine substituted 
analogue Fe 27. The introduction of a chlorine atom in the pyrazine moiety, such as 
in compound Fe 30, further decreases the affinities for the neuronal receptor, α4β2* 
(Ki= 210 nM). This compound also displays the lowest affinity for α7* and α3β4* 
within the series of (-)-norferruginine analogues (Ki= 50,000 and 1,738 nM, 
respectively). As far as diazine substituted ferruginine analogues are concerned, the 
III. Results 140 SAR of Ferruginine analogues 
Fe 31 shows a slightly lower affinity for the α4β2* nAChRs and an improved affinity 
for α7* nAChRs. N-methylation, as already observed for other ferrugininoids 
analogues (e.g. Fe 23, Fe 10, Fe 11), leads to an enhancement of the binding affinity 
for α7* nAChRs. Interestingly, the Fe 31 showed the highest affinity for α3β4* (Ki= 54 
nM) and muscle type nAChRs (Ki = 847 nM). The Ki value for the muscle type was 18-
fold lower than the Ki value of the analogue bearing the pyrimidine group in position 
C-2, Fe 23 (Ki = 15,269 nM). As expected, the introduction of an ester group at 
position C-2 of the azabicyclic skeleton ent-Fe 32 has a negative impact on the 
affinity. This modification markedly diminishes binding affinities for all nAChR 
subtypes investigated. The pyrazine moiety at position C-3, (Fe 33) showed lowest 
affinities towards all subtypes under consideration (Ki = 171 nM, 2,667 nM and 2,754 
nM for α4β2*, α7* and α3β4*, respectively) in the diazine series.  
Table III/4.5: Radioligand binding affinities of diazine analogues (substitution at C-3) of (-)-
ferruginine Fe 1, ent-(-)-ferruginine and (-)-norferruginine Fe 2 for α4β2*, α7*, α3β4*and (α1)2β1γδ 
nAChRs. 
Diazine moieties at position C-3 
N
R1
R3  
N
R1
R3
R2
ent-form
 
R1 R2 R3 No. 
α4β2* 
[3H]EPI 
rat brain 
Ki ( nM) 
α7* 
[3H]MLA 
rat brain 
Ki ( nM 
α3β4* 
[3H] EPI 
pig 
adrenals 
Ki ( nM) 
(α1)2β1γδ 
[3H] EPI 
Torpedo calif. 
electroplax 
Ki ( nM) 
H H 
N
N
 
Fe 26 0.66 ± 0.04 2,500 n.d. n.d. 
H H 
N
N
Cl  
Fe 27 0.708 ± 0.04 3,600 114 n.d. 
H H 
N
N
 
Fe 28 10 ± 2.3 20,000 n.d. n.d. 
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H H 
N
N
 
Fe 29 31 ± 2.4 7,000 n.d. n.d. 
H H 
N
N
Cl  
Fe 30 210 ± 25 50,000 b 1,738b 20,000b 
CH3 H 
N
N
 
Fe 31 1.25 n=1 1,100 ± 36 54.3 ± 10.3 847 n= 1 
CH3 COOCH3 
N
N
 
ent- 
Fe 32 
212 ± 50 > 50,000 5,796 n=1 31,865 ± 456 
CH3 H 
N
N
 
Fe 33 171 2,667 2,754 n.d. 
n= number of experiments 
n.d.= not determined 
 
Further modifications on the azabicyclic skeleton 
The structural modifications introduced in compounds Fe 34 and Fe 35 were the 
reduction of the double bond on the azabicyclic ring by introduction of a hydroxy 
moiety at the same position as pyrazine ring (Tab. III/4.6). This structural alteration 
concerns the positions C-2 for Fe 34 and position C-3 for Fe 35. The introduction of a 
hydroxyl moiety at the position C-3 markedly diminishes the binding affinity for the 
α4β2* subtype (Ki = 8,116 nM). The Ki value is 50-fold lower in comparison with the 
pyrazine analogue Fe 33 (Ki = 171 nM). An equivalent substitution at position C-2 of 
the azabicyclo skeleton also results in a marked decrease of affinity (Ki = 5,800 nM) 
compared to the (-)-ferruginine analogue Fe 25 (Ki = 713 nM). The additional 
hydroxyl group seems to disturb the interaction with all subtypes investigated. 
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Table III/4.6: Radioligand binding affinities of hydroxylated analogues of (-)-ferruginine Fe 1 for 
α4β2*, α7*and α3β4* nAChRs. 
Structure No. 
α4β2* 
[3H]EPI 
rat brain 
Ki ( nM) 
α7* 
[3H]MLA 
rat brain 
Ki ( nM 
α3β4* 
[3H] EPI 
pig adrenals 
Ki ( nM) 
N
N
N
CH3
OH
 
Fe 34 5,800 ± 1,008 ~20,000 20,885 n=1 
N
N
N
CH3
OH
 
Fe 35 8,116 n=1 ~ 20,000 26,535 n=1 
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III/4.4. Discussion 
The affinity profiles of novel (-)-ferruginine Fe 1 and (-)-norferruginine Fe 2 ligands 
(which have heteroaromatic rings at position C-2 or C-3), with the exception of some 
compounds, shows the following sequence of binding potency (in order of 
decreasing affinities) (Fig. III/4.6): 
 
N
N Cl
N
N
N
N
N
N
N
NClN N Cl
> > > > > >
 
Figure III/4.6: Decreasing order of binding potency for (-)-ferruginine Fe 1 and (-)-norferruginine Fe 2 
derivatives related to the N-heterocycle introduced. 
The affinities of the novel ferrugininoids and norferrugininoids will decrease by 
increasing the number of nitrogen atoms in the heteroaromatic moiety thereby 
reducing the electron density in the ring. It is clear that decreasing the electron 
density, the hydrogen bond acceptor capability of the heteroaromatic atom will 
diminish too. Another crucial factor seems to be the position of the halogen in the 
pyridine or diazine ring. There is a special region that may be particularly interesting 
for substitution: the para position to the pivot bond of the aromatic moiety. Indeed, 
the introduction of a chlorine-substituent in position C-2 of the pyridine Fe 11 or 
pyrimidine ring Fe 19 and Fe 27 results in compounds with an improved affinity 
towards the nAChRs. On the contrary, the introduction of a chlorine atom in the C-5 
of the pyrazine moiety, in ortho position to the pivot bond, caused a remarkable 
decrease in affinity Fe 22. One other parameter that seemed to be important for the 
affinity is the position of the heterocycle at the azabicyclic system. The pyridine and 
the diazine moiety were introduced at position C-2 as well as at position C-3. Results 
of structure-affinity-relationship studies show that substitution at position C-3 seems 
to be the one preferred for high affinity binding of the ligands (Fig. III/4.7).  
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Figure III/4.7: Structures of (-)-ferruginine Fe 1 and (-)-norferruginine Fe 2 analogues with a pyridine 
or pyrimidine moiety introduced at position C-3 of the azabicyclic skeleton. 
It has been found that, within the (-)-norferruginine analogues, compound Fe 13, 
having a pyridine moiety at position C-3, shows the highest affinity for α4β2* 
nAChRs (Ki = 0.25 nM), followed by Fe 26 (Ki = 0.66 nM) containing a pyrimidine 
moiety. As far as (-)-ferruginine analogues are concerned, the most potent ligands for 
α4β2* nAChRs were Fe 14, with a pyridine moiety at position C-3 (Ki = 0.96 nM) and 
Fe 31 (Ki = 1.2 nM) with a pyrimidine moiety in the same position. The chlorine atom 
has been shown to increase the affinity of (-)-ferruginine analogues for the ganglionic 
α3β4* nAChR. The affinity of Fe 15 (Ki = 5.5 nM) increases in comparison to Fe 14 (Ki 
= 24 nM) (ca. 5-fold), as well as the affinity of Fe 11 in comparison to Fe 10 (ca. 2-fold) 
(Fig. III/4.8). 
 
N
N
CH3
Cl
N
N
CH3 N
N
CH3 ClN
N
CH3
Fe 14                            Fe 15                     Fe 11                   Fe 10  
Figure III/4.8: Structures of the pyridine derivatives Fe 14 and Fe 11 and chloropyridine derivatives Fe 
15 and Fe 10. 
The effect of the azabicyclic moiety with respect to N-methylation in tropane 
analogues was investigated. In binding assays, typical nicotinic ligands exhibit 
diverse structure-activity patterns with respect to N-substitution. The affinity of (-)-
nicotine 3, e.g. is 20-fold higher than that of its nor-analogue 354. On the contrary, N-
methylation decreases by 2-fold the affinity of (±)-epibatidine 13 157 and by several 
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hundreds that of anatoxin-a An 1 359. In the present study, N-methylation influences 
the affinities in different ways, depending upon the subtypes investigated. On the 
one hand, the presence of a methyl moiety in the azabicyclic system decreases the 
affinity for the α4β2* nAChR subtype, on the other hand, it improves the affinity for 
α7* and α3β4* nAChRs subtypes (e.g. Fe 8 in comparison to Fe 10 or Fe 11). These 
trends are contrary to those found for (-)-nicotine / (-)nornicotine and more similar to 
those found for (-)-cytisine / (-)-caulophylline (N-Methyl-cytisine) 230. The 
enantiomeric analogues of Fe 10 as well as of Fe 11, Fe 23 and Fe 24 have been 
synthesized in order to probe the issue of enantioselectivity that is also important for 
refining the concept of the nicotinic pharmacophore. The binding affinities of (-)-
ferruginine analogues Fe 10, Fe 11, Fe 23 and Fe 24 and their correspondent 
enantiomeric form have been evaluated for all the subtypes under consideration. 
Interestingly, Fe 10, Fe 11, Fe 23 resemble (S)(-)-nicotine 3 with respect to the 
enantioselectivity. Binding results listed in Tab. III/4.2 and III/4.4 reveals that the 
(1R,5S) enantiomers Fe 10, Fe 11 and Fe 23 exhibit a ca. 3 –to 12-fold higher affinity 
towards the α4β2* nAChRs subtypes than the corresponding (1S,5R) form. This 
stereodiscrimination is more or less true in regard to the different nAChRs examined. 
The only exception concerned the pyridazine-substituted analogue Fe 24. This 
compound interacts with the α4β2* nAChRs subtypes in a non-stereoselective 
manner. However, (1S,5R) ent-Fe 24 exhibited a certain degree of enantioselectivity in 
the interaction with α3β4* nAChRs. In conclusion, the bioisosterism approach led to 
the discovery of novel ligands with higher affinity and improved selectivity in 
comparison to the lead compound (-)-ferruginine Fe 1.
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III/5. Pinnamine variants  
III/5.1. Introduction 
In 2000, a novel marine alkaloid, called pinammine, was isolated from the Okinawan 
bivalve Pinna Muricata. It is characterized by a 9-azabicyclo[4.2.1]nonane moiety like 
anatoxin-a and a transannulated with a dihydro-4-pyrone ring (Fig. III/5.1). The 
absolute configuration of the four-stereogenic centres in the pyrano-anatoxinoid core 
was determined to be 1R, 2R, 7S, 10S 360. A total synthesis of enantiopure pinnamine 
was published in 2001 361. 
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Figure III/5.1: Structures of anatoxin- a An 1 and pinnamine Pin. 
According to the Schmitt’s classification scheme (see chapter I/3), pinnamine Pin 
belongs to the E-class of nAChRs ligands where both the cationic and the HBA/π 
(hydrogen bond acceptor π moiety) sites are placed within a fused polycyclic ring 
system.  
III/5.2. Project 
(In cooperation with Prof. Seitz, Department of Pharmaceutical Chemistry, University of Marburg: synthesis of 
the novel pinnamine analogues) 
The structural resemblance between pinnamine Pin and (+)-anatoxin-a An 1, a potent 
nAChR ligand, turns this novel alkaloid into an attractive lead for the design of 
interesting structural analogues. Pinnamine could be considered as a 
conformationally restricted variant of dihydro-anatoxin-a which ring is already 
known as an element of the structure of alkaloids contained in the Darlingia 
darlingiana 344. One other alkaloid isolated from this arboreal plant is the (+)-
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ferruginine Fe 1 whose unnatural enantiomer has been used as a lead compound for 
developing new nAChRs ligands. On the basis of the structural correlation of (+)-
anatoxin-a An 1 and (-)-ferruginine Fe 1, this latter alkaloid was chosen as a 
component of novel synthetic pinnamin derivatives. The new ligands cis-Pin 1 and 
trans-Pin 2 (Fig. III/5.2) can be regarded as a hybrid of the azabicyclic skeleton of (-)-
ferruginine Fe 1 and the dihydropyrano skeleton of pinnamine Pin. Cis-Pin 1 and 
trans-Pin 2 were tested for their in vitro affinities for α4β2* and α7* nAChR subtypes 
by radioligand binding assays (Fig. III/5.2). 
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Figure III/5.2: Structures of (-)-ferruginine Fe 1, pinammine Pin and the corresponding hybrid 
pinammine variants cis-Pin 1 and trans-Pin 2. 
III/5.3. Determination of affinities and structure-activity relationships (SAR)  
The results of radioligands binding studies for the two stereoisomer cis-Pin 1 and 
trans-Pin 2 are listed in Table III/5.1 Neither cis-Pin 1 nor trans-Pin 2 retain the 
affinity of the lead compound (-)-ferruginine Fe 1 for the α4β2* nAChR. The Ki values 
for both pinammine variants are in the high nanomolar (Ki = 961 nM, trans-Pin 2) or 
low micromolar range (Ki = 4,800 nM, cis-Pin 1). Compound cis-Pin 1 is devoid of 
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affinity at the α7* nAChRs subtype, whereas trans-Pi 2 binds with significant affinity 
in the low micromolar range (Ki = 1,360 nM trans-Pin 2). 
Table III/5.1: Radioligand binding affinities of pinnamine and its variants for α4β2*,  α7*, α3β4*and 
(α1)2β1γδ nAChRs. 
Pinnamine variants No. 
α4β2* 
[3H]EPI 
rat brain 
Ki ( nM) 
α7* 
[3H]MLA 
rat brain 
Ki ( nM) 
α3β4* 
[3H]EPI 
pig 
adrenals 
Ki ( nM) 
(α1)2β1γδ 
[3H]EPI 
Torpedo 
calif. 
Electroplax 
Ki ( nM) 
N
CH3
O
O
CH3
H
H
 
cis-Pin 1 4,800 ± 1,630 22,470 ± 680 > 50 000 > 50 000 
N
CH3
O
O
CH3
H
H
 
trans-Pin 2 976 ± 62 1,360 ± 675 7071 n = 1 > 50 000 
n= number of experiments 
 
III/5.4. Discussion  
The pinnamine variants, characterized by a pyranotropane skeleton have been 
synthesized with the aim of a more rigid template for potent nAChR ligands. 
Surprisingly, despite its resemblance to (+)-anatoxin-a An 1, (-)-ferruginine Fe 1, the 
novel compounds cis-Pin 1 and trans-Pin 2 only exhibited affinities in the lower 
micromolar range for the α4β2* and α7* nAChR subtypes. The reasons for their lack 
of affinities may be different. The orientation of the pharmacophoric element could 
be unfavourable, or maybe the ethyl moiety cannot be sterically tolerated. Therefore, 
it will be interesting to investigate whether the presence of a substituent smaller or 
larger than the ethyl moiety could increase the affinity.  
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III/6. Anatoxin-a as a lead compound for novel nAChR ligands 
III/6.1. Introduction  
The anatoxins are a group of neurotoxic alkaloids produced by a number of 
cyanobacterial genera including Anabaena, Oscillatoria and Aphanizomenon that occur 
naturally in freshwater 362. 
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Figure III/6.1: Structure of (+)-anatoxin-a An 1, a toxin produced by the Anabaena flos-aquae 
(cyanobacteria) 363 . 
(+)-Anatoxin-a An 1 is a low molecular weight alkaloid produced by the blue green 
alga Anabaena flos-aquae (Fig. III/6.1). It is commonly found as a bright green layer of 
stagnant water 362. (+)-Anatoxin-a An 1 is known as “very fast death factor”, since 
ingestion of it can be lethal within 4 minutes (in mice, LD50 = 368 µg/kg intravenous, 
200-250 µg/kg intraperitoneal) 362. (+)-Anatoxin-a An 1 exerts its action by 
depolarising the postsynaptic nicotinic acetylcholine receptors 364 365. The victim 
suffers from twitching, muscle spasm, paralysis and respiratory arrest. The toxic dose 
in humans is not known but is estimated to be less than 5 mg for an adult male 366. 
Despite its poisonous nature, (+)-anatoxin-a is of interest because of its high affinity 
and intrinsic activity at nicotinic synapses 264 364 367. (+)-Anatoxin-a An 1 having a 
semirigid bicyclic structure containing a cyclic HBA/π moiety and a cyclic cationic 
site (Fig. III/6.1) is classified as a member of class D in Schmitt’s scheme (see chapter 
I/3). Radioligand binding studies using [125I]αBgt and tritiated 
perhydrohistrionicotoxin ([3H]H12-HTX) revealed the existence of two discrete 
binding sites for (+)-anatoxin-a. The radioiodinated α-Bgt 5 was used for the high 
affinity agonist site 365, while [3H]H12-HTX (known as an ion channel blocker, acting 
inside the channel) was used for the low affinity site, associated with the ion channel 
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368. (+)-Anatoxin-a An 1 has a relatively low affinity for muscarinic acetylcholine 
receptors in rat brain 364. On the contrary, it is a potent agonist at neuronal nAChRs, 
with 1000-fold selectivity for nAChRs compared to mAChRs 364 264. The naturally 
occurring (+)-anatoxin-a An 1 binds with very high affinity to α4β2* receptors (Ki = 
1.1 nM) 228, and with minor affinity to α7* receptors (Ki = 90 nM) 349. On the basis of its 
semirigid bicyclic structure, limiting its possible conformations and its flexible 
functional group chemistry 264, (+)-anatoxin-a An 1 is a useful lead compound. 
Determination of the bioactive conformation of anatoxin-a An 1 could provide 
valuable information concerning the conformational requirements for binding to the 
receptor. Therefore, the pyrido[3,4-b]homotropane (PHT), a bioisosteric and 
conformationally constrained variation of (+)-anatoxin-a An 1, was synthesized and 
evaluated pharmacologically 369. Pyrido[3,4-b]homotropane (PHT) (Fig. III/6.2) is a 
combination of (+)-anatoxin-a An 1 and nornicotine 21. Results from in vitro and in 
vivo assays have revealed that PHT retains much of the potency (IC50 = 2 nM) of the 
natural compound (+)-anatoxin-a An 1 (IC50 = 5 nM) 369.  
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Figure III/6.2: Structure of pyrido[3.4-b]homotropane PHT, a combination of (+)-anatoxina An 1 and 
nornicotine 21. 
Swanson et al. 365 designed novel anatoxin-a analogues in order to evaluate the 
importance of hydrogen-binding strength, planarity, size and steric configuration of 
the chain moiety of (+)-anatoxin-a An 1 for the binding peripheral AChRs. The 
structural modifications on the side chain involved three chemical categories: 
carbonyls, alcohols and amides (Tab. III/6.1). It has been found that steric crowding 
or perhaps hydrophilicity is more important than H-bonding strength for the 
interactions with peripheral AChRs 264. Analogues that retain planar carbonyl moiety 
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and unbranched side chain structures were the more potent compound of this series 
for the muscular type. Therefore a limited size of the side chain might be important 
for the interaction with the peripheral nAChRs.  
Table III/6.1: Structures of (+)-anatoxin-a and the different side chains of the corresponding anatoxin-
a analogues. 
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In 1991, Wonnacott et al. 264 considered the interactions of the same analogues with 
neuronal nicotinic AChRs, α4β2* and α7*, identified by (-)-[3H]nicotine and [125I]α-
Bgt, respectively. They found that the isoxazolidide acid (R 11) and methoxyamide 
acid (R 10) derivatives were the most potent substances for the interaction with 
nicotinic receptors in the brain. Moreover, compounds (R 11) and (R 10) present 
selectivity for α7* over α4β2* (1111-fold for (R 11) and 756-fold for (R 10)) 264. 
Modification of the side chain with hydrophobic moieties (ethyl or methoxy group) 
maintains the affinity for the α4β2* nAChRs receptor, whereas substitution with a 
more polar function elicits severe reduction of the affinity for α4β2* nAChR 264. 
Reduction of a carbonyl to an alcoholic group caused a drastic decrease of the 
binding affinities for α4β2* and α7* nAChRs (Ki = 4600 and > 10 µM, respectively) 
264,370. In the search for a novel analogue with enhanced affinity and selectivity for 
α4β2* nAChR over the α3β4*, the novel ligand UB-165 was designed (Fig. III/6.3) 229. 
It represents a novel (+)-anatoxin-a An 1 /(±)-epibatidine 13 hybrid in which the bulky 
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azabicyclo[4.2.1]nonene moiety of (+)-anatoxin-a An 1 is combined with the 
chloropyridyl pharmacophoric element (HBA component of (±)-epibatidine 13 371). 
Interestingly, in contrast to (±)-epibatidine 13, UB-165 interacts in a stereoselective 
manner with the receptors 229. Its enantioselectivity is associated with the 
azabicyclo[4.2.1]nonene moiety of (+)-anatoxin-a An 1. Sharples et al. measured the 
affinities of UB-165, (±)-epibatidine 13, and (+)-anatoxin-a An 1 for radioligand 
binding sites corresponding to various nAChRs subtypes using (-)-[3H]nicotine and 
[125I]α-Bgt in native and recombinant membrane preparations, UB-165 was identified 
as a potent nicotinic ligand. In competition assays with (-)-[3H]nicotine using rat 
brain membranes it showed a binding affinity for the α4β2* nAChR (Ki = 0.27 nM) 
that was intermediate between (±)-epibatidine 13 (Ki = 0.021 nM) and (+)-anatoxin-a 
An 1 (Ki = 1.25 nM) 371. Comparable Ki values were found for the inhibition of (±)-
[3H]epibatidine binding to α4β2* nAChR in M10 cells. In competition assays with 
[125I]α-Bgt in rat brain membrane preparations, UB-165 (Ki = 2790 nM) showed a 
slightly lower potency than anatoxin-a (Ki = 1840 nM). Results from competition 
binding assays with (±)-[3H]epibatidine at the human α-3 containing nAChRs 
subtypes showed that the rank order of potency was similar to that established for 
the α4β2* nAChR, namely (±)-epibatidine 13 > UB-165 > (+)-anatoxin-a An 1. In 
contrast, UB-165 was less potent at α7* and muscle nAChRs. The rank order of 
potency is: (±)-epibatidine 13 > (+)-anatoxin-a An 1 > UB-165. Therefore, the (±)-UB-
165 resembles (±)-epibatidine 13 in its preference for α4β2* nAChR compared with 
the α7* and muscle nAChR. They also characterized this compound functionally for 
different nAChRs subtypes 371. Functional studies demonstrated that UB-165 is a full 
agonist at α3β2* nAChRs but only a weak partial agonist at α4β2* nAChRs. In fact, it 
failed to elicit significant currents in Xenopus oocytes expressing α4β2* or α2β2* 
nAChRs and produced very little response when tested in the [3H]dopamine release 
assays. On the contrary, it was more potent than (+)-anatoxin-a An 1 in activation of 
Ca2+ fluxes in the SH-SY5Y cell line expressing the α3 nAChR subunit 371. In a later 
publication by Slater et al., the structure of UB-165 was the subject of structure-
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activity-relationship studies with pyridyl-analogues and with a series of diazines 
variants, having been prepared and evaluated 357. 
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Figure III/6.3: Structure of UB-165, a hybrid molecule composed of the azabicyclo[4.2.1]nonene moiety 
of (+)-anatoxin-a An 1 and the chloropyridyl unit of (±)-epibatidine 13 371. 
III/6.2. Project 
(In cooperation with Prof. Seitz, Department of Pharmaceutical Chemistry, University of Marburg, synthesis of 
the novel anatoxin-a analogues) 
The azabicyclo[4.2.1]nonene ring of (+)-anatoxin-a An 1 was used as a lead structure 
to develop novel potent ligands on the basis of its semirigid structure which limits 
the number of stable conformations and its accessibility to structural modifications. 
The aim of the project was to investigate whether the replacement of the acetyl 
moiety of (+)-anatoxin-a An 1 by pyridine (giving the deschloro analogue DUB-65) or 
diazine rings, such as pyrazine, pyrimidine and pyridazine could give novel potent 
ligands with the ability to discriminate further between nAChR subtypes. A schema 
of the structural variations is shown in Fig. III/6.4.  
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Figure III/6.4: Structural variations of (+)-anatoxin-a An 1. 
On the basis of the high affinities for the neuronal nAChRs of (±)-epibatidine 13, 
characterized by a 7-azabicyclo[2.2.1]heptane, and (+)-anatoxin-a An 1, with an 
azabicyclo[4.2.1]nonene ring, great interest has been shown for analogues having an 
azabicyclic core. Barlocco et al. reported the synthesis and the pharmacological 
characterization of a novel class of 3,8 disubstituted 3,8-diazabicyclo[3.2.1]octane 
analogue 224. Among them, the 3-(6-chloro-3-pyridazinyl)3,8-
diazabicyclo[2.2.1]octane (Fig. III/6.5), showed a nanomolar affinity for α4β2* 
nAChRs (Ki = 4.1 ± 0.21 nM) and retained antinociceptive properties at doses of 1 
mg/Kg in mouse hot plate test 224.  
N
N
H Cl
N
NN
NH
Cl
3-(6-chloro-3-pyridizanyl)3,8-diazabicyclo[2.2.1]octane                       epibatidine 13  
Figure III/6.5: Structures of 3-(6-chloro-3-pyridazinyl)3,8-diazabicyclo[2.2.1]octane and (±)-epibatidine 
13. 
Following the bioisosterical approach, a series of enantiopure 3,9-
diazabicyclo[4.2.1]nonane derivatives were synthesized as potential analogues of the 
nicotinic agonist (+)-anatoxin-a An 1 (Fig. III/6.6). These novel ligands are 
structurally related to (+)-anatoxin-a An 1 in that they both incorporate an azabicyclic 
core. However, they show some modifications concerning the bulky 
azabicyclo[4.2.1]nonene moiety of anatoxin-a such as: 
1. Saturation of the bicyclic ring. 
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2. Additional nitrogen in position C-3. 
3. Methylation of the sp3 nitrogen. 
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Figure III/6.6: Different substituents introduced at position N-3 on the bulky 3,9-
diazabicyclo[4.2.1]nonane moiety. 
The enantiopure 3,9-diazabicyclo[4.2.1]nonane derivatives are classified according to 
Schmitt’s classification, as class-C compounds (see chapter I/3). They are 
characterized by the requisite pharmacophoric elements typical of nAChR ligands, 
namely the N-bicycle and the HBA–π system within separate non-fused rings. A 
pivot bond joins the two pharmacophoric elements. In this series, further 
modifications of the lead compound e.g. introduction of pyridine, chloro-pyridine 
and diazines group at position C-3 of the more flexible 3,9-diazabicyclo[4.2.1]nonane 
ring (Fig. III/6.6) have been performed. In vitro radioligand binding assays were 
carried out with the aim of exploiting the scope and potential offered by the resulting 
ligands in the CNS and peripheral nervous system. The binding affinities and 
selectivity among different nAChRs were measured in four different competition 
assays for the α4β2*, α7*, α3β4* and the muscle type nAChRs.  
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III/6.3. Determination of affinities and structure-activity relationships (SAR) 
UB-165 and DUB-165 
To assess the issue of binding selectivity among nAChR subtypes, affinities of the 
chloro-pyridine/pyridine analogues, UB-165 and DUB-165 and diazine analogues An 
2, An 3, An 4 and An 5 listed in Tab. III/6.2, were measured in four different 
competition assays and compared with those of (±)-epibatidine 13 and (+)-anatoxin-a 
An 1. (+)-Anatoxin-a An 1 binding affinities for α4β2* and α7* nAChR subtypes, 
using (±)-[3H]epibatidine and [3H]MLA and P2 membrane fractions of Sprague-
Dawley rat forebrain, were evaluated in previously described competition assays 349. 
Compared to (±)-epibatidine 13, (+)-anatoxin-a exhibited ca. 140-fold lower affinity 
for α4β2* (Ki = 1.1 nM) and approximately 20-fold lower affinity for α7* (Ki = 90 nM). 
In the present study, the affinity of (+)-anatoxin-a An 1 for nAChRs containing α3 
and β4 subunits has been estimated to be in the nanomolar range (Ki = 19 nM), 45-
fold lower than (±)-epibatidine 13 (Tab. III/6.2). Remarkably, UB-165 and DUB-165 
potently interact with all three nAChRs subtypes under consideration with 
comparable high affinities, demonstrating that the electron-withdrawing chlorine 
atom of UB-165 has only little effect on binding affinity. The replacement of the 
acetyl moiety by a pyridine heterocycle (DUB-195) increased the affinity for α7* 
nAChR by a factor of 94. Compared to (+)-anatoxin-a An 1 and UB-165, DUB-165 
exhibits the highest affinity for the α7* nAChR subtype (Ki = 0.95 nM). This affinity 
enhancement can be caused by the loss of the halogen atom. On the contrary, the 
presence of the halogen in the pyridyl ring of UB-165 seems to be favourable for the 
affinity to the α3β4* subtype (Ki = 1.3 nM). UB-165 is more selective for α4β2* 
nAChRs over α7* nAChRs than (+)-anatoxin-a An 1 and DUB-165. 
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Diazine analogues 
The bioisosteric replacement of the acetyl moiety as a structural part of (+)-anatoxin-a 
An 1 by a 4-pyridazinyl (An 4), 5-pyrimidinyl (An 2), 3-chloro-5-pyrimidinyl (An 3), 
or 2-pyrazinyl (An 5) pharmacophoric element led to anatoxinoids (Tab. III/6.2) that 
interact with all four nAChRs subtypes under consideration. In this series, analogue 
An 2, having a 5-pyrimidinyl moiety, turned out to be the most active ligand for the 
α4β2* nAChR (Ki = 0.14 nM). For this subtype, An 2 showed an affinity similar to that 
of the chloro-pyrimidinyl analogue An 3 (Ki = 0.15 nM). Thus, replacement of the 
acetyl moiety by a pyrimidine or chloro-pyrimidine moiety (An 2 and An 3) leads to 
compounds that are ca. 8-fold more active than (+)-anatoxin-a An 1 and slightly less 
potent (2.7- and 3.5-fold) for the α4β2* nAChR compared to DUB-165 and UB-165, 
respectively. The introduction of a pyridazinyl moiety (An 4), resulted in being 
deleterious for the affinity for the α4β2* nAChR, causing a significant drop by a 
factor of ca. 370 (Ki = 19 nM) compared to DUB-165 and a factor of ca. 475 compared 
to UB-165. A similar decrease in affinity was observed for the pyrazine analogue An 
5, with a Ki value of 12 nM for the α4β2* nAChR. Summing up, the rank order of 
potency towards α4β2* nAChR for the diazine derivatives of anatoxin-a is: 
pyrimidine > pyridazine > pyrazine. This affinity profile was observed for analogues 
An 2, An 4 and An 5 and is found to be the same for α3β4* and α7* nAChRs. In fact, 
the analogue An 4, having the pyrazine moiety, possesses the lowest binding affinity 
for α4β2*, α7* and α3β4* nAChRs. 
 
 
 
 
 
 
 
 
III. Results 158 SAR of Anatoxin-a analogues 
Table III/6.2: Radioligand binding affinities of (+)-anatoxin-a An 1, UB-165, DUB-165 and diazine 
analogues for α4β2*, α7*, α3β4*and (α1)2β1γδ nAChRs. 
Structure No. 
α4β2* 
[3H]EPI 
rat brain 
Ki ( nM) 
α7* 
[3H]MLA 
rat brain 
Ki ( nM) 
α3β4* 
[3H]EPI 
pig adrenals
Ki ( nM) 
(α1)2β1γδ 
[3H]EPI 
Torpedo calif. 
electroplax 
Ki ( nM) 
N
H
CH3
O
 
An 1 1.1 ± 0.2 90 ± 4 19 ± 1 n.d. 
Pyridine analogues 
 
N
N
H
 
DUB-165 0.051 ± 0.0006 0.95 ± 0.05 6.2 ± 0.5 >50,000 
N
N
H
Cl
 
UB-165 0.04 ± 0.004 12 ± 2.5 1.3 ± 0.1 >50,000 
Diazine analogues 
N
N
N
H
 
An 2 0.14 ± 0.03 10.7± 1.3 20 ± 1 n.d. 
N
N
N
H
Cl
 
An 3 0.151 ± 0.02 n.d. n.d. n.d. 
NN
N
H
 
An 4 19 ± 2.5 > 10 000 2 500 ± 150 n.d. 
N
N
N
H
 
An 5 12 ± 1.8 250 ± 7.6 259 ± 21 n.d. 
n.d.= not determined 
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3,9-Diazabicyclo[4.2.1]nonane-diazine-derivatives 
Structure activity relationshisp for α4β2*nAChRs: 
Among the pyridine derivatives tested, An 8 (pyridine analogue) exhibited the most 
potent binding affinity for α4β2* nAChRs (Ki = 0.62 nM). The An 8 was found to be 
more potent than (+)-anatoxin-a An 1 (Ki = 1.1 nM). The structural isomer 9-ethyl-3-
(2-pyridine)-3,9-diazabicyclo[4.2.1]nonane, An 6 (Ki = 2.09 nM) was 3-fold less potent 
than the An 8 (Ki = 0.62 nM) analogue for the binding at α4β2* nAChRs. The affinity 
drop-off could be attributed to a different distance between the bicyclic nitrogen 
atom and the heterocyclic nitrogen atom, which is considered important for the 
binding affinity 259. The chlorine analogue of An 6 (An 7) as well as of An 8 (An 9) are 
almost equipotent for their binding affinity for α4β2* nAChRs (ca. 2-fold difference 
in affinity) corroborating the finding that a chlorine atom has only little effect on 
binding affinity. Except for An 13, (a pyrazine analog, Fig. III/6.7), the introduction of 
another diazine moiety can enhance the affinity for α4β2* nAChRs in comparison to 
(+)-anatoxin-a An 1. Analogues An 10 and An 11, with a pyridazine and 
chloropyridazine moiety respectively, showed affinities in the picomolar range (Ki = 
0.55 and 0.52 nM, respectively), thus emerging as the most potent derivatives of this 
series. The introduction of pyrimidine led to analogue An 12 (Ki = 2.8 nM) which 
retained almost the same affinity of the pyridine analogue An 6 (Ki = 2.09 nM) for the 
α4β2* nAChR subtype.  
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Figure III/6.7: The affinity rank order for α4β2* nAChRs of the diazine analogues in the 3,9-
diazabicyclo[4.2.1]nonene series. 
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Structure activity relationships for α7* nAChRs: 
The affinities of the enantiopure 3,9-diazabicyclo[4.2.1]nonane derivatives for α7* 
nAChRs, with the exception of An 13 (Ki > 50,000 nM), are in the higher nanomolar 
range, between 90 and 900 nM (Tab. III/6.3). The analogue An 7 with a 6-chloro-3-
pyridine moiety exhibited the highest affinity for α7* (Ki = 92 nM). Interestingly, the 
introduction of the chlorine atom in position C-6 on the pyridine ring leads to an 
increase in affinity by a factor of 100 compared to the deschloro analogue An 6 (Ki = 
950 nM). The diazine derivatives, An 10 and An 11, even though less potent than An 
7, possess an affinity for α7* nAChR (Ki = 190 and 157 nM, respectively) that is about 
2-fold lower to the one shown by (+)-anatoxin-a An 1 (Ki = 90 nM). The pyrimidine 
analogue, An 12 (Ki = 982 nM), as already observed for the affinity for α4β2*, 
possesses a very similar Ki value to the pyridine analogue An 6 (Ki = 950 nM). 
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Table III/6.3: Radioligand binding affinities of 3,9-diazabicyclo[4.2.1]nonane derivatives for α4β2*, α7*, 
α3β4*and (α1)2β1γδ nAChRs. 
Pyridine and Diazine analogues of 3,9-diazabicyclo[4.2.1]nonane 
N
N
CH3
R
 
R No. 
α4β2* 
[3H]EPI 
rat brain 
Ki ( nM) 
α7* 
[3H]MLA 
rat brain 
Ki ( nM) 
α3β4* 
[3H]EPI 
pig adrenals 
Ki ( nM) 
(α1)2β1γδ 
[3H]EPI 
Torpedo 
calif. 
electroplax 
Ki ( nM) 
N
 
An 6 2.09 ± 0.43 950 ± 134 81.4 ± 0.70 11,900 ± 3.9 
N
Cl
 
An 7 0.873 n=1 92.1± 13 30.6± 1.13 2,326 n=1 
N
 
An 8 0.62 ± 0.15 138± 8.2 23 n=1 3,050 ± 0.55 
N
Cl
 
An 9 1.4 ± 0.07 486 ± 11.9 42.8 ± 4.6 8,467 ± 338 
NN
Cl
 
An 10 0.55 ± 0.15 190 ± 17 30± 0.5 2,540 ± 0.7 
N
N
 
An 11 0.52 ± 0.11 157 ± 10 9.5 ± 2 2,330 ± 0.44 
N
N
 
An 12 2.08 ± 0.14 982 ± 0.08 156 ± 7.1 15,480 ± 2.5 
N
N
 
An 13 265 n=1 > 50 000 > 50 000 > 50000 
n= number of experiments  
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Structure activity relationships for α3β4* and (α1)2β1γδ nAChRs: 
Compound An 11, containing a pyridazinyl moiety, exhibited the highest affinity for 
the α3β4* nAChRs (Ki = 9.5 nM), even higher than (+)-anatoxin-a An1 (Ki = 19 nM). 
The analogues An 7, An 8, An 9 and An 10 possess similar affinities for the α3β4* 
nAChR, with Ki values ranging from 23 to 40 nM (Tab. III/6.3). Analogue An 12 
possesses the lowest affinity for α3β4* nAChRs with a Ki value of 157 nM, namely 8-
fold less potent than (+)-anatoxin-a An 1 (Ki = 90nM). The highest affinity for the 
muscle type was found for the analogues containing a pyridazinyl (An 11; Ki= 2,330 
nM) and chloropyridine moiety (An 7; Ki= 2,326 nM) (Tab. III/6.3). Pyridine and 
pyrimidine carrying derivatives An 6 and An 12, showed a drastic drop in affinity 
for the (α1)2β1γδ nAChR subtype with a Ki value in the higher micromolar range (Ki = 
11,900 and 15,480 nM, respectively). Analogue An 13 did not interact with either 
α3β4* nor with (α1)2β1γδ nAChRs (Ki > 50,000 nM). 
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III/6.4. Discussion 
The alkaloid (+)-anatoxin-a An 1 is known as a potent but not selective modulator of 
nAChRs. Unfortunately, based on its poor ability to discriminate between neuronal 
and peripheral nAChRs and its toxic effects, this ligand can not be used 
therapeutically. It was anticipated that bioisosteric analogues might possess less 
toxicity resulting from higher discrimination between the multifarious receptor 
subtypes. (+)-Anatoxin-a An 1 possesses a semirigid skeleton, which limits the 
number of low-energy conformations and a side chain readily amenable to structural 
modifications. Based on these characteristics, it has been chosen as a useful lead 
compound for the design of potent novel ligands and for structure activity 
relationship studies on nAChRs. In the present study, the influence on the binding 
affinity of the replacement of the acetyl group by a pyridine or chloropyridine 
fragment and by N-heterocycles (pyridine, pyridazinyl, pyrimidinyl or pyrazinyl 
moieties) was investigated. The affinities of UB-165, an already known nAChR 
ligand 357., and its deschloro analogue were evaluated for four different subtypes. The 
Ki values found reveal that both analogues potently interact with the α4β2* with 
comparable affinities. The rank orders of potency is: (±)-epibatidine 13 > (+)-anatoxin-
a An 1 > UB-165 = DUB-165. These results confirm that the chlorine atom has only 
small influence on the binding potency at the α4β2* nAChR subtype. Relative to 
α4β2*, UB-165 has a 300- and 32-fold difference in potency at the α7* and α3β4* 
nAChRs. Therefore, UB-165 turned out to be the most selective compound for α4β2* 
nAChRs over α7* nAChRs (1:300). The replacement of the acetyl moiety by pyridine, 
given DUB-165, increases by 94-fold the affinity for the α7* nAChR (Ki = 0.95 nM). In 
addition, DUB-165 possesses an improved selectivity for α4β2* nAChRs over α3β4* 
nAChRs (1:124). In a later study by Sharples et al. 357, binding studies showed the 
same rank order of potency for binding to α4β2*: (±)-epibatidine > (+)-anatoxin-a > 
UB-165 = DUB-165 and for α7*: (±)-epibatidine > DUB-165 > UB-165 > (+)-anatoxin-a 
in competiton assays. However, the Ki values that they found for the α7* nAChRs 
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subtypes are very high. This discrepancy in values is possibly being attributed to the 
different amount of protein used in their assays.  
In order to investigate whether a bioisosteric replacement of the acetyl moiety of (+)-
anatoxin-a An 1 by diazines can be favourable for binding to each nAChR subtypes, 
the diazine analogues An 2, An 3, An 4 and An 5 were synthesized and evaluated in 
competition binding assays. The main finding of SAR studies performed on this 
series was that the pyrimidine An 2 and chloro-pyrimidine An 3 moiety are the most 
appropriates substituents at the azabicyclic core of (+)-anatoxin-a An 1. Indeed, they 
showed an affinity for the α4β2* nAChRs in the picomolar range (Ki = 0.14 nM An 2 
and 0.15 nM An 3). Based on these data, it was pointed out that the electron-
withdrawing chloro atom of ligand An 3 has no effect on the binding affinity for 
α4β2* nAChRs. The same trend was observed for UB-165 and DUB-165. As 
compared to the lead compound, analogue An 2 has a 7.8- and 9-fold higher affinity 
for α4β2* and α7* nAChRs. In addition, the pyrimidine moiety seems to increase the 
selectivity for α4β2* given that, relative to α4β2* nAChRs, An 2 has a 142-fold 
difference in potency at the α3β4* nAChRs. On the contrary, the introduction of a 
pyrazine or pyridazine moiety, decreases the binding affinity for all subtypes 
examined. This affinity profile closely agrees with the data published in 2002 by 
Sharples et al. 357. They described the synthesis of two classes of UB-165 analogues. 
One class includes positional isomers of the pyridyl moiety and the other one 
consists of selective diazines variants 357. For the diazine variants, they reported 
similar binding profiles for α4β2* and α7* nAChRs. They carried out competition 
studies using α3β4 nAChR stably expressed in Lα3β4* cell line and (±)-
[3H]epibatidine. According to our assessment, they observed that the presence of an 
additional nitrogen atom produces a more π-electron deficient aromatic ring, and 
this exerts a significant effect on the pKa of the nitrogen atom representing the 
hydrogen bond acceptor associated with the ligand-receptor interaction. Thus 
underlining that the high affinity binding of these analogues is significantly 
dependent on the HBA ability of the nitrogen in the pyridyl and diazine rings 357. 
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Following the idea that bioisosteric alterations in the azabyclic core might generate 
ligands that are subtype selective with a minimum of side effects, a novel series of 
diazabicyclo[4.2.1]nonane analogues were synthesized. They are structurally related 
to (+)-anatoxin-a An 1, with some modification concerning the saturation of the 
azabicyclic core, the introduction of an additional nitrogen in position C-3 and 
methylation of the sp3 nitrogen. On the basis of the SAR, it turned out that, with the 
exception of the pyridazine analogue An 13, all new ligands An 6-An 12 retained 
affinity for α4β2*, α7*, α3β4* and muscle type nAChRs. Recently, in a study of 
Sharples et al. 357 is has been found that the 2-pyridyl analogue of UB-165, with a 
reduced distance between the cationic nitrogen and pyridyl nitrogen, had a 
deleterious effect in binding affinity at α4β2*. The same effect was observed with the 
2-pyridyl analogue of DUB-165, wich showed a 3581-fold lower potency at the α4β2* 
than the 3-pyridyl analogue. Analogues An 6 and An 8 (Fig. III/6.8) have been 
characterized in in vitro binding experiments in order to explore the effect of 
translocation of the pyridyl nitrogen which is proposed to act as a hydrogen bond 
acceptor in pharmacophore models. 
Figure III/6.8: Structures of the diazabicyclo[4.2.1]nonane analogues An 6 and An 8. 
In the present study, both the 2- and 3-pyridyl moiety are suitable moieties for high 
affinity binding at the α4β2* nAChRs (Ki values ranging between 0.62 to 2.09 nM). On 
the contrary, results of binding studies performed at α7* nAChRs have shown that 
they possess only moderate affinity for these neuronal nAChR subtypes. Hence 
showing that this novel series of diazabicyclo[4.2.1]nonane analogues exhibited a 
certain degree of preference for the α4β2* compared to the α7* nAChRs. 
Interestingly, they also showed a modest affinity in the low micromolar range for the 
muscle nAChR.  
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III/7. Quinuclidin-2-ene based derivatives as ligands for nicotinic 
acetylcholine receptors 
III/7.1. Introduction 
The semirigid ring of the quinuclidine moiety has been extensively used to design 
novel muscarinic receptors ligands. One of the most potent and efficacious ligand 
within the series of the 3-heteroaryl-substituted quinuclidin-3-ol was the 1,2,4-
oxadiazole analogue n 1. It has been observed that the introduction of a double bond 
between C-2 and C-3 in the quinuclidine ring n 1, affording a quinuclidin-2-ene 
derivative n 2, was detrimental (444-fold) for the efficacy and affinity for muscarinic 
receptors 373. 
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Figure 7.1: Structures of the muscarinic agents n 1, n 2, n 3 
Bioisosteric replacement of the 1,2,4-oxadiazole moieties by a pyridine ring n 3 
proved to be unfavourable for the affinity to muscarinic receptors 202. The evident 
structural correlation of n 3 to the highly potent semirigid nAChRs agonist (±)-
epibatidine 13 and UB-165 gave rise to investigate compounds of type n 3 as novel 
nicotinic nAChRs ligands (Fig. III/7.1). 
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III/7.2. Project 
(In cooperation with Prof. Seitz, Department of Pharmaceutical Chemistry, University of Marburg, synthesis of 
the novel quinuclidine analogues) 
Based on the obvious similarity of the pyridine derivative of the quinuclid-2-ene with 
the structure of (±)-epibatidine 13 and UB-165, other quinuclid-2-ene analogues 
containing the 2-choropyridine and a pyrimidine moiety have been synthesised (Fig. 
III/7.2). 
R
N
R =
N N Cl
N
N
Qu 1             Qu 2              Qu 3   
Figure III/7.2: Structure of the novel ligands Qu 1, Qu 2, Qu 3. One pharmacophoric element is 
represented by a quinuclidin-2-ene moiety. 
The quinuclidine analogues Qu 1, Qu 2 and Qu 3 were evaluated for their ability to 
compete for (±)-[3H]epibatidine and [3H]MLA binding sites in membrane fraction of 
rat forebrain (α4β2*, α7*), pig adrenals (α3β4*) and Torpedo californica electroplax 
((α1)2β1γδ) using radioligand binding assays. 
III/7.3. Determination of affinities and structure-activity relationships (SAR) 
Results of radioligand binding assays demonstrated that a quinuclidin-2-ene 
skeleton, substituted in position C-3 by a pyridine moiety, could be considered as a 
suitable nicotinic ligand. The novel analogues Qu 1, Qu 2 and Qu 3 showed affinity 
in the low nanomolar range for neuronal and peripheral nAChRs and a subtype 
selectivity for α4β2*. The chloropyridine containing ligand Qu 2 turned out to be the 
most active analogue for α4β2*, α7*, α3β4* and muscle nAChRs. The chlorine atom 
seems to produce a positive effect on the binding affinities of this series for nAChRs 
under investigation. Indeed, the chloropyridine analogue Qu 2 has ca. 4-fold higher 
affinity for α4β2* compared to the pyridine analogue Qu 1. The pyrimidine 
derivative Qu 3, although 5-fold less potent than Qu 2 for α4β2* (Ki = 12.2 nM) shows 
the highest subtype selectivity for α4β2* over α7* and α3β4* nAChRs. 
III. Results 168 SAR Quinuclidin-2-ene  
Table III/7.1: Radioligand binding affinities of quinuclidin-2-ene based ligands for α4β2*,  α7*, 
α3β4*and (α1)2β1γδ nAChRs. 
Structure No. 
α4β2* 
[3H]EPI 
rat brain 
Ki ( nM) 
α7* 
[3H]MLA 
rat brain 
Ki ( nM) 
α3β4* 
[3H]EPI 
pig adrenals 
Ki ( nM) 
(α1)2β1γδ 
[3H]EPI 
Torpedo calif. 
electroplax 
Ki ( nM) 
N
N
 
Qu 1 7.5 ± 0.49 85.2 ± 2.7 103 ± 13 237 ± 12 
N
N
Cl
 
Qu 2 2.2 ± 0.52 26.8 ± 4.1 19.2 ± 1.1a 49 n=1 
N
N
N
 
Qu 3 12.2 ± 0.18 751 ± 52.3 112 ± 41 100 n=1 
n= number of experiments 
III/7.4. Discussion  
In previous studies 373 282, the quinuclidine nucleus was used as a template to design 
ligands for the muscarinic acetylcholine receptor. However, the introduction of a 
pyridine moiety in position C-3 of a quinuclidin-2-ene skeleton proved to be 
detrimental to the affinity to muscarinic receptors. On the contrary, this modification 
leads to a pyridine analogue Qu 1 with nanomolar affinities for the α4β2* (Ki = 7.5 
nM) and α7* nAChR (Ki = 85.2 nM) and subtype selectivity for α4β2*. The 
quinuclidin-2-ene skeleton substituted with a pyridine ring possesses all the 
structural elements required in order to be a potent nicotinic agonist. Indeed, it has 
basic nitrogen, which can be protonated to provide a cationic centre and π-HBA 
system. Novel analogues have been synthesized bearing a choropyridine and 
pyrimidine moiety. The analogue Qu 2 with the 2-chloropyridine moiety is the most 
potent ligand for all subtypes under consideration. It also showed subtype selectivity 
for α4β2* over α7* and α3β4* nAChRs. The pyrimidine derivative Qu 3 showed 
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similar affinity to Qu 1 and Qu 2 for the α4β2* and α3β4* but it has a lower affinity 
for the α7* nAChR (Ki = 751 nM). Therefore, Qu 3 showed the highest subtype 
selectivity for α4β2* over α7* and α3β4* nAChRs.  
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III/8. Choline analogues as ligands for nicotinic acetylcholine receptors 
III/8.1. Introduction  
Choline 4 (2-hydroxyethyltrimethylammonium) is a metabolic product of ACh 
hydrolysis by cholinesterases (Fig. III/8.1). It is taken back into the cholinergic 
terminals by a high affinity transporter and then reused in transmitter synthesis. 
 
Choline +  Acetyl CoA
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Figure III/8.1: Metabolism of choline 4. Structure of choline 4. 
 
Choline 4 is a physiological component of the cerebral spinal fluid (CSF) and is 
important for the structural integrity of the membrane. It plays a key role in lipid and 
cholesterol transportation 171. The choline 4 concentration in the brain is ca. 10 µM but 
it increases up to 100 µM in a number of pathophysiological conditions due to an 
abnormal phospolipid metabolism occurring in chronic degenerative disorders, like 
Alzheimer’s disease 375. Choline 4 is also an important component in the human diet 
and therefore the Food and Drug Administration (FDA) Modernization Act, 376, 
recognized it as essential in 2001. A supplementation of choline 4 in adult diet has 
been shown to have benefits in both verbal and visual memory 377. Choline 4 crosses 
the blood brain barrier (BBB) via a specific carrier 375 that has also been thought to 
play a significant role in the brain’s uptake of choline derivatives 378 (Fig. III/8.2). 
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Figure III/8.2: Choline carrier: the transport mechanism from plasma to brain. 
 
Choline 4 has been shown to be a full and highly selective, but not potent, agonist at 
the α7* subtype of the nicotinic acetylcholine receptors in neurons cultured from rat 
hippocampus, olfactory bulb and thalamus as well as in PC12 cells 171,284. In functional 
assays, choline 4 acts as a partial agonist at α3β4-containing nAChRs in PC12 cells 
and does not activate α4β2 nAChRs on hippocampal neurons 284. Choline 4, like (-)-
nicotine 3, has been shown to protect neural cells from cytotoxicity induced by 
growth factor deprivation 379. Unfortunately, the mechanism for the cytoprotective 
effect has not been fully elucidated 380. The structure of choline (2-
hydroxyethyltrimethylammonium) (Fig. III/8.3) 4 can be found in a multiplicity of 
substances with different pharmacological effects, e.g. in drugs with antihistaminic 
and analgesic effects, like diphenhydramine 37 and nefopam 38, which display 
affinities in the micromolar range for neuronal nicotinic AChRs 374.  
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Figure III/8.3: Structures of diphenhydramine 37, nefopam 38 and choline 4. 
 
The pharmacological properties of choline phenyl ether analogues are of some 
interest. They were studied by Hunt and Renshaw (1929) 381 as powerful ganglionic 
stimulants. Further studies on aryl ether analogues of choline 4 demonstrated their 
amine-oxidase-inhibitory activity 382,383. The substitution at the ortho-position and the 
para-position in the choline phenyl ether increases the amine-oxidase-inhibitory 
activity, whilst a meta-substitution decreases it 382,383. In 2003, Simsek and co-workers 
384 showed that several 3-pyridyl ether analogues of choline 4 (Fig. III/8.4) display 
antinociceptive properties and also nanomolar affinities for (-)-[3H]nicotine sensitive 
binding sites.  
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Figure III/8.4: Structure of the lead compound used by Simsek et al. to investigate the 3-pyridyl ether 
analogues of choline as antinociceptive agents. In the coloured rectangle the structure of choline 4 is 
represented. 
 
III. Results 173 SAR of Phenylcarbamate 
Abreo et al. described similar analogues of choline with a very high affinity for the 
α4β2* and the amine function being incorporated in a cyclic carbon skeleton which 
can be an azetidine or a pyrrolidine ring (Fig. III/8.5) 202. 
N
R2
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R   =
R2 = H, CH3  
Figure III/8.5: Analogues of choline with the amine function incorporated in a cyclic carbon skeleton. 
Extending choline 4 with an amide moiety to obtain the carbamate function leads to 
carbacholine, a known muscarinic ligand. In 1988, Abood et al. described carbamate 
esters of choline 385 and used radioligand binding studies to evaluate their possible 
interaction with (-)-[3H]nicotine sensitive and [3H]MCC sensitive binding sites. They 
reported that the introduction of one or two methyl substituent on the amide 
function of carbamylchloride, producing 2-dimethylaminoethyl (DMAE) and 3-
trimethylaminoethyl (TMAE) phenylcarbamate, increased the affinity for neuronal 
nicotinic receptors. Recently N-methylated and dimethylated analogues of 
carbacholine Cch 17 were evaluated for their nicotinic activity 177. N,N-
dimethylcarbachol (DMCC) 19 proved to possess the highest selectivity for nicotinic 
over muscarinic acetylcholine receptors within this series 177. Recently, the carbamate 
derivative containing an azabicyclic system was claimed in a patent from Astra 
Laboratories 389 as an α7* selective compound. During the past few years, choline and 
its derivatives has not received much attention as selective for α7* nAChRs. Agonists 
for the α7* nAChRs are thought to be useful in the treatment or prophylaxis of 
psychotic disorders (schizophrenia, mania, maniac depression and anxiety) and 
intellectual impairment disorders (Parkinson’s disease, Alzheimer’s disease, memory 
loss, autism and Attention Deficit Hyperactivity Disorder (ADHD)). They might also 
be useful in the treatment of inflammatory bowel diseases, for example ulcerative 
colitis 386. 
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III/8.2. Project  
(Matthias Andrä, Lenka Munoz, Department of Pharmaceutical Chemistry, University of Bonn: synthesis of 
novel phenylcarbamate analogues) 
In order to achieve greater insight into structural requirements for nAChRs, 
especially for the α7* nAChR, the binding affinities of known and novel choline 
derivatives have been evaluated for different nAChR subtypes. The phenyl ether of 
choline was investigated for its in vitro binding affinity for different nicotinic nAChR 
subtypes for the first time. Extending choline 4 with an amide moiety to obtain the 
carbamate leads to a phenylcarbamate derivative. DMAE and TMAE were re-
synthesized and their affinity evaluated for the α4β2* α7*, α3β4* and muscle types 
nAChRs. Since the ortho and para positions at the phenyl moiety in phenylcarbamate 
derivatives have proved to strongly increase the affinity for muscarinic receptors as 
well as to increase the anesthetic effect 387, the meta position of the phenyl ring was 
selected for the introduction of various substituents, such as bromine, fluorine, 
methyl and trifluoromethyl moiety (Fig. III/8.6).  
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Figure III/8.6: Structures of choline 4, phenyl ether of choline CA 1 and phenylcarbamate 
 derivatives CA 2-7. 
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The analogues CA 1-7 have been tested in radioligand binding assays in order to 
determine their affinity towards four different classes of nicotinic acetylcholine 
receptors. It is known that ligands with a quaternary amino function generally show 
high affinity for nicotinic receptors 388. However, it is also recognized that 
incorporating the nitrogen of the quaternary amine group into a rigid ring system 388 
can enhance cholinergic potency. This observation prompted us to incorporate the 
nitrogen of compound CA1 into diverse azacyclic systems. Two isomeres of the 
methyl-piperidine derivatives were synthesized, one bearing the phenylcarbamate at 
position C-2 and the other one at position C-3 of the piperidine moiety (Fig. III/8.7). 
The prepared compounds CA 8-20 were evaluated for their ability to compete for (±)-
[3H]epibatidine and [3H]MLA binding sites in rat forebrain (α4β2*, α7*), pig adrenals 
(α3β4*) and Torpedo californica electroplax ((α1)2β1γδ) membrane fractions using 
radioligand binding assays.  
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Figure III/8.7: Structures of phenylcarbamate derivatives bearing different azacyclic skeletons. 
To discover whether the introduction of the carbamate moiety can improve the 
selectivity of these quinuclidine analogues in favour of α7* or other nicotinic AChR 
subtypes, the ability of the prepared compounds CA 22-28 (Fig. III/8.7) to compete 
for four different nAChRs subtypes was evaluated using radioligand binding assays 
179 180 374. 
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III/8.3. Determination of affinities and structure-activity relationships (SAR) 
The phenylether of choline CA 1 showed nanomolar affinities for neuronal nAChR 
subtypes with a preference for α4β2* (Tab. III/8.1) (Ki = 22.3 nM). The introduction of 
a carbamate moiety, converting the compound CA 1 to the corresponding carbamate 
analogue CA 3 (Ki = 38.9 nM) leads to an α7* selective compound. Abood and co-
workers have reported the ability of CA 2 and CA 3 to inhibit the specific binding of 
neuronal nicotinic and muscarinic receptors but no results were obtained for other 
nAChR subtypes. The introduction of a fluorine atom at position C-3 of the phenyl 
moiety leads to a carbamate derivative CA 5 with slightly reduced affinities for α4β2* 
and α7* nAChR (Ki = 1,412 and 62 nM, respectively) compared to CA 3, but retains 
the subtype selectivity for α7* nAChR. The selectivity and affinity for the α7* nAChR 
is increased again by the introduction of a trifluoromethyl group in position C-3 of 
the phenyl ring (CA 7, Ki = 29 nM). In contrast, the analogues CA 2, CA 4 and CA 6 
having a tertiary acyclic amine function show dramatically reduced affinities for 
nAChRs. Interestingly, the phenylether of choline CA 1 possesses the highest affinity 
for the ganglionic (Ki = 135 nM) and the muscle type (Ki = 697 nM). For α3β4* and 
muscle nAChRs, CA 1 exhibits 17- and 28-fold higher affinity than the corresponding 
carbamate analogue CA 3. 
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Table III/8.1: Radioligand binding affinities of the phenyl ether of choline and carbamate analogues of 
choline for α4β2*,  α7*, α3β4*and (α1)2β1γδ nAChRs. 
Phenyl ether of choline and phenylcarbamate analogues 
Structure No. 
α4β2* 
[3H]EPI 
rat brain 
Ki ( nM) 
α7* 
[3H]MLA 
rat brain 
Ki ( nM) 
α3β4* 
[3H]EPI 
pig adrenals 
Ki ( nM) 
(α1)2β1γδ 
[3H]EPI 
Torpedo calif. 
electroplax 
Ki ( nM) 
O
N
+CH3
CH3 CH3
Br
 
CA 1 22.3 ± 4.3 196 ± 9.19 135 n=1 697 
N
H
O
N
CH3
OCH3  
CA 2 > 20,000 12,836 ± 2,762 n.d. n.d. 
N
H
O
N
+
O
CH3
CH3 CH3
I
 
CA 3 835 ± 0.7 38.9 ± 2.9 2,200 n=1 > 20,000 
N
H
O
N
CH3
OCH3
F  
CA 4 > 20,000 11,000 23,157 n=1 > 20,000 
N
H
O
N
+CH3
OCH3
F
CH3
I
 
CA 5 1,412 ± 17 62 2,500 n.d. 
N
H
O
N
CH3
OCH3
CF3  
CA 6 > 20,000 > 20,000 n.d. n.d. 
N
H
O
N
+CH3
OCH3
CF3
CH3
I
 
CA 7 6,000 ± 23 29 ± 3 3,800 > 20,000 
n.d. = not determined 
n = number of experiments 
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The cyclization of the amino function in the pyrrolidine- (CA 8-12), piperidine- (CA 
12-20) and quinuclidine-rings (CA 20-28), produces analogues, which exhibit a 
surprisingly different binding profile for diverse nAChR subtypes (Tab. 8.2, 8.3, 8.4). 
Furthermore, they were synthesized with the purpose of penetrating through the 
blood-brain-barrier. 
N-methyl-pyrrolidine analogues 
The SAR of N-methyl-pyrrolidine derivative CA 8-12 does not follow the trend 
discussed previously for CA 3, CA 5 and CA-7. Compounds CA 8, CA 9, CA 10, CA 
11 and CA 12 have Ki values for α4β2* nAChRs in the higher nanomolar to the lower 
micromolar range. Despite the presence of a carbamate moiety that should determine 
selectivity for the α7* nAChR, they showed only lower affinity (high µM range) for 
the α7* subtype (Table III/8.2). Thus, analogues CA 8,CA 9, CA 10, CA 11 and CA 12 
showed an opposing selectivity profile compared to the analogues CA 3, CA 5 and 
CA 7. The rank order of potency is: α4β2* > α3β4* > α7*. The most potent and 
selective compound for α4β2* nAChRs was CA 10 containing a bromine atom at 
position C-3 of the phenyl ring (Ki = 528 nM). The trifluoromethyl analogue CA 12 
did not significantly influence the affinity for all nAChRs. The analogue CA 8 
showed the highest affinity for the α3β4* nAChRs, in this series (Ki = 2,582 nM). N-
methyl-pyrrolidine derivatives CA 8, CA 9 and CA 12 showed no effect at (α1)2β1γδ 
nAChR (Ki = > 20,000 nM). 
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Table III/8.2: Radioligand binding affinities of N-methyl-pyrrolidine analogues for α4β2*,  α7*, α3β4* 
and (α1)2β1γδ nAChRs. 
N-methyl-pyrrolidine analogues 
Structure 
 
No. 
 
α4β2* 
[3H]EPI 
rat brain 
Ki ( nM) 
α7* 
[3H]MLA 
rat brain 
Ki ( nM) 
α3β4* 
[3H]EPI 
pig adrenals 
Ki ( nM) 
(α1)2β1γδ 
[3H]EPI 
Torpedo calif. 
electroplax 
Ki ( nM) 
N O N
H
OCH3
 
(S) 
CA 8 1,100 ± 223 5,853 ± 212 2,582 ± 211 > 20,000 
N O N
H
OCH3
F  
(S) 
CA 9 1,633 ± 62 15,000 a 13,443 a > 20,000 
N O N
H
O
Br
CH3
 
(S) 
CA 10 526 ± 19 10,810 a 6,146 ± 294 n.d. 
N O N
H
O
CH3
CH3
 
(S) 
CA 11 1,248 ± 126 14,108 a 6,000 a n.d. 
N O N
H
OCH3
CF3  
(S) 
CA 12 1,050 ± 103 13,000 a 7,790 a > 20,000 
a = values are the mean from n=2 
n.d.= not determined. 
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N-methyl-piperidine analogues 
The N-methyl-piperidine series (CA 13-20, Tab. III/8.3) have been evaluated in 
radioligand binding studies in order to explore whether the position of the carbamate 
moiety at C-2 or C-3 of the piperidine ring exerts an evident impact on the subtype 
selectivity of these derivatives. Compounds CA 18-20, with the phenylcarbamate 
moiety at position C-3 on the piperidine ring, show a preference for α7* nAChR with 
Ki values in the low micromolar range (Ki ranging from 2,600 to 4,400 nM) (Tab. 
III/8.3) and no effect at α4β2* nAChR. CA 19, with a K  value of 2,600 nM for α7* 
nAChR, is the most selective compound for this subtype over α4β2* nAChR. In 
contrast CA 13-17, which have the carbamate function at position C-2 on the 
piperidine ring, display a complex pattern of subtype selectivity. Analogues CA 14 
and CA 17 with fluorine and trifluoromethyl substituents demonstrate poor receptor 
binding affinities for all subtypes under investigation (K  ranging from 20,000 to 
30,000 nM). Interestingly, the unsubstituted compound CA 13 proves to be the most 
selective analogue for the α3β4* nAChR. Analogues CA 15 and CA 16, containing a 
bromine or methyl moiety at the phenyl ring (K  = 3,700 and 175 nM, respectively), 
are the most potent ligands in the piperidine series for α4β2* nAChR. They have a 
subtype profile similar to that of their pyrrolidine analogues CA 8-12, namely α4β2* 
> α3β4* > α7*. 
i
i
i
 
 
 
 
 
 
 
 
 
III. Results 181 SAR of Phenylcarbamate 
Table III/8.3: Radioligand binding affinities of N-methyl-piperidine analogues for α4β2*, α7*, α3β4* 
and (α1)2β1γδ nAChRs. 
N-methyl-piperidine analogues 
Structure No. 
α4β2* 
[3H]EPI 
rat brain 
Ki ( nM) 
α7* 
[3H]MLA 
rat brain 
Ki ( nM)  
α3β4* 
[3H]EPI 
pig adrenals 
Ki ( nM) 
(α1)2β1γδ 
[3H]EPI 
Torpedo calif. 
electroplax 
Ki ( nM) 
N
O N
H
CH3 O  
CA 13 > 20,000 15,000 a 6,100 a > 20,000 
N
O N
H
CH3 O
F  
CA 14 > 20,000 22,000 a 11,392 a > 20,000 
N
O N
H
CH3 O
Br  
CA 15 3,770 ± 79 27,000 a 6,357 a n.d. 
N
O N
H
CH3 O
CH3  
CA 16 175 ± 12 31,800 a 14,392 a > 20,000 
N
O N
H
CH3 O
CF3  
CA 17 > 20,000 13,000 a > 20 000 > 20,000 
N
CH3
O N
H
O
 
CA 18 > 20,000 3,600 a 23,712 a > 20,000 
N
CH3
O N
H
O
F  
CA 19 > 20,000 2,600 a 6,963 a > 20,000 
N
CH3
O N
H
O
CF3  
CA 20 > 20,000 4,400 a 17,303 a > 20,000 
a = values are the mean from n=2 
n.d.= not determined. 
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Quinuclidine analogues 
The presence of an azabicyclic moiety was investigated in the series CA 22-27. The 
quinuclidine derivatives CA 22-27, like their corresponding derivatives CA 3, 5, 7, 
exhibit remarkable selectivity for α7* versus α4β2*. CA 23 shows the highest 
selectivity for the α7* nAChRs over the α4β2* (1:113). The affinities of the 
biphenylderivative CA 27 and the non-substituted CA 22 were evaluated by Naito et 
al. 387 on muscarinic receptors. In 2001, the affinities of these compounds together 
with CA 23 and CA 25 were tested for different nAChR subtypes and proved to be 
selective α7* nAChRs ligands 389. The azabicyclic carbamate derivative CA 22 was 
used as a lead compound for further substitution at the phenyl moiety, such as a 
phenyl (CA 27) and a styryl moiety (CA 28). Bulkier groups at the phenyl moiety 
reduce the subtype selectivity for α7* nAChRs and the affinity for α4β2* and α3β4* 
nAChR (Tab. III/8.4). Analogues in the quinuclidine series CA 22-28 present 
structural elements that are similar to that of the carbamate derivatives bearing a 
pyrrolidine or piperidine moiety CA 8-20. Indeed, they have basic nitrogen, which 
can be protonated to provide a cationic centre, a carbamate moiety and an π-electron 
system. Nevertheless, the quinuclidine series CA 22-28 possesses a much higher 
affinity and selectivity for α7* nAChR compared to analogues CA 8-20. Moreover, all 
(S)-pyrrolidine derivatives CA 8-12 and the piperidine analogues CA 15 and CA 16 
exhibit higher affinities for α4β2* nAChR. These results suggested that the carbamate 
moiety, in combination with a certain spatial distance between the oxygen and the 
nitrogen of the choline fragment in these derivatives, is crucial for the interaction 
with the α7* nAChR. The azabicyclic core of the quinuclidine moiety or the acyclic 
variant can provide a structure with an optimal distance between the choline oxygen 
and nitrogen. Furthermore, results listed in Table III/8.4 reveal that, compared with 
the pyrrolidine and piperidine series, the quinuclidine phenylcarbamate derivatives 
CA 22-27 examined have a higher affinity for α3β4* nAChRs. The Ki values are in the 
low micromolar range, with the exception of CA 24 (Ki = 715 nM).  
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Table III/8.4: Radioligand binding affinities of quinuclidine analogues for α4β2*, α7*, α3β4* and 
(α1)2β1γδ nAChRs. 
Quinuclidine analogues 
Structure No. 
α4β2* 
[3H]EPI 
rat brain 
Ki ( nM) 
α7* 
[3H]MLA 
rat brain 
Ki ( nM) 
α3β4* 
[3H]EPI 
pig adrenals 
Ki ( nM) 
(α1)2β1γδ 
[3H]EPI 
Torpedo calif.
electroplax 
Ki ( nM) 
N
OH
 
CA 21 5,924 ± 624 7,761 a 14,604 ± 869 n.d. 
N
O N
H
O
 
CA 22 3,084 a 44 ± 23 1,627 ± 123 > 20,000 
N
O N
H
O
F  
CA 23 4,203 a 37.3 ± 5 1,581 ± 22 > 20,000 
N
O N
H
O
Br  
CA 24 2,988 ± 66 273 ± 25 715 ± 33 n.d. 
N
O N
H
O
CH3  
CA 25 2,695 a 321 ± 3.5 1,478 ± 78 n.d. 
N
O N
H
O
CF3  
CA 26 1,718 a 173 ± 23 1,200 ± 66 > 20,000 
N
O N
H
O
 
CA 27 7,772 a 1,135± 431 1,448 ± 66 n.d. 
N
O N
H
O
 
CA 28 5,350 a 6,100 a 5,976 a n.d. 
a = values are the mean from n=2 
n.d.= not determined. 
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III/8.4. Discussion 
Radioligand binding studies carried out for the phenylether of choline, N-methyl-
pyrrolidine, N-methyl-piperidine- and quinuclidine phenylcarbamate derivatives 
revealed that choline derivatives CA 1-28 possess different subtype selectivity for 
nAChRs. Abood and co-workers 385 have reported the ability of CA 2 (2-
dimethylaminoethyl) and CA 3 (3-trimethylaminoethyl) phenylcarbamate to inhibit 
the specific binding of (-)-[3H]nicotine and [3H]methylcarbamylcholine in rat brain 
membranes at milli- (for CA 2) and micromolar (for CA 3) concentrations, but no 
results have been obtained for other nAChR subtypes. The phenylcarbamate 
derivatives CA 3-5-7 showed the highest affinities and subtype selectivity for α7*. 
The position of the phenylcarbamate moiety at the piperidine ring within the N-
methyl-piperidine series CA 13-20 influenced the subtype selectivity towards α7* 
and α3β4* nAChRs. On the contrary, all (S)-pyrrolidine derivatives CA 8-12 and the 
piperidine analogues CA 15 and CA 16 exhibited higher affinities and subtype 
selectivity for α4β2* nAChR. Furthermore, in order to study the influence of the 
azacyclic core, a series of phenylcarbamate derivatives was synthesized where the 
amine function is constrained in a quinuclidine moiety. This azabicyclic system 
provides quite a rigid structure with a protonable nitrogen. Such compound could 
cross the blood-brain-barrier (BBB). These properties make the quinuclidine moiety a 
good basis for the development of ligands for nicotinic receptors in the CNS. The 3-
bromophenyl carbamate analogues CA 10, CA 15 and CA 24 show very remarkable 
binding profiles. The quinuclidine analogue CA 24 and the (S)-pyrrolidine analogue 
CA 10 display a contrary profile for subtype selectivity. The first one CA 24, is the 
most potent compound for α7* with a Ki value of 273 nM, whereas the second one 
has the highest affinity for α4β2* (Ki = 526 nM). Analogue CA 24 exhibited the 
highest affinity for α3β4* nAChR, with a Ki value of 715 nM, whereas CA 10 and CA 
15 possessed similar but a ca. 9-fold lower affinity for the ganglionic subtype. None 
of the phenylcarbamate derivatives examined showed activity for the muscle type 
nAChR. Recently, interest for choline 4 and its derivatives has been renewed due to 
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the discovery that choline is a full agonist at α7* nAChRs. Based on the fact that 
activation of this subtype produces a variety of biological responses, the biological 
significance of α7* nAChRs is at present a topic of great interest. The most relevant 
pharmacological effects are in vitro neuroprotection and modulation of glutamate 
and GABA release. Currently, the development of choline derivatives potentially 
selective for α7* nAChRs, is receiving significant attention. AstraZeneca produced a 
compound (-)-AR-R17779 20, containing a spiroquinuclidine moiety as a rotationally 
restricted analogue of acetylcholine 1. This compound was the first known ligand to 
possess in vitro subtype selectivity for α7* over α4β2* nAChRs (Ki value for α7* = 92 
nM ([125I]α-Bgt), Ki value for α4β2* = 16,000 nM ((-)-[3H]nicotine )178. The 3-
quinuclidinole CA 21 was used for the synthesis of CA 22-28. It can be considered a 
rigid choline derivative. Interestingly, it displays Ki values in the micromolar range 
for different neuronal nAChRs and no selectivity between α4β2* and α7* nAChRs. 
Quinuclidine analogues CA 22-28 not only possess high nanomolar affinities for the 
neuronal nAChR, but also display the highest affinities and subtype selectivity for 
α7* nAChRs. The most selective and active compound was the quinuclidine 
phenylcarbamate CA 23, with a selectivity for the α7* nAChRs comparable to that of 
AR-R17779 20. 
N
O N
H
O
N
CH3
O N
H
O
 
CA 22 
Ki = 44 nM (α7* nAChRs) 
CA 13 
Ki = 15,000 nM (α7* nAChRs) 
Figure III/8.9: The structure of choline is highlighted in compound CA 22 and CA 13. 
The difference in subtype selectivity among the phenylcarbamate derivatives can be 
explained on the basis of the choline substructure incorporated (Fig. III/8.9). The CA 
13 derivative, even presenting structural elements similar to that of the quinuclidine 
derivative CA 22, such as a basic nitrogen, which can be protonated to provide a 
cationic centre, a carbamate moiety and a π-electron system, does not seem to possess 
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an optimal distance between the nitrogen atom and the oxygen. This parameter 
seems to be crucial for the interaction with the α7* nAChR. 
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The in vitro characterization and further insight into structure-activity relationships 
of novel synthetic analogues of the natural toxic alkaloids (-)-cytisine Cy 1, (+)-
ferruginine Fe 1, and (+)-anatoxin-a An 1 as well as of choline 4 derivatives were the 
focus of this work. The natural toxins possess high affinity for α4β2* nAChR, 
representing the major population of nACh receptors in mammalian brain, but no 
appropriate selectivity, i.e. the interaction of these ligands with ganglionic and 
neuromuscular nAChRs is thought to be responsible for cardiovascular, 
gastrointestinal and neuromuscular side effects, limiting their utility as therapeutic 
agents. Therefore, it will be of interest to get more information about the structural 
requirements of nicotinic ligands for these subtypes. To date, systematically 
structure-activity relationship studies of (-)-cytisine Cy 1, (+)-ferruginine Fe 1, and 
(+)-anatoxin-a An 1 based ligands have not been reported for different nAChR 
subtypes.  
Beside the templates derived by toxic alkaloids, choline, a selective activator of 
α7-type nAChRs with neuroprotective activity, is a possible candidate for drug 
development regarding different diseases of the CNS and PNS.  
In general, since the molecular recognition between ligands and nAChRs 
might be based on cation-π interactions 57 and a hydrogen bond formation between 
the receptor site and the ligand (HBD-HBA interaction), all high affinity compounds 
bear the cationic and HBA motifs. Unfortunately, additional characteristics for the 
ligand receptor interaction, which might be important for subtype selectivity, could 
not be obtained so far.  
Up to now this study is the first one, which evaluated a wide range of mostly 
novel ligands, based on different templates for four different nAChR subtypes. The 
findings are:  
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A successful systematic evaluation of known and novel ligands  
Previously described competition assays have been successfully re-evaluated in 
order to screen different novel analogues of natural toxins and choline derivatives for 
α4β2*, α7*, and (α1)2β1γδ nAChR subtypes.  
A radioligand binding assay for α3β4* nAChRs using native tissue was 
established 
Within the scope of testing novel ligands a new radioligand binding assay using 
native calf or pig adrenal glands was successfully established. (±)-[3H]Epibatidine has 
been proved to be a suitable radioligand to characterize α3β4* nAChRs located in 
native calf or pig adrenal glands. In a concentration range of 2-2400 pM, (±)-
[3H]epibatidine binds with a KD of 54 ± 4.6 pM and shows a Bmax value of 99 ± 11 
fmol/mg protein for whole membrane fractions of pig adrenals and similar values 
(KD of 39 ± 5.3 pM and Bmax of 91 ± 10 fmol/mg protein) for whole membrane fractions 
of calf adrenals. This novel assay has proved to be a valid procedure for screening 
novel nicotinic ligands for their affinities to α3β4* nAChRs. In addition, it possesses 
also economic advantages in comparison to other systems, such as cell cultures or 
assays performed with rat adrenal glands. 
Structure activity relationships studies for toxin analogues 
The structure-activity relationships of novel toxins analogues have been evaluated 
for four different nAChR subtypes. In particular, important information have been 
obtained concerning the structural requirements that enhance selectivity of toxin 
analogues for α4β2* nAChR over other nAChRs investigated. 
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Cytisine analogues 
 
NH
N
O
NO2, Cl, Br, I
NO2, Cl, Br, I
S
Methyl, Acetyl, Benzyl
Hydrogenation 
3
5
11Carbonyl
Carbonyl
Fused ring
 
 
The introduction of a substituent at the secondary nitrogen of the bispidine ring 
results in a dramatic loss of affinity for all nAChRs investigated. In contrast, a 
dimethylation, determining the formation of a quaternary amino function, increase 
the affinity for α4β2* (Cy 5, Ki = 0.238 nM). Cytisine Cy 1 with multiple oxygen 
functionalities (Cy 10) showed a low affinity for the α4β2* subtype and proved to be 
a weak ligand for α7*, α3β4* and muscle nAChRs (Cy 10, Ki = 95,000, 50,000 and 
20,000 nM, respectively). 
 
Ki (nM) for α4β2* nAChR 
NH
N
O
 
N
+
N
O
CH3
CH3
 
NH
N
O
O
O CH3
O
 
Cytisine Cy 1 Ki (nM) = 0.124 Cy 5 Ki (nM) = 0.238 Cy 10 Ki (nM) = 9,400 
 
With the exception of the muscle type, the introduction of a halogen atom in position 
C-3 of the pyridone ring improves the affinities of cytisine for α4β2* as well as for 
α7* and α3β4* nAChRs. Therefore, this structural variation could only greatly 
improve the selectivity for α4β2* over the muscle nAChR. The introduction of 
halogen atoms at position C-5 (for example in Cy 16) leads to a slightly decrease in 
IV. Summary and Outlook 190  
affinity for α4β2* but an increased affinity for the α7* nAChR and α3β4* nAChRs in 
comparison to Cy 1.  
 
 
NH
N
O
 
NH
N
O
Br  
NH
N
S
 
 Cy 1 Ki (nM) Cy 16 Ki (nM) Cy 29 Ki (nM) 
α4β2* 0.124 0.338 0.832 
α7*  250 28 4,000 
α3β4* 18 5 632 
 
Another observation of particular interest concerns the influence of a bioisosteric 
replacement of oxygen by sulphur on the pyridone ring. This modification resulted 
in novel analogue Cy 29, which shows a subnanomolar affinity for the α4β2* subtype 
(Ki = 0.832 nM) and the best affinity-selectivity profile for α4β2* over α7* and α3β4*. 
Results of radioligand binding assays performed for thiocytisine derivatives showed 
that none of the additional structural modifications introduced were able to enhance 
the selectivity for non-α4β2* subtypes under examination. Hydrogenation of the 
pyridone ring (Cy 7) proved to be deleterious for the affinity for all subtypes. The 
conformationally constrained analogue Cy 11 showed dramatically reduced affinities 
for α4β2* and α7* nAChRs in comparison to the lead compound Cy1. 
 
 
N
N
O
CH3 O
 
N
N
NH
N
O
CF3
F3C  
 Cy 7 Ki (nM) Cy 11 Ki (nM) 
α4β2* > 20,000 5,333 
α7*  > 50,000 > 50,000 
α3β4* > 50,000 n.d. 
muscle type > 50,000 n.d. 
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Ferruginine analogues 
 
N
R1
N
R1
H, CH3R1 =
2
3
Substituents at  C-2  and C-3  
 
Amide moieties at C-2 in the azabicyclic substructure of ferruginine resulted in 
dramatic decrease of affinity for α4β2* (Fe 3, Ki = 3,790 nM; Fe 6, Ki = 20,000 nM; Fe 5, 
Ki = 2,027 nM) being not suitable surrogates for the acetyl group of ferruginine Fe 1 
(Ki = 120 nM).  
N O
NH2
CH3
N S
N(CH3)2
CH3
N O
N(CH3)2
CH3
Fe 6Fe 3 Fe 5  
On the contrary, replacement of the acetyl moiety by a heteroaromatic ring increase 
the binding affinity for α4β2*. The electronic properties of the heterocycles moiety 
(hydrogen bond acceptor (HBA) capability) influence the potency, therefore the 
following rank order was observed: pyridine > pyrimidine > pyridazine > pyrazine. 
Furthermore, the binding affinity proved to be influenced by the position of the 
pyridine or diazine ring at the 8-azabicyclo[3.2.1]octene skeleton of ferrugine and 
norferrugine. 
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Ki (nM) for α4β2* nAChR 
N
N
H
 
N
N
H
 
N
N
CH3
 
N
N
CH3
 
Fe 13 Ki (nM) = 0.25  Fe 8 Ki (nM) = 1.6 Fe 14 Ki (nM) = 0.96  Fe 10 Ki (nM) = 3.4 
 
Compared to analogues with a pyridine moiety at position C-2 (Fe 8, Fe 10) of the 
azabicyclic skeleton, analogues bearing a pyridine moiety at position C-3 (Fe 13, Fe 
14) possess a higher affinity for α4β2* nAChR (Ki = 0.25 nM and Ki = 0.96 nM, 
respectively). A double substitution, such as an additional introduction of an ester 
moiety in the 8-azabicyclo[3.2.1]octene-skeleton is significantly detrimental to the 
affinity for all subtypes examined (ent-Fe 16, Fe 14). 
 
 
N
N
CH3
H3COOC
 
N
N
CH3
 
 ent-Fe 16  Fe 14 
α4β2* Ki (nM) 4,931 0.96 
α7* Ki (nM) > 50,000 73.6 
α3β4* Ki (nM) > 30,000 24 
 
A general trend can be observed for the affinities of the ferruginine and 
norferruginine analogues for the α7* subtypes. N-methylation of the azabicyclic 
system improves the affinity for this nAChR subtype. The ferruginine Fe 1 possess 
303-fold higher affinity than its desmethylated analogue, norferruginine Fe 2. The 
ferruginine analogue Fe 10 exhibited the highest affinity for the α7* nAChRs (Ki = 53 
nM), which is ca. 7- fold higher than the affinity of its demethylated analogue (Fe 8). 
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Ki (nM) for α7* nAChR 
N
CH3
CH3
O
 
N
H
CH3
O
 
Fe 1 Ki (nM) = 330 Fe 2 Ki (nM) = 100,000 
N
CH3 N
 
N
H N
 
Fe 10 Ki (nM) = 53 Fe 8 Ki (nM) = 396 
 
The introduction of a pyridyl moiety in position C-3 (Fe 14) had a positive influence 
on the affinity to muscle nAChRs. Compound Fe 15, bearing a chloro-pyridyl moiety 
proved to be the most active ligand at (α1)2β1γδ nAChR subtype (Ki = 80 nM), being 
625-fold more potent than the lead compound ferruginine Fe 1. 
Ki (nM) for (α1)2β1γδ nAChR 
 
N
H
CH3
O
 
Fe 1 Ki (nM) = 50,000 
N
N
CH3
 
N
N
CH3
Cl  
Fe 14 Ki (nM) = 314 Fe 15 Ki (nM) = 80 
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Pinnamine analogues 
Neither of the two novel pinnamine derivatives retains the affinity of the lead 
compound (-)-ferruginine Fe 1 for the α4β2* nAChR subtype. Analogue cis-Pin 1 
showed only a weak interaction to the α7* nAChRs subtype (Ki = 22,470 nM), 
whereas trans-Pin 2 binds in the low micromolar range (Ki = 1,360 nM, α7* nAChR). 
The loss of the affinity could be due to the unfavourable orientation of the 
pharmacophoric elements and/or the ethyl moiety cannot be sterically tolerated. 
Therefore, it will be interesting to investigate whether the presence of a substituent 
smaller or larger than the ethyl moiety could increase the affinity. 
 
 
N
CH3
O
O
CH3
H
H  
N
CH3
O
O
CH3
H
H  
α7* Ki (nM) Cis-Pin 1 = 22,470 Trans-Pin 2 = 1,360 
 
Anatoxin-a analogues 
The binding affinity of the epibatidine-anatoxin-hybrid UB-165 was re-evaluated for 
α4β2* and α7* nAChRs and its affinities for the α3β4* and muscle type nAChRs was 
determined for the first time. The UB-165 and its novel deschloro analogue, DUB-
165, showed similar affinities for the α4β2* (Ki = 0.04 nM and 0.051 nM, respectively) 
and selectivity over the muscle type (Ki values were in the high micromolar range). 
Interestingly, DUB-165 showed a 94-fold higher affinity (Ki = 0.95 nM) than UB-165 
for the α7* nAChR. In addition, they displayed Ki values for α3β4* in the lower 
nanomolar range (Ki = 1.3 nM and 6.2 nM, respectively). On the basis of these data, 
UB-165 possess the highest affinity for α4β2* nAChRs (Ki = 0,051 nM), but lower 
subtype selectivity for α4β2* over α3β4* nAChRs compared with DUB-165. 
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N
N Cl
N
N
N
N
N
NN N Cl
N
H
R
N
H
CH3
O
R =
= > > > >
DUB-165            UB-165                   An 2                  An 3                   An 5                  An 4
An 1
α4β2* Ki  (nM) 0.051 0.04 0.14 0.15 12 19 
α7* Ki  (nM) 0.95 12 10.7 n.d. 250 10,000 
α3β4* Ki  (nM) 6.2 1.3 20 n.d. 259 2,500 
 
Among the diazine biosiosteres (An 2, An 3, An 4 and An 5) the most active 
compounds described were the pyrimidine and chloro-pyrimidine containing 
bioisoster An 2 and An 3, with Ki values for α4β2* nAChRs in the picomolar range, 
0.14 and 0.15 nM, respectively. An 2 also showed high affinity for α7* (Ki = 10.7 nM) 
and α3β4* nAChRs (Ki = 20 nM) and proved to be more potent, but similarly selective 
than the natural anatoxin-a An 1. The introduction of a pyrazine or pyridazine 
moiety, resulting in compounds An 4 and An 5, respectively, decreases the binding 
affinity for all nAChRs. 
Diazabicyclo[4.2.1]nonane derivatives 
Pyridine and diazine moieties are suitable for high affinity binding at the α4β2* 
nAChRs (Ki values ranging between 0.62 to 2.09 nM) in the diazabicyclo[4.2.1]nonane 
series. On the contrary, they possess only moderate affinity for α7* nAChRs 
exhibiting a certain degree of preference for the α4β2* compared to the α7* nAChRs. 
Analogue An 13, bearing a pyrazine moiety, neither interacted with α7*, α3β4* nor 
with (α1)2β1γδ nAChRs (Ki > 50,000 nM). 
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N
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N
N
 
 An 11 An 10 An 8 An 7 An 13 
α4β2* Ki (nM) 0.52  0.55  0.62  0,873  265  
α7* Ki (nM) 157  190  138  92  > 50,000  
α3β4* Ki (nM)  9.5  30  23  30,6  > 50,000  
(α1)2β1γδ Ki (nM) 2,330  2,540  3,050  2,326  > 50,000  
 
In future studies, it would be very interesting to find out whether bulkier 
substituents at position C-2 or C-3 of the azabicyclooctene or -nonene skeleton of 
ferruginine or anatoxin-a would be able to improve the selectivity toward a certain 
type of nACh receptors. First attempts have been very recently shown in a study of 
Karig et al. using DUB-165 as a template 372. They introduced a phenyl ring at 
different positions of the pyridyl moiety and found that a phenyl substituent at 
position 4´ of the pyridine ring could be favourable for the interaction with α7* 
nAChR.  
Quinuclidine analogues 
In the past, the introduction of a pyridine moiety in the quinuclidin-2-ene skeleton 
proved to be detrimental for the affinity for muscarinic receptors whereas in this 
actual study, it leads to an analogue with nanomolar affinities for the α4β2* and α7* 
nAChR (Ki = 7.5 and 83 nM, Qu 1). The pyrimidine derivative Qu 3 showed the 
highest subtype selectivity for α4β2* over α7* nAChRs.  
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N
N
 
N
N
N
 
 Qu 1 Qu 3 
α4β2* Ki (nM) 7.5 12 
α7* Ki (nM) 85 751 
α3β4* Ki (nM) 103 112 
(α1)2β1γδ Ki (nM) 237 100 
 
Structure activity relationship studies for choline analogues 
Phenylcarbamate derivatives led to compounds with different subtype selectivity for 
nAChRs. Compounds CA 5, CA 7, together with the quinuclidine analogue CA 23, 
displayed the highest affinities and subtype selectivity for α7*. 
 
N
H
O
N
+CH3
OCH3
F
CH3
I
 
N
H
O
N
+CH3
OCH3
CF3
CH3
I
 
N
O N
H
O
F  
CA 5 CA 7 CA 23 
Ki α7* = 62 nM Ki α7* = 29 nM Ki α7* = 37 nM 
Ki α4β2* = 1,412 nM Ki α4β2* = 6,000 nM Ki α4β2* = 4,000 nM 
 
Unexpectedly, the pyrrolidine derivatives (for example, CA 10 and CA 11) and the 
piperidine analogues CA 15 and CA 16 exhibited higher affinities and subtype 
selectivity for α4β2* nAChR. The difference in subtype selectivity among the 
phenylcarbamate derivatives could possibly be based on the distance existing 
between the nitrogen and the oxygen of the choline substructure incorporated. 
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CA 10 CA 11 CA 15 CA 16 
Ki α4β2* = 526 nM Ki α4β2* = 1,248 nM Ki α4β2* = 3,770 nM Ki α4β2* = 62 nM 
Ki α7* = 10,800 nM Ki α7* = 14,108 nM Ki α7* = 27,00 nM Ki α7* = 31,800 nM 
 
Another important parameter able to influence the subtype selectivity towards α7* 
and α3β4* nAChRs is the position of the phenylcarbamate moiety at the piperidine 
ring within the N-methyl-piperidine series (CA 13 in comparison to CA 18).  
 
N
O N
H
CH3 O  
N
CH3
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O
 
CA 13 CA 18 
Ki nM α7* = 15,000  Ki α7* = 3,600 nM 
Ki nM α3β4* = 6,100  Ki α3β4* =23,712 nM 
 
Carbamates, and specially phenylcarbamates, are known as compounds exhibiting 
diverse pharmacological profiles. They have analgesic, spasmolytic and local 
anesthetic properties. Therefore, it will be interesting in future to evaluate these 
compounds for their affinities to other receptors (muscarinic, 5-HT3, etc ). Further 
possible structural modification may regard the replacement of the piperidine, 
pyrrolidine and quinuclidine moiety with other azabicyclic systems and the 
carbamate moiety by an amide substructure.  
In general, it will be of great importance to examine these novel ligands for 
their functionality using different approaches (FLIPR, patch-clamp, [3H]monoamine 
release), since affinity values normally reflect the interactions with one or more 
desensitised states of the nACh receptor.  
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 V. Experimental Section 
V/1.1. General Information 
V/1.1.1. Instruments 
Filter:    Whatman GF/B, Brandell, Gaithersburg, MD, U.S.A. 
Harvester:   Brandell M48, M24, Gaithersburg, MD, U.S.A. 
Homogenizator: RW 16 basic, IKA Labortechnik, Germany 
LSC-counter:  Tricarb® 2900 TR, Canberra Packard/Perkin Elmer, Dreieich, 
Germany 
pH Meter: WTW, pH-197, with pH-Electrode SenTix41, IKA Labortechnik, 
Germany 
Photometer:  Beckman DU ®, 530 Life Science, Germany 
Pipette:   Eppendorf Research und Eppendorf Multipipette plus 
Ultraschallbad: Sonorex RK52H, Bandelin, Germany 
Ultraturrax:  T25 basic, IKA Labortechnik, Germany 
Vortex:  MS2, Minischaker, IKA Labortechnik, Germany 
Centrifuge:  Beckman Avanti TM, J-20 XP, Beckman Coulter, U.S.A. 
V/1.1.2. Materials 
Chemical substances 
Tris[hydroxymethyl]aminomethane          T 1503 Sigma Aldrich 
Tris[hydroxymethyl]aminomethane-hydrochloride        T 3253 Sigma Aldrich 
D(+)-Sucrose          84097 Fluka Biochemika 
Hepes N-[2-Hydroxyethyl]piperazine- 
N´[2-ethanesulfonic acid]                                                                 H 3375-Sigma Aldrich 
Sodium Chloride              S 7653 Sigma Aldrich 
Magnesium Chloride Hexahydrate         M 2670 Sigma Aldrich 
Calcium Chloride Dihydrate           C 3306 Sigma Aldrich 
Potassium Chloride                        P 9541 Sigma Aldrich 
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Ethanol p.a.      Merck KG Darmstadt Germany 
DMSO (dimethylsulfoxide)    Merck KG Darmstadt Germany 
Nicotine hydrogen tartrate salt          N 5260 Sigma Aldrich 
methyllycaconitine citrate (MLA)           M 168 Sigma Aldrich 
Water ELGA Pure Lab ultra, Vivendi, Water Company  
Ultima Gold TM                                      Perkin Elmer and Analitical Science, M.A, U.S.A. 
is a mixture of: 
Ethoxylated alkylphenol 10-20 % 
Bis(2-ethylhexyl) hydrogen phospate 10-20 % 
Docusate sodium ≤ 2.5% 
Triethyl phosphate ≤ 2.5% 
Diisopropyl naphthalene isomers 60-80 % 
2,5-Diphenyloxazole ≤ 2.5% 
1,4-bis(4-methyl-alpha-styryl) benzene ≤ 2.5% 
Radioligands  
(±)-[3H]Epibatidine (S.A.: 33.3 - 66.6 Ci/mmol) obtained from Perkin Elmer Life 
Science Products (Cologne, Germany). 
[3H]Methyllycaconitine ([3H]MLA) (S.A.: 20 - 39.8 Ci/mmol) obtained from TOCRIS 
Cookson Ltd, Northpoint Fourth Way Avonmouth, Bristol, UK 
Tissues  
Frozen Torpedo Californica electroplax was purchased from Marinus Inc. (Long 
Beach, CA, U.S.A.).  
Frozen Sprague-Dawley rat brains were purchased from Pel-Freez Biologicals 
(Rogers, AR, U.S.A.). 
Pig adrenals were purchased from Pel-Freez Biologicals (Rogers, AR, U.S.A.). 
Calf adrenals were obtained from a local slaughterhouse (Cologne, Germany) 
Buffers Solutions 
TRIS buffer 25 mM/ pH 7.4 (rinse buffer) 
4 mM Tris Base ® (Tris[hydroxymethyl]aminomethane)  
V. Experimental Section - 201 –   
21 mM Tris HCl ® (Tris[hydroxymethyl]aminomethane-hydrochloride)  
HEPES-salt solution (HSS) pH 7.4 (assays incubation buffer, buffer for membrane 
preparation) 
15 mM HEPES  
120 mM NaCl 
5.4 mM KCl 
0.8 mM MgCl2 
1.8 mM CaCl2 
adjust pH 7.4 
Sucrose Solution (for membrane preparations) 
320 mM D(+)-Sucrose  
25 mM Tris HCl 
adjust pH 7.4 
V/1.2. Membrane Preparation 
V/1.2.1. General Remarks 
Binding assays are carried out using native membrane preparations. Whole 
membrane preparations have been obtained from pig/calf adrenal glands and 
Torpedo Californica electroplax, whilst P2 membrane fractions have been prepared 
from rat forebrain. Both membrane fractions are relatively homogeneous and easy to 
handle in binding studies. The use of native tissue enriched in synaptosomes 
(particles containing the organelles of the synapse) avoids the problems that are 
present with assays on intact cells (e.g. presence of endogenous agonist, and an high 
non-specific binding). Results obtained from binding assays carried out using P2 
membrane fractions are not comparable with results from assays performed using 
whole membrane fractions. Actually, the P2 membrane fractions represent a first 
stage of refinement over the crude homogenate and compared to the crude 
homogenate are 1.5 fold enriched in synaptic receptors. In the next section (V/1.2.2) 
will be described in major details the procedure used to obtain the P2 membrane 
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fractions. Sections V/1.2.3, V/1.2.4. and V/1.2.5 report the specific protocols for the 
preparation of whole membrane fractions. Generally, soft tissue such as brain is 
homogenized using a Potter homogeniser with a rotating Teflon pestle. The pestle 
should be motor driven with variable speed and high torque. By the vertical 
movement in a small diameter tube, small particles are formed and subsequently 
fractionated. Instead, tough tissue, such as adrenal glands and smooth muscle are 
best homogenized with a Polytron IKA ultraturrax. This latter instrument relies on a 
blender principal, with rotating blades contained within a cylindrical cavity through 
which the homogenate circulates. The particles have different sedimentation 
constants and may be separated by centrifugation. To avoid or reduce the auto 
protolysis process, the entire procedure should be conducted on ice. 
V/1.2.2. Preparation of rat brains 
Frozen rat brains were thawed slowly before the preparation of the P2 rat brain 
membrane fractions. They were placed on ice for 30 to 60 min and then placed on a 
plastic plate. A single cut just behind the inferior colliculi was done to exclude the 
cerebellum and medulla. After the determination of the wet weight, the brains are 
pressed into a pulp using a syringe and homogenized in sucrose buffers with a glass 
teflon homogenizator (Potter, 10 seconds). A single rat brain weights on average 1.32 
g. The tissue is centrifuged (1,000 x g, 20 min, 4°C) for the production of the 
supernatant, S1 and the pellet, P1. The supernatant will be aspirated with a Pasteur 
pipette and stored on ice. The P1 pellet (enriched in cell nuclei, unbroken cells, and 
brain micro vessels) was re-suspended in sucrose buffer, and the centrifugation was 
repeated (1,000 x g, 20 min, 4°C) to produce S1´ and P1´. The two supernatant (S1+ 
S1´) were combined and centrifuged (25 000 x g, 20 min, 4°C) to produce P2 and S2. 
The P2 fractions obtained represent the so-called crude mitochondria pellet, which 
contains the majority of the synaptosome. The buffer volume added is calculated on 
the basis of the wet weight in a ratio of 1:2. The final pellet was re-suspended in 
assay buffer and stored in aliquots at –80°C. On the day of assay, pellets are thawed, 
re-suspended in a fresh HSS and used for binding assay. 
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V/1.2.3. Preparation of pig adrenals  
Frozen (-80°C) pig adrenals were thawed on ice for 30 to 60 min before preparation 
and cut in small pieces. After the determination of the wet weight (every adrenal 
gland weights ca. 2.8 g) the tissue was homogenized in HSS (pH 7.4, ice-cold) using a 
motor-driven polytron IKA ultraturrax (setting 6 / rpm = 24,000, 10 sec.). The 
homogenate was centrifuged (30,000 x g, 10 min, 4°C), the pellets were collected and 
washed. This procedure was repeated five times. The buffer volume used to re-
suspended the pellets is calculated on the basis of the wet weight in a ratio of 1 : 6.5. 
Afterwards the tissue is stored in aliquots at - 80°C. Before each assay, the tissues 
were homogenized in HSS. After centrifugation (25,000 x g, 20 min, 4°C), the 
resultant pellets were re-suspended in fresh HSS and used for binding assay. 
V/1.2.4. Preparation of calf adrenals  
Frozen (-80°C) calf adrenals were thawed on ice for 30 to 60 min before preparation 
and cut in small pieces. After the determination of the wet weight (one piece weights 
in average 4-6 g) the tissue was homogenized in HSS (pH 7.4, ice-cold) using a 
motor-driven polytron IKA ultraturrax (setting 4 / rpm = 19,000, 5 sec.,2-times). The 
homogenate was centrifuged (30,000 x g, 10 min., 4°C). The pellets were collected and 
washed. This procedure was repeated five times. The buffer volume used to re-
suspended the pellets was calculated on the basis of the wet weight in a ratio of 1 : 
6.5. Afterwards, the tissue is stored in aliquots at - 80°. Before each assay, the tissues 
were homogenized in HSS. After centrifugation (25,000 x g, 20 min, 4°C), the 
resultant pellets were re-suspended in fresh HSS and used for binding assay. 
V/1.2.5. Preparation of Torpedo californica electroplax 
Frozen samples of Torpedo Californica electric organ were thawed for 30 to 60 min 
before membrane preparation. Total membrane fractions were isolated by 
homogenisation of the tissue in ice-cold HSS using a Polytron IKA ultraturrax 
(setting 6 / rpm 24,000,) and followed by centrifugation (30,000 x g, 10 min., 4°C). The 
pellets were collected, washed four times with HSS through re-homogenisation and 
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centrifugation at the same settings. The remaining pellets were collected, re-
suspended in HSS and stored in aliquots at - 80°C. 
For each assay, the samples of membrane fractions were thawed, homogenized, and 
centrifuged (30,000 x g, 10 min., 4°C). The resultant pellets were re-suspended in HSS 
and used in binding assays. 
V/1.3. Protein Determination 
V/1.3.1. Bradford protein determination 
The Biorad protein assay (Nr.500-0002) is a dye-binding assay based on the 
observation that the absorbance maximum for an acidic solution of Coomassie 
Brillant Blue G 250 shifts from λ= 465 nm to λ= 595 nm when binding with protein 
occurs. To determine the concentration of the protein following the Bradford 
procedure, a master solution was prepared, made of 0.1 g Coomassie brilliant Blue G 
diluted in 50 % ethanol (v/v), with 100 ml phosphoric acid (85%) and pure water up 
to 240 ml. The dye reagent is provided as a 5-fold concentrate. Therefore it must be 
diluted in a ratio of 1 to 5 with pure water and filtered over paper filters prior to use. 
The filtration is useful for removing any particulates that may form as a result of the 
dilution. The dilute reagent should be discarded after 2 weeks due to the formation 
of precipitates. Bovine’s serum albumin was used as a standard protein. The 
Coomassie protein assay was calibrated within a protein concentration range from 10 
to 250 µg (λ = 595 nm). The samples are diluted with pure water so that their 
concentrations amount to approximately 10-100 µg proteins. A volume of 0.1 ml of 
these dilutions was mixed with 2.0 ml Bradford reagent. The sample-dye mixtures 
were assayed within 1 hour of mixing, due to the progressive reduction of the optical 
density. 
V/1.3.2. Lowry protein determination 
This procedure (Sigma-Aldrich Protein Assay, No. P5656) is one of the most used for 
quantification of soluble proteins. Protein concentrations are determined and 
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reported with reference to standards of a common protein (e.g. bovine serum 
albumin (BSA)). A series of dilutions of the protein standard is prepared in 
appropriately labelled test tubes (Tab. V/1.1).  
Table V/1.1: Dilutions of the bovine serum albumin (BSA) 
Protein standard solution (µl) deionised water (µl) protein concentration (µg/ml)
62,5 
125 
250 
375 
500 
437,5 
375 
250 
125 
0 
50 
100 
200 
300 
400 
 
The Folin-Ciocalteau reagent is prepared by mixing 1 part of 2N phenol reagent of 
the working solution with 1 part of deionised water (Fig. V/1.1). A volume of 1 ml of 
Lowry reagent is added to 0.2 ml of protein sample (appropriately diluted) and 
incubated exactly 10 minutes at room temperature. The last step is to add the Folin-
Ciocalteau reagent and incubate it 30 minutes at room temperature (Fig. V/1.1). 
 
Figure V/1.1: Test tube procedure (Lowry’s method) 391 
Absorbance is read at a suitable wavelength of 750 nm. The concentration of each 
unknown protein sample is determined based on the standard curve. 
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V/1.4. Radioligand binding studies for α4β2*nAChR 
Saturation assays using (±)-[3H]epibatidine and rat brain (P2 fraction) 
In saturation studies, membrane preparations (60-90 µg protein) were incubated in 
the presence of 1-500 pM of (±)-[3H]epibatidine in polypropylene tubes containing 
HSS. The membranes were incubated at 22 °C for 4 h in a total volume of 4 ml. A 
dilution series of 11 concentration of the radioligand (±)-[3H]epibatidine was 
prepared. Non-specific binding was determined in the presence of 300 µM (-)nicotine 
hydrogen tartrate salt. The experiments were carried out in quadruplicates. 
Incubations were terminated by vacuum filtration through Whatman GF/B glass fibre 
filters, pre-soaked in 1 % poly(ethylenimine) using a Brandel 48 - channel cell 
harvester. The vials were rinsed three times with 4 ml aliquots of ice-cold Tris buffer 
(25 mM, pH 7.4). Thus, the bound and the free radioligands were separated. The 
filters are punched out, transferred in 4 ml scintillations vials and filled with 2.5 ml 
Ultima Gold Cocktail. The samples are left to incubate with scintillation fluid, long 
enough (> than 9 hours) for the tritium to diffuse out of the filter and interact with 
the scintillator. The radioactivity was measured, 1 minute per sample, using a liquid 
scintillation counter (LSC) (Tri-Carb 2100 TR, Packard, Dreieich, Germany). 
Competition assay using (±)-[3H]epibatidine and rat brain (P2 fraction) 
Assays were carried out in HSS at 22°C. Each assay was performed in duplicates. The 
test substances were dissolved in ethanol (EtOH), dimethylsulfoxide (DMSO) or 
acetonitrile (ACN) depending on the stability of the substances. A dilution row of 7-9 
concentrations of the test compound was prepared. Non-specific binding was 
determined in the presence of 300 µM (-)nicotine hydrogen tartrate salt. Each assay 
sample, with a total volume of 0.5 ml contained: 100 µl of membrane protein (60 µg), 
100 µl of (±)-[3H]epibatidine (0.5 nM), 100 µl of HSS and 200 µl of a test compound 
(Tab. V/1.2). The tissue was added last of all and all the components were mixed very 
well with the help of a vortex. The samples were incubated for 90 min, and the 
incubation was terminated by vacuum filtration through Whatman GF/B glass fibre 
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filters, pre-soaked in 1 % poly(ethylenimine) using a Brandel 48 - channel cell 
harvester. The vials were rinsed three times with 4 ml aliquots of ice-cold Tris buffer 
(25 mM, pH 7.4). Thus, the bound and the free radioligands were separated. The 
filters were punched out, transferred in 4 ml scintillations vials and filled with 2.5 ml 
Ultima Gold Cocktail. The samples were left to incubate with scintillation fluid long 
enough (> than 9 hours) for the tritium to diffuse out of the filter and interact with 
the scintillator. The radioactivity was measured, 1 minute per sample, using a liquid 
scintillation counter (LSC) (Tri-Carb 2100 TR, Packard, Dreieich, Germany). 
 
Table V/1.2: Competition assay with (±)-[3H]epibatidine and rat brain (P2 fraction) 
 Parameter Concentration Volume 
1 Buffer (HSS)  100 µl 
2 Radioligand: (±)-[3H]epibatidine 0.5 nM 100 µl 
3 Protein: rat brain (P2 fraction) 60 µg/vial 100 µl 
4a Test-compound Defined concentrations 200 µl 
4b  Total binding  Buffer (HSS)  200 µl 
4c Nonspecific binding (-)nicotine hydrogen tartrate 
salt (300 µM) 
50 µl + 150 µl 
buffer(HSS) 
 Final Volume  500 µl 
 
V/1.5. Radioligand binding studies for α7* nAChR 
Saturation assay with [3H]MLA and rat brain (P2 fraction) 
Saturation experiments for the α7* subtype were carried out in quadruplicates by 
incubating rat brain membranes (120 µg protein) at 22 °C for 2.5 h in HSS with 
concentrations of [3H]MLA ranging between 0.1 and 40 nM (Tab. V/1.3). A dilution 
series of 11 concentrations was prepared. Nonspecific binding was determined in the 
presence of MLA (50 µM). Incubations were terminated by rapid filtrations under 
vacuum through Whatman GF/B filters pre-soaked in 1% poly(ethylenimine). The 
filters were punched out, transferred in 4 ml Scintillations vials and filled with 2.5 ml 
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Ultima Gold Cocktail. The samples were allowed to incubate with scintillation fluid 
long enough (> than 9 hours) for the tritium to diffuse out of the filter and interact 
with the scintillator. The radioactivity was measured, 1 minute per sample, using a 
liquid scintillation counter (LSC) (Tri-Carb 2100 TR, Packard, Dreieich, Germany). 
 
Table V/1.3: Saturation assay with [3H]MLA and native rat brain P2 fraction (α7* nAChR) 
 Parameter Concentration Volume 
1 Radioligand: [3H]MLA 
(S.A. = 20 Ci/mmol) 
0.1 nM to 40 nM 
 
100 µl 
2 Protein: rat brain, P2 fraction  100-120 µg/vial 100 µl 
3a Total binding  Buffer (HSS) 50 µl 
3b Nonspecific binding MLA (50 µM) 50 µl 
 Final Volume  250 µl 
 
Competition assay with [3H]MLA and rat brain (P2 fraction) 
Assays for the α7* subtype were carried out in HSS at 22°C and were performed in 
quadruplicates following published procedures 349 355. Nonspecific binding was 
determined in the presence of 1 µM MLA (methyllycaconitine). Each assay sample 
contained 50 µl of the test compound, 100 µl [3H]MLA to achieve a final 
concentration of 1 nM, and 100 µl re-suspended membranes (Tab. V/1.4). The 
samples were incubated for 2 hours at 22°C. Incubations were terminated by rapid 
filtrations under vacuum through Whatman GF/B filters pre-soaked in 1% 
poly(ethylenimine). The filters were punched out, transferred in 4 ml scintillations 
vials and filled with 2.5 ml Ultima Gold Cocktail. The samples were left to incubate 
with scintillation fluid long enough (> than 9 hours) for the tritium to diffuse out of 
the filter and interact with the scintillator. The radioactivity was measured, 1 minute 
per sample, using a liquid scintillation counter (LSC) (Tri-Carb 2100 TR, Packard, 
Dreieich, Germany). 
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Table V/1.4: Competition assay with [3H]MLA and native rat brain P2 fraction (α7* nAChR) 
 Parameter Concentration Volume 
1 Radioligand: [3H]MLA 1 nM 100 µl 
2 Protein: rat brain P2 fraction 100-120 µg/vial 100 µl 
3a Test-Compound Defined concentrations 50 µl 
3b  Total binding  Buffer (HSS) 50 µl 
3c Nonspecific binding MLA (1 µM) 50 µl 
 Final Volume  250 µl 
 
V/1.6. Radioligand binding studies for α3β4*nAChR 
Saturation assay with (±)-[3H]epibatidine and native pig and calf adrenal 
membrane (α3β4* nAChR) 
In saturation studies, whole membrane fractions of pig adrenals (60-90 µg protein) 
were incubated in the presence of 2-2400 pM of (±)-[3H]epibatidine in polypropylene 
tubes containing HSS. The membranes were incubated at 22 °C for 4 h in a total 
volume of 4 ml. A dilution series of 11 concentration of the radioligand (±)-
[3H]epibatidine was prepared. Nonspecific binding was determined in the presence 
of 600 µM (-)nicotine hydrogen tartrate salt. The experiments were carried out in 
quadruplicates (Tab. V/1.5). Incubations were terminated by vacuum filtration 
through Whatman GF/B glass fibre filters, pre-soaked in 1% poly(ethylenimine) 
using a Brandel 48 - channel cell harvester. The vials were rinsed three times with 4 
ml ice-cold tris buffer, in order to separate the bound and the free radio ligands. The 
filters were punched out, transferred in 4 ml scintillations vials and filled with 2.5 ml 
Ultima Gold Cocktail. The samples were left to incubate with scintillation fluid long 
enough (> than 9 hours) for the tritium to diffuse out of the filter and interact with 
the scintillator. The radioactivity was measured, 1 minute per sample, using a liquid 
scintillation counter (LSC) (Tri-Carb 2100 TR, Packard, Dreieich, Germany). 
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Table V/1.5: Saturation assay with (±)-[3H]epibatidine and native pig and calf adrenal membrane 
(α3β4*nAChR) 
 Parameter Concentration Volume 
1 Radioligand:(±)-[3H]epibatidine 2 -2400 pM 100 µl 
2 Protein: pig and calf adrenals 60 µg/vial 100 µl 
3a Total binding  Buffer (HSS) 2000 µl 
3b Nonspecific binding (-)nicotine hydrogen tartrate 
salt (600 µM) 
50 µl + 
1950 µl (HSS) 
 Final Volume  2200 µl 
 
Competition assay with (±)-[3H] epibatidine and native pig and calf adrenal 
membrane (α3β4*nAChR) 
The binding assay was performed following a new procedure. Pig and calf adrenal 
membranes were prepared following a procedure described in sections V/1.2.3 and 
V/1.2.4., respectively. On the day of the assay, in order to reduce the presence of the 
fat, the whole membrane fractions of pig and calf adrenals were washed and then 
centrifuged (25,000 x g, 10 min., 4°C). Dilution series of tested compounds (200 µl) 
were put in the tubes. (±)-[3H]Epibatidine (100 µl) and the tissue (100 µl) were added 
(Tab. V/1.6). The nonspecific binding was determined in the presence of 600 µM (-)-
nicotine hydrogen tartrate salt. Each assay was performed in duplicates. After 
incubation (90 min), the samples were filtrated through Whatman GF/B glass fibre 
filters; pre-soaked for 20 minutes in 1 % poly(ethylenimine). The filters were 
punched out, transferred in 4 ml scintillations vials and filled with 2.5 ml Ultima 
Gold Cocktail. The samples were left to incubate with scintillation fluid long enough 
(> than 9 hours) for the tritium to diffuse out of the filter and interact with the 
scintillator. The radioactivity was measured, 1 minute per sample, using a liquid 
scintillation counter (LSC) (Tri-Carb 2100 TR, Packard, Dreieich, Germany). 
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Table V/1.6: Competition assay with (±)-[3H]epibatidine and native pig and calf adrenal membranes 
(α3β4*nAChR) 
 Parameter Concentration Volume 
1 Radioligand (±)-[3H]epibatidine 0.5 nM 100 µl 
2 Protein: whole membrane fractions of 
pig or calf adrenals  
60 µg/vial 100 µl 
3 Buffer  (HSS) 100 µl 
4a Test-Compound Defined concentrations 200 µl 
4b  Total binding  Buffer (HSS)  200µl 
4c Nonspecific binding (-)nicotine hydrogen tartrate 
salt (600 µM) 
50 µl + 150 µl 
(HSS) 
 Final Volume  500 µl 
 
V/1.7. Radioligand binding studies for (α1)2β1γδ nAChR 
Competition assay with (±)-[3H]epibatidine and Torpedo Californica electroplax 
Assays were carried out in HSS at 22°C. Each assay was performed in duplicates. 
Nonspecific binding was determined in the presence of 300 µM (-)-nicotine hydrogen 
tartrate salt. Membranes were incubated for 90 min in 0.5 ml HSS containing 2 nM 
(±)-[3H]epibatidine and different concentrations of test compounds (Tab. V/1.76). The 
reaction was terminated by vacuum filtration through Whatman GF/B glass fibre 
filters, pre-soaked in 1% poly(ethylenimine) using a Brandel 48 - channel cell 
harvester. The filters were punched out, transferred in 4 ml scintillations vials and 
filled with 2.5 ml Ultima Gold Cocktail.  The samples were left to incubate with 
scintillation fluid long enough (> than 9 hours) for the tritium to diffuse out of the 
filter and interact with the scintillator. The radioactivity was measured, 1 minute per 
sample, using a liquid scintillation counter (LSC) (Tri-Carb 2100 TR; Packard, 
Dreieich, Germany). 
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Table V/1.7: Competition assay with (±)-[3H]epibatidine and Torpedo Californica Electroplax 
 Parameter Concentration Volume 
1 Buffer (HSS)  100 µl 
2 Radioligand: (±)-[3H]epibatidine 2 nM 100 µl 
3 Protein: Torpedo Californica  60 µg/vial 100 µl 
4a Test Compound Defined concentrations 200 µl 
4b  Total binding  Buffer (HSS)  200 µl 
4c Nonspecific binding (-)nicotine hydrogen tartrate 
salt (300 µM) 
50 µl + 150 µl buffer 
(HSS) 
 Final Volume  500 µl 
 
V/1.8. Analysis of data 
V/1.8.1. Competition experiments 
The competition binding data was analysed using non-linear regression analysis. The 
Ki values were derived from measured IC50 and KD values by the Cheng-Prusoff 
equation (Ki = IC50/(1 + F/KD)276 where F is the concentration of unbound radioligand. 
The KD value is 0.01 nM for binding of (±)-[3H]epibatidine to α4β2*, the KD value is 
0.05 nM for binding of (±)-[3H]epibatidine to α3β4*. The KD value is 2 nM for binding 
of (±)-[3H]epibatidine to muscle type nAChR and the KD value is 1 nM for [3H]MLA. 
V/1.8.2. Saturation experiments 
Data of the binding saturation experiments was analysed using Scatchard-Rosenthal 
plot (linear regression analysis). The KD values were obtained from experiments 
performed in quadruplicate on the membrane preparations that were used for the 
competition assays.  
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VI. Abbreviations 
α Intrinsic activity 
ABT-089 2-methyl-3-((S)-1-pyrrolidin-2-ylmethoxy)-pyridine 
ABT-418 3-methyl-5-((S)-1-methyl-pyrrolidin-2-yl)-isoxazole 
ABT-594 5-((R)-1-azetidin-2-ylmethoxy)-2-chloro-pyridine 
α-Bgt α-bungarotoxin 
AC Adenilyl cyclase  
ACh Acetylcholine 
AChE Acetylcholinesterase 
AChPB Acetylcholine binding protein 
AD Alzheimer’s Disease 
ADHD Attention deficit hyperactivity disorders 
A-85380 3-((R)-1-azetidin-2-ylmethoxy)-pyridine 
An 1 Anatoxin-a 
ANS Autonomic nervous system 
APLs Allosterically potentiating ligands 
AR-R17779 Spiro[1-azabicyclo[2.2.2]octane-3,5´-oxazolidin-2´-one] 
Bmax Receptor density 
Bq Bequerel 
cAMP cyclic Adenosine-3´-5´monophosphate 
CCh Carbamoylcholine 
CD Crohn´s disease  
Ch Choline 
ChCA  Ccholinergic channel activator  
Ci Curies  
Ci/mmol Curies per mili moles 
CNS  Central Nervous System 
Cy 1 Cytisine 
 
VI. Abbreviations  214 -  
cpm Counts/min  
DA Dopamine  
DHβE Dihydro-beta-erythroidine 
DMAE (2-dimethylaminoethyl) phenylcarbamate 
DMCC N,N dimethycarbamoylcholine  
DMSO Dimethylsulfoxide 
dpm Disintegrations per minute  
dps Disintegration per second 
DUB-165 (5-pyridyl)-9-azabicyclo[4.2.1.]non-2-ene 
E Efficacy 
EC Electron capture 
EPI (exo-2-(6-chloro-3-pyridyl)-7-azabicyclo-[2.2.1] heptane) 
Fe 1 Ferruginine 
FLIPR Fluorescence image plate reader 
GABAAR γ-aminobutyric acid receptor type Areceptors 
GABACR γ-aminobutyric acid receptor type C receptors 
GPCRs Protein coupled receptor family  
GTS-21 
(DMXBA) 
(3-(2,4)-dimethoxybenzylidine)anabaseine 
GluRCl Chloride permeable glutamate receptors 
GlyR Glycine receptors 
H3 Histamine  
HADNFLE Human autosomal dominant nocturnal frontal lobe epilepsy 
HBA Hydrogen bond acceptor 
HBD Hydrogen bond donator 
HEK Human embryonic kidney  
HEPES N-[2-Hydroxyethyl]piperazine-N´[2-ethanesulfonic acid] 
HSS HEPES-salt solution 
5-HT 5-hydroxytryptamine, serotonin 
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∆E Energy emitted 
H3 Histamine  
KD Dissociation constant 
eV Electron voltage  
Ki Inhibition constant 
kon Rate constant for association  
koff Rate constant of dissociation 
KO Knock Out  
KD Dissociation constant 
IC50 Concentration of the inhibitor required to inhibit the binding by 
50% 
IBD Inflammatory bowel disease  
L Ligand 
LD50 Lethal Dosis 
LGIC Ligand-gated ion channel 
LR Ligand-receptor complex 
LSC Liquid scintillation counting 
mAChR Muscarinic acetylcholine receptor 
MAO-B Monoamine oxidase B 
MCC Methylcarbamoylcholine  
MHb Media habenula  
min Minutes 
MLA  Methyllycaconitine 
n Neutron 
nAChR  Nicotinic acetylcholine receptor 
NaI Sodium iodide 
NCA Non competitive antagonist 
NCB Non competitive blockers 
n.d. Not determined  
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NE  Norepinephrine 
nm Nanometer 
nM Nanomolar 
NMDA N-methyl-D-aspartic acid  
NMR Nuclear magnetic resonance 
NMS  N-methyl-scopolamine 
NS Nonspecific 
NSAIDs Non-steroidal anti-inflammatory drugs 
p Proton  
PD  Parkinson’s Disease  
PEI polyethylenimine 
PET Positron Emission Tomography 
PHT Pyrido[3.4b]homotropane  
Pin Pinnamine  
pM Picomolar 
PM Photomultiplier 
PNS Peripheral nervous system 
P2 Second pellet 
PX2R Purinoreceptor 
R Receptor 
Rpm Rounds pro minutes 
RT Room temperature 
S Specific 
SDS Sodium dodecylsulfate 
Sec Seconds 
SIB-1508Y 3-Ethynyl-5-((S)-1-methyl-pyrrolidin-2-yl)-pyridine 
SIB-1663 7-methoxy-2,3,3a,4,5,9b-hexahydro-1-H-pyrrolo[3,2-h]isoquinoline 
SIB-1553A 4-[2-((S)1-methyl-pyrrolidin-2-yl)ethylsulfanyl]phenol 
SPECT Single photon emission computer tomography 
 
VI. Abbreviations  217 -  
Tab. Table 
TB Total binding 
TC-2599 [(E)-4-(5-ethoxy-pyridin-3-yl]-but-3-enyl]methyl-amine 
TMAE 3-trimethylaminoethyl phenylcarbamate 
TNF  Tumor necrosis factor  
T1/2 Half life 
TRIS Tris[hydroxymethyl]aminomethane 
TRIS-HCl Tris[hydroxymethyl]aminomethane-hydrochloride 
TS Gilles de la Tourette´s syndrome 
UB-165 (2-chloro-5-pyridyl)-9-azabicyclo[4.2.1.]non-2-ene 
UC Ulcerative colitis 
UV Ultraviolet 
VIP Vasoactive intestinal polypeptide  
VTA Ventral tegmental area 
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